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Chapter 1.  Introduction to PPAPs 
 
1.1 Introduction 
 
  Natural products, especially those derived from plants, have been used for 
medicinal purposes since ancient times. Clay tablets of the Babylonian, Assyrian, and 
Sumerian eras dated 2600 - 4000 BC are thought to be the earliest recordings of plant 
usage as herbal remedies.
1
  Egyptians also had many paintings of medicinal plants on 
their tomb walls dated around 2200 – 2700 BC.
1
 The Ebers papyrus, which dates from 
around 1550 BC, is the most famous medical document of ancient Egypt.
1
 It was 
discovered by professor George Ebers in a tomb at Thebes in 1872 and contains more 
than 800 medicinal recipes using medicinal plants.
1
 Traditional Chinese medicine, 
thought to be more than 5000 years old, is based on natural laws that govern good health 
and longevity, namely yin and yang, and their medicinal practice is comprised mainly of 
the use of medicinal plants.
1
 Ancient medicine practiced in India, Ayurveda, meaning ― 
the science of life‖, is also based on using medicinal plants.
1
 Concoctions of different 
parts of medicinal plants were made depending on the bodily humors.
1
 
  This centuries-old usage of natural products certainly continues into the 
present, as half of prescription drugs in the market today contain plant-derived 
ingredients. The use of natural products as a source of drugs in the modern 
pharmaceutical era began with the use of foxglove extract.
2
 William Withering used 
foxglove extract to treat heart patients, and he published this application in 1785. Digoxin 
was discovered due to this treatment; GlaxoSmithKline markets this drug as Lanoxin, and 
it is used to treat arrhythmia and congestive heart failure.
3
  In 1806, Freidrich Serturner 
extracted morphine from poppies, which led to the usage of controlled morphine doses 
for pain and also led to a greater understanding of morphine receptors and the pathways 
that are associated with them.
3
 Arthur Eichengrün and Felix Hoffmann at Bayer 
Company created aspirin in 1897.
2,3
 Aspirin was the first synthetic drug synthesized from 
a natural product, salicylic acid, extracted from the willow bark.
3,4
 Then in 1928 
 
 
2 
 
Alexander Fleming discovered Penicillin from penicillium mold, and this discovery 
changed modern medicine and the treatment and understanding of infectious disease.
3,4
 
 
1.2 Introduction to PPAPs 
 
 Another  plant used for medicinal purposes is St. John‘s wort (Hypericum 
perforatum), which is a yellow flowering plant that has been used since ancient times for 
treatment of depression and anxiety.
5
 Hypericum perforatum belongs to the plant family    
Guttiferae, and the widespread interest in its antidepressant activity has increased 
investigation of metabolites from this family.
6
 Many of these metabolites are biologically 
active compounds which contain an acylphloroglucinol moiety.
6
 Guttiferae consists 
mainly of tropical plants of 40 genera and about 1200 species, most of which are woody.
7
 
The Guttiferae family produces numerous xanthones,
8
 including complex xanthones such 
as morellin,
9,10
 3,8-linked biflavonoids such as morellflavone (fukugetin),
11
 lactones, 
phenolic acids, benzophenones (phloroglucinols) and polyprenylated benzophenones
 
 
(Figure 1.1).
7,12
 The word ―xanthone‖ is derived from Greek and means yellow and 
designates the chemical compound dibenzo-[g]-pyrone.
8
 Biogenetically, all of the 
―isoprenylated benzophenone" derivatives may be derived from acylphloroglucinols such 
as maclurin, which is regarded as a precursor for many xanthones in higher plants (Figure 
1.1).
13,14
  
  
 
 
Figure 1.1:  Xanthone, morellin, phloroglucinol, maclurin 
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Common to plants belonging to the family Guttiferae is their property of wound healing, 
which has been connected to the established antimicrobial activities of the 
phloroglucinols.
6
 
 In 1971, Gurevich and coworkers isolated hyperforin (1) from Hypericum 
perforatum L. (St. John‘s wort), and it showed antimicrobial activity against gram-
positive bacteria.
15
 In 1975, Bystrov and coworkers determined the structure of 
hyperforin, which belongs to the class of polycyclic polyprenylated acylphloroglucinols, 
not the xanthone structure described above (Figure 1.2).
16
 
 
 
 
 
 
 
 
Figure 1.2: Hyperforin (1) 
 
In 1973, Rama Rao and coworkers isolated two interesting isoprenylated benzophenones, 
xanthochymol (96) and cycloxanthochymol (107), from C. xanthochymus (Figure1.3).
17
 
The bioactivity of these molecules was not recorded at that time.
17
 
 
 
 
   
 
 
 
 
Figure 1.3: Xanthochymol   and cycloxanthochymol                             
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1.3 Phloroglucinols and monocyclic polyprenylated acylphloroglucinols (MPAPs) 
 
 Phloroglucinols are 1,3,5-benzenetriols, and MPAPs are derivatives of 
these phloroglucinols which contain an acyl group and two or three 3-methyl-2-butenyl 
(prenyl) side chains as substituents in the aromatic nucleus.
18
 MPAPs are reported to 
show antimicrobial, antifungal and antifeedant activity.
19,20
 For example, Humulus 
lupulus (Cannabinaceae), commonly known as hops, is used in folk medicine as an 
antibacterial agent (in the form of wound powders and salves), a tranquilizer (sleep 
inducer), a diuretic, and to alleviate the symptoms of menopause.
21
 The cones of the hop 
plant, Humulus lupulus L. (Cannabaceae), are also an important raw material for the beer 
brewing industry. After brewing, the essential oil and the bitter acids from the cones 
contribute to the specific aroma and taste of the final product, beer.
21
 These compounds 
are monocyclic prenylated derivatives of phloroglucinols (MPAPs) and consist of -
acids, mainly humulone, cohumulone and adhumulone, and -acids, mainly lupulone, 
colupulone and adlupulone (Figure 1.4).
22
 The α-acids are converted during the brewing 
process into iso-α-acids, compounds responsible for the flavor and the bitter taste of 
beer.
23
 However, the β-acids do not add any taste during the brewing process.
6
 Although 
β-acids are not important to the brewing industry, they show radical scavenging activity, 
inhibition of lipid peroxidation, and antimicrobial activity.
6
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                    α-acids                                               β-acids 
R α-acids β-acids 
i-Pr cohumulone colupulone 
i-Bu humulone lupulone 
s-Bu adhumulone adlupulone 
 
Figure 1.4:  Hops-derived α- and β-acids 
 
1.3.1. Biosynthesis of the hop α-acids and β-acids 
 
Three types of reactions take place in this biosynthesis: the formation of 
aromatic intermediates, the introduction of several prenyl side chains into the aromatic 
ring, and the oxidation of a carbon atom from the phenolic nucleus (applies to -acids) 
(Scheme 1.1).
21
 The first reaction is similar to the initial step in the biosynthesis of 
flavonoids; the successive condensations of three molecules of malonyl-CoA to 
isobutyryl-CoA or isovaleryl-CoA lead to the formation of phloroglucinol 
intermediates.
21
 It‘s believed that PPAPs are biosynthetically made through these 
acylphloroglucinol (MPAPs) intermediates.
6
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Scheme 1.1 Proposed biosynthesis pathway of α-acids and β-acids 
 
1.4. Survey of polycyclic polyprenylated acylphloroglucinols (PPAPs) 
 
 Polycyclic polyprenylated acylphloroglucinols (PPAPs) consists of a 
bicyclo[3.3.1]nonane-2,4,9-trione skeleton with one acyl group and several prenyl and 
geranyl groups.
6
 These PPAPs can further cyclize to give adamantanes, 
homoadamantanes, or dihydrofurano- or pyrano- fused structures.
6
 Some of these 
products have been shown to possess antioxidative, antiviral and antibiotic properties.
6
 
The PPAPs can be divided into three classes: type A, B and C. Type A PPAPs 
have a C(1) acyl group and an adjacent C(8) quaternary center; type B PPAPs have a 
C(3) acyl group, and type C PPAPs have a C(1) acyl group and a distant C(6) quaternary 
center (Figure 1.5).
24
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Figure 1.5: Type A, B and C PPAPs 
  
Lists of type A, B, and C PPAPs reported and isolated to date is presented in Tables 1-3, 
respectively. All the presented PPAPs have been isolated from the Guttiferae plant 
family. The majority of these compounds are type A and B; garcinelliptones K (144), L 
(146) and M (145) are reported to have type C structures.
25
 
 
1.5. History of PPAPs 
 
 In 1937, the indian scientist Sanjive Rao isolated a yellow crystalline 
levorotatory phenol from Garcinia morella and named it morellin.
9
 Rao determined the 
composition of morellin to be C30H34O6 and found that it contained four hydroxyl groups. 
However, due to insufficient data, Rao et. al could not assign any structure to morellin.
9
 
In 1962 Kartha et al found morellin to be one of the few natural products containing a 
bicyclo[2.2.2]octane ring system, making morellin a phloroglucinol.
10
 By 1961 there 
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were 18 naturally occurring xanthones found from various families including guttiferae 
and most of them were phloroglucinols.
8
 
 Hyperforin was the first isolated PPAP
15
, and it is now classified as type 
A. 
26
 In 1975 Bystrov and coworkers were able to detemine hyperforin‘s structure and its 
absolute stereochemistry.
16
  
 The first two type B PPAPs were isolated in 1973 by Rama Rao and 
coworkers from fruits of G.xanthochymus, and they were named xanthochymol and 
isoxanthochymol. The structure given at the time for xanthochymol was monocyclic.
17
  
Due to the low resolution of NMR and many overlapping peaks, this structure was 
incorrectly assigned.
17
 In addition, the chemical shifts were very different from the 
literature values today. In 1974 David L. Dreyer isolated a compound from fruits of the 
autograph tree (Clusia rosea) and named it as xanthochymol.
27
 He used the following 
findings as evidence to compare with Rao‘s xanthochymol structure: (a) three aromatic 
protons, (b) three vinyl protons, (c) a C=CH, group, and (d) an uncertain number of vinyl 
C-methyls.
27
 
 In 1976 John F. Blount and Thomas H. Williams revised the structure of 
xanthochymol and corrected the structure using NMR and X-ray crystallography.
28
 In 
there methodology, they used CDCl3 as a solvent and TMS for the reference peak. Blount 
et al clearly assigned the proton peaks and found that xanthochymol has gem-dimethyl 
groups in the bicyclo[3.3.1]nonane (main skeleton) where previously they were assigned 
in the bicyclo[3.3.0]octane ring (Figure 1.6). Overall, they were able to detemine the 
correct structure with absolute configuration.
28
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   147                                            96 
 
 
Figure 1.6: Rao’s first proposed structure of xanthochymol (135) and corrected 
structure of xanthochymol (96) 
 
The type B PPAP clusianone (112) was first isolated from the bark extraction of 
Clusia congestiflora, and the structure was determined using X-ray crystallography in 
1976 (Figure 1.7).
29
 
 
   
 
 
 
 
 
  
Figure 1.7: Structure of clusianone  
 
Nemorosone (5) and hydroxynemorosone (6) were first isolated by de Oliveira 
who assigned them to be type C PPAP.
30
 In 2001, Cuesta-Rubio isolated nemorosone 
from floral resins of Clusia rosea and showed that nemorosone in fact had the type A 
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structure, where the positions of the bridgehead substituents were swapped from their 
originally assigned positions.
26
  
The first type C PPAP was reported by the Lin group in 2004, and they have 
isolated garcinielliptones M (145) and L (146) from the seeds of Garcinia subelliptica 
(Figure 1.8).
25
  
 
                                 
 
 
 
 
 
 
 
Figure 1.8: Garcinielliptones L and M 
 
1.5.1. Reassignment of certain PPAPs’ relative stereochemistry 
 
 To assign the correct structure of PPAPs, it is very important to know the 
correct stereochemistry. Due to their complex structure and overlapping NMR chemical 
shifts, this is a difficult task. In fact, the structure of garcinielliptone I (40) has been 
assigned the same structure as hyperibone B (33) in previous literature. Later, NMR 
spectral data and optical rotation data showed that garcinielliptone I (40) is the other 
enantiomer of hyperibone A (39).
31,32
 
In 2000, Grossman and Jacobs explained that the orientation of the C(7) 
substituent in the PPAPs (endo or exo) can be easily determined from the 
1
H and 
13
C 
NMR spectral data. 
33
 The stereochemistry at C(7) was identified by examining the 
chemical shift difference of the two H(6) or H(8) atoms and the chemical shift of C(7).
33
 
The C(7) stereochemistry is endo when the difference in the chemical shifts of the two 
H(6) atoms is 0.3-1.2 ppm and the chemical shift of C(7) is 41-44 ppm, and it is exo 
when the difference in the chemical shifts of the two H(8) atoms is 0.0-0.2 ppm and the 
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chemical shift of C(7) is 45-49 ppm. 
33
  In 2002, Matsuhisa et al reported isolation of new 
type A PPAPs with exo C(7) substituents, hyperibones A (39), B (33), C (41), D (17), E 
(20), F (21), G (15), H (109), and I (110) form aerial parts of Hypericum scabrum. 
31
 But 
using the above data, Grossman and Ciochina proposed that hyperibones C (41), E (20), 
F (21), H (109), and I (110) have an endo C(7) substituent, contrary to the originally 
proposed exo orientation.
24
 Also, they noticed, using NMR and optical rotation data, that 
garcinielliptone I (40) is in fact enantiomeric to hyperibone A (39) and not identical to 
hyperibone B (33), as originally proposed.
31,34
 
So far only the absolute configurations of hyperforin (1),
24
 xanthochymol (96),
14
 
and isoxanthochymol (106)
14
 have  been determined experimentally. Some PPAPs 
(hyperibone G (15)  and propolone D (16)
31
,
35
 hyperibone A (39) and garcinielliptone I 
(40),
31,34-36
 guttiferone E (91) and garcinol (92),
12,37-41
 isoxanthochymol (106)  and 
isogarcinol (105)
12,39,40,42-44
) have been isolated in both enantiomeric forms. When we 
draw the structures of PPAPs, we choose to draw the C(9) ketone pointing toward the 
reader, although it may not be the absolute configuration of any particular structure. We 
include each PPAP‘s specific rotation in the tables because the specific rotation of a 
compound can reveal its absolute configuration.   
 
In the Tables, the lavandulyl and -isolavandulyl groups are defined as below.   
 
 
 
 
 
 
 
(R)- lavandulyl                      ω- isolavandulyl 
 
Figure 1.9:  Lavandulyl and ω- isolavandulyl groups
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1.6. Biosynthesis of PPAPs 
 
It is believed that PPAPs are biosynthetically derived from MPAPs.
6,13,14
 The -
acid is an example of MPAP, and labeling experiments of these bitter acids has provided 
evidence of their biosynthesis pathway.
45
 The acylphloroglucinol moiety is 
biosynthetically made via a polyketide pathway with association of one acyl-CoA group 
and three malonyl-CoA groups (Scheme 2).
46,47
 Enzyme-assisted combination of an acyl-
CoA group and three malonyl-CoA groups give the tetraketide product intermediate, and 
it is cyclized via Claisen condensation into an acylphloroglucinol.
48-50
 Further 
electrophilic substituted reactions on acylphloroglucinol moiety and dimethylallyl 
diphosphate (DMAPP) or geranyl diphosphate (GPP) result in prenylated or geranylated 
product of acylphloroglucinol (Figure 1.21). 
50
  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.2: Biosynthesis of MPAPs 
 
Cuesta-Rubio proposed a mechanism for the cyclization of MPAPs to type A and 
type B PPAPs via a common intermediate (Figure 1.22).
26
 One prenyl group of the 
geminal prenyl groups of the MPAP attacks prenyl pyrophosphate to result in a stable 
tertiary carbocationic intermediate. Attack of the C(1) enol moiety on the carbocation 
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would give a type A PPAP, and the attack of the C(5) enol would result in a type B 
PPAP. The stereochemistry of the C(7) prenyl group of PPAPs is established during the 
initial stage when prenyl pyrophosphate attacks the MPAP. A single diastereomer of the 
carbocationic intermediate leads to a type A PPAP with a C(7) exo prenyl group or to a 
type B PPAP with a C(7) endo prenyl group. A majority of type A PPAPs have C(7) exo 
prenyl groups, whereas most type B PPAPs have C(7) endo prenyl groups.
24
 Adam and 
coworkers proposed a similar mechanism for the biosynthesis of hyperforin.
46
 Type C 
PPAPs may be made biosynthetically from MPAPs having a quaternary center attached 
to the acyl group instead of a prenyl group. This will lead to a tertiary carbocationic 
intermediate with reaction of prenyl or geranyl pyrophosphate. Then, the attack of C(1) 
from the carbocationic intermediate would result in a type C PPAP (Figure 1.23).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.3: Proposed biosynthesis mechanism for type A and B PPAPs 
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Scheme 1.4:  Proposed biosynthesis mechanism for type C PPAP 
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Table 1.1: Type A PPAPs 
 
The following table of type A PPAPs was taken from a review article written by Dr.  
Ciochina and Prof. Grossman.
24
 Seven newly isolated natural products were added to the 
table: prolifenone A (11), prolifenone B (12), sundaicumone A (25), sundaicumone B 
(26), sampsonione N (36), sampsonione O (37) and sampsonione Q (73).  
 
No. R groups Name Sourcea [α]D
b 
 
 
 
 
   
1 
R1 = isopropyl;  
R2, R3, R4 = prenyl 
Hyperforinc,
15,16,51 H. perforatum +41 (e, 5) 
2 
R1 = s-Butyl;  
R2, R3, R4 = prenyl 
Adhyperforin
52,d
 H. perforatum NR 
3 
R1 = isopropyl; 
R2, R3 = prenyl; R4 = H 
Hyperevolutin A
53
 H. revolutum Vahl 
+84.4 
(m,0.5) 
4 
R1 = s-Butyl;  
R2, R3 = prenyl; R4 = H 
Hyperevolutin A
d,53
 H. revolutum Vahl NR 
5 
R1 = Ph; R2 = H;  
R3, R4 = prenyl 
Nemorosone
7,26,30,54
 
Cuban propolis, C. 
rosea, C. 
grandiflora, C. 
insignis, C. 
nemorososa 
+113 (0.1);  
OMe: +150 
(m, 0.8) 
and +49 
(1.4) 
O 
R 
3 
O 
R 
4 
H O 
O 
R 
1 
R 
2 
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   Table 1.1 (continued).    
6 
R1 = 3-hydroxyphenyl;  
R2 = H;  
R3, R4 = prenyl 
Hydroxy-
nemorosone
7,d 
C. nemorososa 
OMe: +143 
(m, 0.7) 
7 
R1 = Ph; R2 = H;  
R3 = lavandulyl;  
R4 = prenyl 
Chamone Ie,
54 C. grandiflora NR 
8 
R1 = isopropyl; R2 = H;  
R3 = CH2CH2CMe2OH;  
R4 = prenyl 
Garcinielliptone A
34
 G. subelliptica –33 (0.6) 
9 
R1 = sec-butyl;  
R2 = CH2CH2CMe2OH 
Garcinielliptone D
34
 G. subelliptica –22 (0.1) 
10 
R1 = s-butyl; R2 = H;  
R3 = prenyl;  
R4 = (E)-CH=CHCMe2OH 
Garcinielliptone F
34
 G. subelliptica –23 (0.09) 
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Table 1.1 (continued).    
     
11 
R1 = 2-butyl; R2 = geranyl;  
R3 = H; R4 = prenyl 
Prolifenone A
55
 H. prolificum L. 
+0.87 
(0.57) 
12 
R1 = isopropyl;                 
R2 = geranyl; R3 = H;  
R4 = prenyl 
Prolifenone B
55
 H. prolificum L. 
+13.3 
(0.57) 
 
 
   
13 
R1 = Ph; X= H 
R2 = prenyl 
Plukenetione D/E
f,56 
C. plukenetii 
OAc: 
+34.5 
(0.03) and 
–37.6 (0.1) 
14 
R1 = Ph; X = OAc 
R2 = prenyl 
Insignone
g,56
 C. inignis 
OMe: 
+92.7 (1.6) 
     
     
     
     
     
O 
O 
R 
2 
H O 
O 
R 
1 
X 
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Table 1.1 (continued). 
   
15 
R1 = Ph;  
R2, R3 = prenyl 
Hyperibone G
31
 H. scabrum –29.3 (0.9) 
16 
R1 = Ph;  
R2, R3 = prenyl 
(enantiomer) 
Propolone D
35
 Cuban propolis +48.5 (0.7) 
17 
R1 = Ph; R2 = prenyl;  
R3 = 
CH2CH(OH)CMe=CH2 
Hyperibone De,
31 H. scabrum –61.9 (0.7) 
18 
R1 = isopropyl;  
R2, R3 = prenyl 
Garsubellin A
32,57
 G. subelliptica –21 (e, 1.1) 
19 
R1 = sec-butyl;  
R2, R3 = prenyl 
Garsubellin Be,
57 G. subelliptica –36 (e, 0.6) 
     
     
     
     
     
O 
O 
R 
3 
O 
O 
R 
1 
R 
2 
H O 
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Table 1.1 (continued).    
 
 
   
20 
R1 = 
CH2CH(OH)CMe=CH2;  
R2 = H;  
R3 = (E)-CH=CHCMe2OH 
Hyperibone Ee,f,
31 H. scabrum –56.0 (0.2) 
21 
R1 = prenyl; R2 = H;  
R3 = (E)-CH=CHCMe2OH 
Hyperibone Ff,
31 H. scabrum –31.0 (0.2) 
22 R1, R2, R3 = prenyl Sampsonione Ke,
58 H. sampsonii –5.6 (1.1) 
23 
R1, R3 = prenyl;  
R2 = H 
Sampsonione L
58
 H. sampsonii +55 (0.06) 
24 
 
24 G. subelliptica –40 (0.2) 
     
     
     
O 
O 
R 
1 
O 
O 
P h 
R 
3 
H O 
R 
2 
O 
O O 
O 
i - P r 
H O 
O H 
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Table 1.1 (continued).    
25 
 
25 C. sundaicum +52  (0.2) 
26 
 
26 C. sundaicum +48  (0.1) 
 
 
   
27 X = OH Furohyperforin
60
 H. perforatum  
28 X = OOH 
33-Deoxy-33-
hydroperoxy-
furohyperforin
61
 
H. perforatum +75 (1.2) 
     
     
O H 
H O 
H 2 O C 
O H 
O 
O O 
O 
H 2 O C 
O H 
O 
O O 
O 
O 
O O 
O 
i - P r 
X 
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Table 1.1 (continued).    
29 
 
No name
62
 C. obdeltifolia +30.9 (0.3) 
30 
 
Propolone C
35
 Cuban propolis +35.7 (0.2) 
 
 
   
31 
R1 = isopropyl;  
R2 = prenyl 
Garsubellin D
57
 G. subelliptica –12 (e, 0.4) 
32 R1 = s-butyl; R2 = prenyl Garsubellin E
57
 G. subelliptica –7 (e, 0.4) 
33 R1 = Ph; R2 = prenyl Hyperibone B
31,35
 H. scabrum 
–20.8 
(0.5);  
–42.2 (0.1) 
34 
R1 = 3,4-dihydroxyphenyl;  
R2 = (R)-lavandulyl 
Garcinielliptone FB
63
 G. subelliptica –66 (0.2) 
O 
O O 
O 
P h 
O H 
O 
O O 
O 
R 
1 
R 
2 
H O 
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Table 1.1 (continued).    
35 
 
Sampsonione M
58
 H. sampsonii +55 (0.04) 
     
     
     
     
     
     
     
     
     
     
     
     
     
     
O 
O O 
O 
P h 
H O 
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Table 1.1 (continued).    
36 
 
Sampsonione N
64
 H. sampsonii 
+22.0  
(0.09) 
37 
 
 Sampsonione O
64
 H. sampsonii 
+87.9 
(0.073) 
 
 
   
38 R = isopropyl    Garsubellin C
32,57
 G. subelliptica  +39 (e,0.4) 
39 R = Ph               Hyperibone A
31,35
    H. scabrum 
+57 (0.2); 
+63.7 (0.4) 
40 R = Ph (enantiomer) Garcinielliptone Ig,
34 G. subelliptica      -37.7(1.1) 
    
O 
O O 
O 
P h 
H O 
O O 
P h 
O O 
O H 
O 
O O 
O 
R 
H O 
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Table 1.1 (continued).    
41 
Hyperibone C
31
 H. scabrum -27.3 (0.3) 
42 
 
Chamone IIe,
54 C. grandiflora NR 
43 
 
Propolone Be,
35 Cuban propolis +38.2 (0.6) 
44 
 
15,16-Dihydro-16-
hydroperoxy-
plukenetione F
65
 
C. havetiodes var. 
stenocarpa 
+24.7 (0.3) 
     
O 
O O 
O 
P h 
 O 
O H 
O 
O O 
O 
P h 
O 
O O 
O 
P h 
O H 
H O O H 
O 
O O 
O 
P h 
O O H 
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Table 1.1 (continued).    
 
 
   
45 
R1 = i-Pr; R2 = H;  
R3 = CH3 
  Papuaforin B
66
    H. papuanum NR 
46 
R1 = Ph; R2 = H;  
R3 = prenyl 
Scrobiculatone B
67 
 C. scrobiculata +44.7 (0.2) 
47 
R1 = Ph; R2 = H;  
R3 = prenyl 
Plukenetione Fh,
56  C. plukenetii 
-53.6 
(0.03) 
48 R1 = Ph; R2, R3 = prenyl 
  Hypersampsone Ff,
68 
 
   H. sampsonii +30 (0.2) 
 
 
   
49 
R1 = Ph; R2 = H;  
R3 = prenyl 
Plukenetione Gh
56 C. plukenetii NR 
     
     
O 
O O 
O 
R 
1 R 
3 
R 
2 
O 
O 
O 
R 
1 R 
3 
O 
R 
2 
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Table 1.1 (continued).    
 
 
   
50 R1 = i-Pr; R2, R3 = prenyl 
Pyrano[7,28-b]-
hyperforin
69
 
 
H. perforatum +83.5 (0.3) 
     
     
     
     
     
     
     
     
     
     
     
O 
O 
O 
R 1 
R 2 
O 
R 3 
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51 
R1 = Ph; R2 = H;  
R3 = prenyl 
Scrobiculatone A
66,67 
C. scrobiculata 
+44.6 
(0.2) 
52 
R1 = i-Pr;  
R2 = H; R3 = CH3 
Papuaforin A
66
 H. papuanum +13(0.1,m) 
53 
R1 = s-Bu;  
R2 = H; R3 = CH3 
Papuaforin Ce
66 H. papuanum +23 (.1,m) 
54 
R1 = s-Bu;  
R2 = prenyl; R3 = CH3 
Papuaforin De
66 H. papuanum +64(0.1,m) 
55 
R1 = i-Pr;  
R2 = prenyl; R3 = CH3 
Papuaforin E
66
 H. papuanum +41(0.1,m) 
 
 
   
56 R = Ph Propolone A
41
 Cuban propolis +40 (0.1) 
57 R = i-Pr Garcinielliptone B
34
 G. subelliptica -23 (0.1) 
     
     
O 
O 
O 
R 
O 
Table 1.1 (continued). 
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Table 1.1 (continued).    
 
 
   
 
 
58 
 
 
R = prenyl 
 
 
8-Hydroxy-
hyperforin-8,1-
hemiacetal
61
 
H. perforatum +34 (1.0) 
59 R = CH3 Hyperibone J
70
 H. scabrum +16.9 (0.3) 
60 
 
Oxepahyperforin
61
 H. perforatum -73.7 (0.8) 
 
 
   
61 R = prenyl Garcinielliptin oxide
2
 G. subelliptica +1 (0.3) 
62 R = CH2CH2CMe2OH Garcinielliptone E
34
 G. subelliptica -51 (0.2) 
O 
O 
i - P r 
R 
O 
O 
O H 
O 
O 
i - P r 
O 
O H O 
O 
O 
O 
H 
O H O 
i - P r 
R 
 
 
29 
 
O 
O 
i - P r 
O 
H O 
O 
H O 
Table 1.1 (continued).    
63 
 
Garcinielliptone H
34
 G. subelliptica -14.3 (0.1) 
 
 
64 
 
 
 
Garcinielliptone G
34
 
 
 
G. subelliptica 
 
 
-53 (0.1) 
 
 
65 
 
Garcinielliptone J
34
 G. subelliptica -166 (0.2) 
 
 
   
66 
R1 = prenyl;  
R2 = CH=CMe2 
Plukenetione A
71
 C. plukenetii +1 (0.8) 
     
     
O 
O O 
O 
i - P r H O 
H O O H 
O H 
O 
O 
i - P r 
O 
O 
O O 
P h 
O 
O 
R 1 
R 2 
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Table 1.1 (continued).    
67 
R1 = prenyl;  
R2 = (S)-2,2-
dimethyloxiranyl 
28,29-Epoxy-
plukenetione A
65
 
C. havetiodes var. 
stenocarpa 
-4.4 (1.0) 
68 
R1 = geranyl;  
R2 = (S)-2,2-
dimethyloxiranyl 
Sampsonione J
58
 H. sampsonii +1.48 (0.2) 
69 
 
No name
62
 C. obdeltifolia +10.0 (0.4) 
70 
 
Sampsonione I
58
 H. sampsonii 
+16.88 
(0.1) 
 
 
   
71 R = geranyl Sampsonione A
72
 H. sampsonii -49 (0.4) 
72 R = prenyl Sampsonione B
72
 H. sampsonii NR 
O O 
P h 
O 
O 
H 
O H 
O O 
P h 
O 
O 
H O H 
O O 
P h 
O 
R 
O H 
O 
H 
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Table 1.1 (continued).    
 
 
   
73 R = prenyl Sampsonione Q64 H. sampsonii 
-9.64 
(0.401) 
 
 
   
74 R = prenyl 
Plukenetione C
56,65
 
 
C. plukenetii +65.9 (0.1) 
75 
R = (E)-
CH=CHCMe2OOH 
33-hydroperoxy-
isoplukenetione C
65
 
C. havetiodes var. 
stenocarpa 
-3.9 (0.2) 
 
 
   
76 
R1 = Ph; R2 = prenyl;  
R3 = CMe2OH 
Plukenetione B
56
 C. plukenetii 
+17.2 
(0.03) 
77 
R1 = Ph; R2 = geranyl;  
R3 = i-Pr 
Hypersampsone D
68
 H. sampsonii -35 (0.2) 
O O 
P h 
O 
R O 
O 
O O 
P h O 
R O 
O 
O 
O H 
H 
O O 
R 1 
O 
R 2 O 
H 
R 3 
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Table 1.1 (continued).    
 
 
 78 
 
R1 = i-Pr; R2 = geranyl;  
R3 = CMe=CH2 
 
 
Hypersampsone A
68
 
 
 
H. sampsonii 
 
 
+21 (0.3) 
79 
R1 = Ph; R2 = geranyl;  
R3 = CMe2OH 
Sampsonione C
58
 H. sampsonii +13 (0.2) 
80 
R1 = Ph; R2 = geranyl;  
R3 = isopropenyl 
Sampsonione D
58
 H. sampsonii +12 (0.2) 
81 
R1 = Ph; R2 = geranyl;  
R3 = O (ketone) 
Sampsonione E
58
 H. sampsonii 
+57.6 
(0.03) 
82 
R1 = Ph; R2 = geranyl;  
R3 = H 
Sampsonione H
58
 H. sampsonii +5.2 (0.07) 
 
 
   
83 R = geranyl Sampsonione F
58
 H. sampsonii +14.5 (1.1) 
84 R = prenyl Sampsonione G
58
 H. sampsonii 
+10.0 
(0.01) 
     
     
     
     
O O 
P h O 
R O 
H 
O H 
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Table 1.1 (continued).    
 
 
   
 
 
85 
 
R1, R2 = i-Pr 
 
 
Hypersampsone B
68
 
 
 
H. sampsonii 
 
 
+12 (0.3) 
86 R1 = i-Pr; R2 = H Hypersampsone C
68
 H. sampsonii +14.3 (0.2) 
87 R1 = Ph; R2 = i-Pr Hypersampsone E
68
 H. sampsonii +39 (0.2) 
 
aC. = Clusia, G. = Garcinia, H. = Hypericum.   
bOMe or OAc indicates the specific rotation was measured for that derivative.  The 
values in parentheses are the concentration and the solvent (e = EtOH, m = MeOH, no 
indication = CHCl3).  NR = not reported.  
cThe absolute configuration is known to be as shown.   
dThe first scientists to isolate nemorosone (5) and hydroxynemorosone (6) had the acyl 
group on C(5) and the prenyl group on C(1) switched from what is shown;
7,73
 later on, the 
structure of nemorosone was revised to 5, as shown in the table,
26
 but the structure of 6 
was not revisited, so we are correcting its structure in this paper.   
eNot all the stereocenters‘ configurations have been assigned.   
fThe stereochemistry of the C(7) substituent has been reassigned on the basis of the NMR 
spectra;
33
 see the text.  
O O 
R 
1 O 
O 
H 
R  
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1.7. Biological activity of PPAPs 
Many of the PPAPs have shown important biological activity including 
anticancer, anti-HIV and antiviral properties.  
1.7.1. Type A PPAPs 
1.7.1.1. Hyperforin and its close analogues 
St John's wort (Hypericum perforatum extracts) was used by the ancient Greeks 
as a remedy for many skin injuries, burns, neuralgia and depression.
74,75
 Evidence from 
several clinical trials confirms that St. John‘s wort is an effective antidepressant for mild 
to moderate depression versus placebo and standard antidepressants.
76
 Experts attribute 
this activity to the presence of hyperforin.
6,24,46,77
 The relatively low rate of side effects 
and good tolerability results in high acceptance by patients.
78
 
St. John‘s wort extract also has an approximately equally broad inhibitory effect 
on the neuronal uptake not only of serotonin, noradrenaline, and dopamine but also of  
broad inhibitory profile γ-aminobutyric acid (GABA), L-glutamate, and other 
antidepressants that are either specific to one system or show overlapping inhibitory 
effects.
79
 Hyperforin (1) and its structural analogue adhyperforin (2),  both derived from 
St. John‘s wort, have been found to be inhibitors of reuptake of investigated 
neurotransmitters.
79
 However, hyperforin (1) does not act as a competitive inhibitor at the 
transmitter binding sites of the transporter proteins but instead affects the sodium gradient 
which then leads to an inhibition of uptake.
79
 
Hyperforin (1) is also a known antibacterial agent,
15
 and it inhibits the growth of 
all gram-positive bacteria at low concentrations (0.1 mg/mL).
74
 Experiments indicate that 
penicillin-resistant (PRSA) and methicillin-resistant Staphylococcus aureus (MRSA) 
were susceptible to hyperforin. 
74
 However, hyperforin has not shown activity against 
gram-negative bacteria or against Candida albicans.
74
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Hyperforin (1) is a promising and novel anticancer agent.
50
 By induction of 
apoptosis in a dose-dependent manner with IC50 values 3-20 M, hyperforin was able to 
inhibit the growth of a wide range of human and rat tumor cell lines.
80,81
 Also, it has 
potential for reducing the invasion and metastasis growth of tumor cells,
82
 and it inhibits 
angiogenesis in vivo and several key steps of this process in vitro.
83
  
Hyperforin is a mixture of interconverting tautomers (enolized -dicarbonyl), and 
pure hyperforin is unstable when exposed to light and oxygen.
52,84
 This instability is a 
serious problem for standardization and could also have dramatic effects on the 
pharmacological activity of the extracts.
61
 On the other hand, the dicyclohexylammonium 
salt of this compound was found to be stable at room temperature and also in air.
85
 A 
majority of commercial St. John‘s wort extract contains 1-5% of 1. Extraction in aqueous 
alcoholic medium has been used for this preparation.
86
 Although the ammonium salt of 1 
is stable, hyperforin (1) itself is susceptible to air oxidation. The oxidized products of 
natural hyperforin are dependent on the nature of oxidizing agent, the solvent, and the 
type of 1 used (ammonium salt or free acid form).
87
 The hyperforin (1) can be converted 
to hemiacetal 58, possibly through the C(3)-hydroxylated intermediate after treatment 
with peroxidic reagents. The furan (136) and pyran (49) derivatives are the main products 
when nonperoxidic reagents are used for oxidizing hyperforin (Figure 1.10).
24,87
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Figure 1.10 Products of oxidation of hyperforin 
Hyperforin (1) is a potential antimalarial agent as its lithium salt showed modest 
activity against Plasmodium falciparum with an IC50 = 2 M. Plasmodium falciparum is 
the most dangerous of the four Plasmodium species causing malaria in humans.
88
 Verotta 
et al. have synthesized different analogues of enolized -diketone moiety by O-acylation, 
O-alkylation, -alkylation, or oxidative -functionalization of natural hyperforin.88 The 
homolog adhyperforin (2) (assayed as its dicyclohexylammonium salt) showed activity 
(IC50 = 1.4 M) against Plasmodium falciparum, which was similar to hyperforin. O-
Acylation of the enol moiety of hyperforin showed activity between the electron-poor and 
more hydrolysis-sensitive nicotinate 137 (IC50 = 4.8 M) and the electron-rich and more 
hydrolytically stable trimethoxybenzoate 138 (IC50 > 27 M); the reason for the higher 
IC50 value for 138 might simply be related to its stability in the assay medium (Figure 
1.11).
88
 The enol ethers 139 show decreased activity (7.8 M), while the stable analogue 
furohyperforin (27) showed a similar potency to the natural product (1.7 M), suggesting 
a specific role for the oxygen-sensitive enolized -dicarbonyl.88  
O 
O O 
O 
i - P r 
O H O 
O 
i - P r 
O 
O 
O 
i - P r 
O 
O 
O H 
5 8 1 3 6 
4 9 
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Figure 1.11 O-protected analogs of hyperforin 
1.7.1.2. Nemorosone 
 Nemorosone (5), another type A PPAP, is found in the resins and latex of 
plants of the Clusia (Clusiaceae) species.
54
 This latex normally spreads throughout the 
plant tissues and acts as a defensive agent against insect and microbial invasion when 
tissues are damaged.
54
 This latex resin is used by bees to build their hives and helps to 
harden the cell walls of the hive.
54
 In ancient times, people knew nemorosone to be 
antiseptic. Propolis is now believed to be a reinforcing agent of the structure of the hive, 
preventing diseases and parasites from entering the hive.
89
 
 In 1996, de Oliveira and coworkers isolated 4 new PPAPs: clusianone 
(109), 7-epi-clusianone (99), nemorosone (5), and hydroxynemorosone (6).
26
 According 
to their data, the structure of nemorosone suggested that it was a type C PPAP.
26
 In 2001, 
Cuesta-Rubio and coworkers found disputing evidence from their isolation of 
nemorosone from Clusia rosea. With the help of NOE and saturation experiments, this 
group proved that nemorosone is in fact a type A PPAP (5).
26
 
O 
O O 
O 
i - P r 
O N 
O 
O O 
O 
i - P r 
O 
O 
O 
O 
O 
O O 
O 
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O 
O 
O 
i - P r 
O H O 
1 3 7 1 3 8 
1 3 9 2 7 
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 In vivo studies have shown that nemorosone (5) is a potential antileukemic 
agent.
90
 Nemorosone has been shown to be cytotoxic in both parental and chemoresistant 
leukemia cell lines with IC50 values between 2.10 and 3.10 µg/mL.
90
 This compound 
also has shown cytotoxic activity against epitheloid carcinoma (HeLa), epidermoid 
carcinoma (Hep-2), prostate cancer (PC-3) and central nervous system cancer (U251) 
while O-methylated nemorosone exhibited less biological activity.
38
 
 Bacterial activity studies of 5 and O-methylnemorosone (5a)  have shown 
that only 5 has antibacterial activity.
54
 This suggests that the presence of the enol 
functionality is essential to antibacterial activity.
38,54
 
 The prenylation pattern also plays an important role for antibacterial 
activity in these types of natural products. Nemorosone showed more bacterial activity 
against Paenibacillus honeybee pathogen with respect to chamone II (42) (Figure 
1.22).
38,54
 
 
 
 
Figure 1.12 Nemorosone derivatives 
  
In addition to antimicrobial activity, nemorosone has shown antioxidant activity and 
anticancer activity.
38
 Nemorosone (5) has shown IC50 (3.3-7.2 µM) values against four 
cancer cell lines comparable to those of doxorubicin.
38
  Also, 1 has shown activity (EC50 
= 0.8 µM) against HIV infected C8166 human T lymphoblastoid cells.
91
  
 
1.7.1.3. Garsubellin A 
 Garsubellin A (18) was isolated from the wood of Garcinia subelliptica 
(Guttiferae), a tree which is grown for windbreaking in the Okinawa islands, Japan.
57
 
Researchers found that 18 could enhance choline acetyltransferase (chAT) activity by 
O 
O H O 
O 
P h 
O 
O M e O 
O 
P h 
O 
O O 
O 
P h 
4 2 5 5 a 
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154% at 10 M in comparison with the control culture containing 0.5% EtOH in a P10 
rat septal neurons culture.
32
 Choline acetyltransferase is a key enzyme for the synthesis of 
the neurotransmitter acetylchlorine, and a deficiency of chAT is believed to contribute 
diseases like Alzheimer‘s disease.
32
 
 
Table 1.2: Type B PPAPs 
The following table of type B PPAPs was taken from a review article written by Dr. 
Ciochina and Prof. Grossman.
24
 Eight newly isolated natural products were added to the 
table: sampsonione P (108) and oblongifolines A-G (101-102, 113-115, 117-118). 
 
No. Structure Name Sourcea []D
b
 
 
   
 
88 
R1, R2 = prenyl, R3 = OH Guttiferone A
12,92
 
 
  S. globulifera,  
  G. livingstonei,  
  G. humilis 
+34 (1.7) 
     
     
O 
R 
1 
O H O 
O 
R 
3 
O H 
R 
2 
 
 
 
40 
 
Table 1.2 (continued).    
  
89 
R1 = -lavandulyl  
R2 = prenyl; R
3
 = OH 
Guttiferone Cc 
 
  S. globulifera 
as  mix 
with 90 
+92 (0.9) 
 
90 
R1 =  lavandulyl;  
R2 = prenyl, R
3
 = OH 
Guttiferone Dc  
as  mix 
with 89 
+92 (0.9) 
 
 
91 
R1 = (S)-lavandulyl;  
R2 = H; R
3
 = OH 
Guttiferone E
12,38,41
 
 
   
  Cuban propolis,  
  C. rosea  
  G. ovafolia                             
+101 
(0.5) 
 
92 
R1 = (S)-lavandulyl;  
R2 = H; R
3
 = OH 
(enantiomer) 
Garcinol 
(camboginol)
39,40
 
 G. cambogia,                
G. indica 
–138 
(0.1) 
 
93 
R1 = (R)-lavandulyl;  
R2 = H; R
3
 = OH 
Guttiferone F
93
 
  Allanblackia  
stuhlmannii 
–293 
(0.4) 
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Table 1.2 (continued).    
 
 
94 R1 = prenyl;  
R2 = H; R
3
 = OH 
Aristophenoned,
94,95
 
 
  G. xanthochymus 
+58 
(0.1);  
OAc: 
+53 
(0.1), 
+54 (0.1) 
 
95 
R1 = geranyl;  
R2 = H; R
3
 = OH 
Guttiferone Ie,
96   G. griffithii –68 (1.2) 
 
 
96 R1 = (S)--lavandulyl;  
R2 = H, R
3
 = OH 
Xantho-
chymolf,
17,27,28,38,41,44,95,97 
Cuban propolis, 
 G. xanthochymus,  
G. mannii, 
 G. staudtii,  
G. subelliptica, 
Rheedia madrunno 
+138 
(0.1) 
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Table 1.2 (continued).    
 
97 
 
R1 = (S)-lavandulyl;  
R2 = H; R
3
 = H 
   14-deoxygarcinol
98
   M. coccinea
98
 −42 (0.3) 
  
 
   
 
98 
 
R1 = (S)-lavandulyl;  
R2 = H 
    7-epi-Garcinol    M. coccinea
98
  
  
   
 
99 
R1 = CH3; R
2 = Ph Hyperibone L
70
  H. scabrum 
+69.5 
(0.2) 
     
O 
R 
1 
O H O 
O 
O H 
O H 
R 
2 
O 
O H O 
R 
2 
O 
R 
1 
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Table 1.2 (continued).    
 
100 
R1 = CH3; R
2 = i-Pr Hyperpapuanone
66
  H. papuanum 
+15 (0.1, 
m) 
 
101 
 
R1 = prenyl; R2 = Ph 
 
7-epi-Clusianone
73,99-101
 
 
 C. sandinensis, 
 C. torresii 
+62.3 
(1.1) 
 
 
 
 
 
 
   
O 
R 
1 
O H O 
O 
O H 
O H 
R 
2 
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Table 1.2 (continued).    
 
102 R
1, R2 = prenyl 
   
  Guttiferone G
92,102
 
 
 G. humilis,  
 G. macrophylla 
 
–25 
(0.04) 
 
103 
 
    R1 = prenyl; R2 = H 
 
 Oblongifolin A
103
 
  
  G. oblongifolia 
 
+23 
   (0.35) 
 
104      R
1 = geranyl; R2 = H   Oblongifolin D
103
   G. oblongifolia 
 
+44.6 
(0.21) 
 
 
   
 
105 R = prenyl 
 Isogarcinol    
(cambogin)g,
39,40 
  G. indica,   
  G. cambogia 
   G. pedunculata 
–224 (m, 
0.1) 
     
O 
O O 
O 
O H 
O H 
R 
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Table 1.2 (continued).    
 
106 R = prenyl 
(enantiomer) 
Isoxanthochymolf,
12,42-44 
  G. pyrifera 
  G. subelliptica  
  G. xanthochymus 
     G. ovafolia 
+181 (e, 
0.6) 
 
107 
R = CH2CH2CMe=CH2 Cycloxanthochymol
43,44
 
  G. pyrifera  
  G. subelliptica 
as 2:3 
mix with 
72: +158 
(m, 0.1) 
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Table 1.2 (continued).    
 
 
 
   
 
108 
 
R = prenyl 
    
   7-epi-isogarcinol
98
 
 
   Moronobea  
 coccinea 
–158 
(1.0) 
  
   
 
109 
R = (E)-CH=CHCMe2OH Hyperibone Hd,
31   H. scabrum 
+12.4 
(0.4) 
 
110 
R = prenyl Hyperibone Id,
31   H. scabrum 
+13.3 
(0.3) 
O 
O O 
O 
O H 
O H 
R 
O 
R 
O O 
P h O 
O H 
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Table 1.2 (continued).    
 
 
111 
 
 Sampsonione P
64
   H. sampsonii 
+18.6 
(0.022) 
  
   
 
 
112 
R1 = Ph;  
R2, R3 = prenyl 
Clusianone
7,29,100
 
  C. congestiflora,   
C. spiritu-santesis, 
C. torresii 
+58.3 
(0.7) 
OMe: 
+61 (1.4) 
 
113 
R1 = isobutyl;  
R2 = CHPhCH2CO2H;  
R3 = prenyl 
Laxifloranone
104
   Marila laxiflora 
+23.6 
(m, 0.8) 
    
    
    
O 
O 
P h O 
O 
O H 
O 
O H O 
R 
1 
O 
R 
2 
R 
3 
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Table 1.2 (continued).    
  
114 
R1 = Ph; R2 = prenyl;  
R3 = lavandulyl 
 Spiritone
c67
 
  C. spiritus- 
sanctensis 
NR 
  
   
 
115 
R1 = H; R2 = geranyl Guttiferone B
12
   S. globulifera –44 (0.5) 
 
 
   
 
116 
 
R1 = OH, R2 = prenyl 
   
 Oblongifoline B
103 
   
   G. oblongifolia 
 
+17.6 
(0.21) 
     
O 
R 
2 
O H O 
O 
O H 
O H 
R 
1 
O 
O H O 
O 
R 
1 
O H 
R 
2 
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Table 1.2 (continued).    
 
117 
 
R1 = OH, R2 = geranyl 
 
 Oblongifoline C
103 
 
   G. oblongifolia 
 
+14.5 
(0.21) 
 
118 
R = H; R2 = geranyl   Oblongifoline E
105 
  G. oblongifolia
 
+65.1    
(0.4) 
 
 
119 
 
  Guttiferone Hc
,67
 
95   G. xanthochymus 
+94 
(0.006) 
  
   
 
120 
 
R
2
 = prenyl;  
R
3
 = geranyl; R
4
 = H 
Oblongifoline F
105
   G. oblongifolia 
−85.6   
(0.41) 
     
O 
O H O 
O 
O H 
O H 
O 
O O 
O 
O H 
R 
2 
R 
3 R 
4 
O H 
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Table 1.2 (continued).    
 
 
   
 
121 
 
R
2
 = prenyl; R
3
 = H; R
4
 = 
geranyl 
  Oblongifoline G
105
   G. oblongifolia 
+5.9   
(0.41) 
 
 
122 
 
 
  Coccinone A
98
    M. coccinea 
+ 28 
(1.0) 
 
    
O 
O O 
O 
O H 
R 
2 
R 
3 R 
4 
O H 
O 
O O 
O 
O H 
O H 
H 
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Table 1.2 (continued). 
   
 
 
123 
 
 
    Coccinone B
98
    M. coccinea −55 (0.3) 
 
 
124 
 
 
    Coccinone C
98
     M. coccinea −60 (0.2) 
 
    
O 
O O 
O 
O H 
O H 
O H 
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Table 1.2 (continued). 
   
 
 
125 
 
 
   
 
126 
 
     
    Coccinone D
98
 
 
   M. coccinea 
   −76  
(0.4) 
 
127 
 
 
   
    Coccinone E
98
 
 
  M. coccinea 
 
   −70  
(0.3) 
O 
O O 
O 
O H 
O H 
O H 
O H 
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Table 1.2 (continued). 
   
 
 
128 
 
 
    Coccinone F
98
   M. coccinea −32 (0.7) 
 
 
 
129 
 
 
                
   Coccinone G
98
   M. coccinea −16 (1.0) 
O 
O H O 
O 
O H 
O H 
O 
O H O 
O 
O H 
O H 
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Table 1.2 (continued). 
   
 
 
130 
 
 
   Coccinone H
98
     M. coccinea +2 (1.0) 
 
131 
 
Enaimeone A
66
   H. papuanum 
+27.8 
(0.1, m) 
 
 
 
 
   
     
O 
O H O 
O 
O H 
O H 
O 
O H O 
i - P r O 
O H 
C H 3 
O 
O H O 
R O 
O H 
C H 3 
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Table 1.2 (continued).    
 
132 
 
R = i-Pr 
 
Enaimeone B
66
 
 
  H. papuanum 
 
+29.4 
(0.1, m) 
 
133 
 
R = s-Bu 
 
Enaimeone Cc,
66 
 
  H. papuanum 
 
+32.9 
(0.1, m) 
  
   
 
  134 
R1 = i-Pr;  
R2 = CMe=CH2 
Ialibinone A
106
   H. papuanum –22 (0.1) 
 
  135 
R1 = s-Bu;  
R2 = CMe=CH2 
Ialibinone Cc,
106   H. papuanum –26 (0.1) 
 
  136 
R1 = i-Pr;  
R2 = CMe2OH 
1´-Hydroxy- 
ialibinone A
66
 
  H. papuanum 
+3.7 
(0.1, m) 
O 
O H O 
R 
1 
O 
H 3 C 
H 
R 
2 
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Table 1.2 (continued).    
  
   
 
  137 
R1 = i-Pr;  
R2 = CMe=CH2 
Ialibinone B
106
   H. papuanum –91 (0.1) 
   
  138 
R1 = s-Bu;  
R2 = CMe=CH2 
Ialibinone Dc,
106   H. papuanum –72 (0.1) 
 
  139 
R1 = i-Pr;  
R2 = CMe2OH 
1´-Hydroxy- 
ialibinone B
66
 
 H. papuanum 
–35.7 
(0.1, m) 
 
  140 
R1 = s-Bu;  
R2 = CMe2OH 
1´-Hydroxy- 
ialibinone Dc,
66 
  H. papuanum 
–30.3 
(0.1, m) 
 
 
141 
 
Ialibinone E
106
   H. papuanum –33 (0.1) 
     
     
O 
O H O 
R 
1 
O 
H 3 C 
H 
R 
2 
O 
O H O 
i - P r O 
H 3 C 
H 
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Table 1.2 (continued).    
 
 
 
142 
 
Gambogenone
c,95 
G. xanthochymus 
-5 
(0.003), 
(m) 
 
 
143 
 
Hyperibone K
70
 H. scabrum 
+22.3 
(0.3) 
 
aC. = Clusia, G. = Garcinia, H. = Hypericum, S. = Symphonia.   
bOMe or OAc indicates the specific rotation was measured for that derivative.  The 
values in parentheses are the concentration and the solvent (e = EtOH, m = MeOH, no 
indication = CHCl3).  
cNot all the stereocenters‘ configurations have been assigned.   
dThe stereochemistry of the C(7) substituent has been reassigned on the basis of the 
NMR spectra; see the text.
33
  
eTwo different compounds reported almost simultaneously have both been named 
guttiferone I.
96,102
   
fThe absolute configuration is known and is opposite to what is shown.   
gThe absolute configuration is known to be as shown. 
H O 
O 
O 
O H 
O H 
O O 
O O 
P h 
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1.7.2. Type B PPAPs 
 
1.7.2.1. Garcinol and its derivatives 
 Garcinol (92) and isogarcinol (105), also known as camboginol and 
isocamboginol, were isolated from the hexane extract of the fruit rind of Garcinia 
indica.
14,24,39,40
 In traditional Indian cooking, the dried rind of G. indica (‗Kokum‘) is 
used as a garnish for curry.
107
 Garcinol (92) has shown many bioactivities including 
antioxidative activity, chelating activity, free radical scavenging activity, antiglycation, 
antiinflammatory activity and antitumor activity.
108-110
 Garcinol (92) has the ability to 
scavenge 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical three times more effectively  
than DL-α-tocophenol, and the hydroxy radical more effectively than DL-α-tocophenol, and 
methyl radical, and superoxide anion.
107,110
 Very common diseases caused by hydroxy 
radicals include stress-induced gastric ulcers and nonsteroidal antiinflammatory drug-
induced gastric,
111
 so garcinol may be very useful for curing these disease.
111
 
Helicobacter pylori is another important pathogen/carcinogen which is responsible for 
various gastrointestinal disorders including chronic gastritis, gastric inflammatory 
diseases, peptic ulcer disease and gastric cancer. Garcinol (92) might be a solution for 
these illnesses because it has shown excellent inhibition against Helicobacter pylori.
107,110
 
The antiinflammatory activity of garcinol is dose-dependent. Recently, a group of 
scientists found that garcinol showed activity against the TPA-induced ear inflammation 
of CD-1 mice.
108
 Garcinol exhibits strong antibacterial activity against methicillin-
resistant S. aureus (MRSA) (MIC = 6-25 µg/mL) while standard vancomycin only has 
MIC = 6 µg/mL.
43
  
 
1.7.2.2. Clusianone and 7-epi-clusianone 
 Clusianone (112) was first isolated from the hexane extract of bark and 
broken twigs of Clusia congestiflora (Guttiferae) which was collected near Fresno, 
Columbia in 1974.
29
 The structure was identified by X-ray diffraction.
29
 From this X-ray 
data, it was clear that the prenyl group at C-7 was in an exo orientation. However, no 
NMR data was reported for this compound at that time.
29
 In 1991, delle Monache and 
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coworkers isolated 112 from Clusia sandiensis, and for the first time NMR data was 
reported. Unfortunately, due to the complexity of the data and the unavailability of an 
authentic sample of clusianone, no mention was made of the C(7) stereochemistry.
99
 In 
1996, de Oliveira and coworkers isolated 112 from Clusia spiritus-santensis and reported 
the NMR data and X-ray crystal structure.
7
 The NMR data reported was different from 
delle Monache‘s NMR data. In 1998, Santos and coworkers isolated 7-epi-clusianone 
(99) from Rheedia gardneriana and reported its NMR and X-ray crystal structure, 
showing C(7) endo stereochemistry.
101,112
  
 The anti-HIV activity and toxicity of clusianone and 7-epi-clusianone 
(101) was tested in C8166 human T lymphoblastoid cells infected with HIV-1MN.
91
 7-epi-
Clusianone (101) showed potent anti-HIV activity with an in vitro EC50 value of 2 µM.
91
 
On the other hand, clusianone (112) showed activity at very low concentration, (EC50 = 
0.02 µM) but also showed increased cytotoxity.
91
 In this experiment, propolone A (56) 
showed the most promising activity with an EC50 value of 0.32 µM. After comparison of 
the anti-HIV activities of the above prenylated benzophenones, it is clear that the keto-
enolic equilibrium is not essential to the antiviral activity. Also 112 (EC50 = 0.02 µM and 
TC50 = 0.1 µM) and 101 (EC50 = 2 µM and TC50 = 20 µM) showed very distinct EC50 and 
TC50 values. This difference may be due to the stereochemistry (exo and endo) at C-7 
(Figure 1.13).
91
     
 
 
 
 
 
 
 
 
 
Figure 1.13: Structure of clusianone, 7-epi-clusianone and propolone A 
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 Streptococcus mutans is an important microbial agent that utilizes sucrose 
to form both acids and glucans which cause dental cariogenicity.
113
 7-epi-Clusianone 
(101) has been found to inhibit the development and acidity of S. mutans  biofilm in vitro 
by inhibition of glucan synthesis, disruption of acid production, and acid tolerance.
113
  
 7-epi-Clusianone (101) is also inhibits the anaphylactic contraction of 
isolated guinea-pig ileum and prevents allergen-evoked histamine release with similar 
effects to the standard antiallergic agent azelastine.
1
 The IC50 value of 101 in this system 
is 2.3 µM and the IC50 for standard azelastine is 3.33 µM.
114
 
 The flagellate protozoan Trypanosoma cruzi affects 18 million people in 
Latin America and is responsible for 45,000 deaths every year by inducing Chagas 
disease.
73
 7-epi-Clusianone (101) has shown activity against T. cruzi present in murine 
blood (IC 50 = 260 µg/mL, 518 µM) in vitro, 29 times higher than the control drug 
Gentian Violet (LC50 = 7 µg /mL, 18 µM).
73
 7-epi-Clusianone has also shown strong 
toxicity (LC50 = 25 ppm, 49.7 µM) in the brine shrimp lethality (Artemia salina Leach)  
assay, and it may be a potential anticancer agent.
73
 7-epi-Clusianone has shown an 
endothelium-dependent vasodilator effect at low concentrations in the rat aortic rings.
115
  
 
 
1.7.2.3. Guttiferones A-E, Xanthochymol and their analogues 
 
Xanthochymol (96), guttiferone E (91) and guttiferone H (119) were isolated from 
the edible tropical fruit Garcinia xanthochymus.
116
 These compounds were tested for 
inhibition activity of three human colon cancer cell lines HCT116, HT29, and SW480 
and found to induce loss of the mitochondrial membrane potential and G1 arrest at their 
IC50 concentrations and induced caspase activation at IC50 * 2 concentrations.
116
 All 
three compounds and all three cell lines have shown an increase in gene expression of 
XBP1, ATF4 and DDIT3/CHOP genes. These genes are components of the endoplasmic 
reticulum stress response. The DDIT4/REDD1 genes can be up regulated by inhibition of 
the mTOR survival pathway.  Xanthochymol (96), guttiferone E (91), and guttiferone H 
(119) have a high chance to inhibit human clone cancer cells growth at least in part, by 
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activating the endoplasmic reticulum stress response and inhibiting the mTOR cell 
survival pathway.
116
 It is believed that these results may contribute to the anticancer 
activity of these novel compounds.
116
   
Also, xanthochymol (96) and cycloxanthochymol (107) were isolated from 
Garcinia indica and tested for activity against the human cancer cell line clone (COLO-
320-DM), breast (MCF-7) and liver (WRL-68) in the MTT assay.
117,118
 It was found that 
pure xanthochymol and cycloxanthochymol showed activity against the cell lines but that 
the activity was even higher when they were in a mixture.
117
 Testing mixtures of 
xanthochymol (96) and cycloxanthochymol (107)  for cytotoxicity in MTT assay at (1:1), 
(1:2) and (2:1)  showed that the (1:2) mixture showed maximum cytotoxic activity 
against the cell lines.
117
 
Pure xanthochymol showed strong antibacterial activity against methicillin-
resistant S. aureus with MIC range from 3.13-12.5 µg/mL. Similarly, its activity against 
MRSA is nearly equal to that of antibiotic vancomycin (6.25 µg/mL).
119
 Also it was 
found that the C(1) hydroxyl group plays a role in this activity against the MRSA.
119
 
Xanthochymol (96) shows inhibitory activity against the DNA topoisomerases I 
and II.
119
 For topoisomerase I IC50 = 30 µg/mL, standard camptothecin was 0.87 µg/mL, 
while for  topoisomerase II IC50 = 40 µg/mL, standard control etoposide was IC50 = 70 
µg/mL.
119
 It was also found that absence of hydroxyl group caused diminution of above 
activity.
119
  
Inseparable mixtures of 91 and 96 were extracted from Garcinia and Clusia 
species.
12
 The crude extract of G. pyrifera containing 40% of 96 and 91 mixture showed 
strong inhibitory activity against tubulin depolymerization (IC50 = 20 µM), suggesting it 
may be a possible inhibitor for cell replication. For the same experiment, paclitaxel 
(Taxol) showed IC50 = 0.5 µM.
44
 This inhibition activity of microtubule depolymerization 
vanished after etherifying the enol by methylation, or cyclization and the same result was 
observed after protection or oxidation of the hydroxyl groups.
44
. However, the activity 
remained if one of the hydroxyl groups was protected.
44
 Also, reduction of double bonds 
led to a total loss of activity.
44
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 Guttiferone A (88), B (115), C (89), and D (90) were isolated from Calophyllum 
lanigerum (Guttiferae), although guttiferone C (89) and D (90) were obtained as an 
inseparable mixture 
12
. All these compounds showed inhibition activity against the 
cytopathic effect of in vitro HIV infection in human lymphoblastoid CEM-SS cells with 
EC50 values of 1-10 µg/mL. However, there was no indication of a decrease in viral 
replication.
12
  
 The HIV-inhibitory activity of guttiferone F (93) in extracts of Allanblackia 
stuhlmannii was tested. Compound 93 showed cytoprotection activity against HIV in 
vitro (EC50 = 23 µg/mL) and cytotoxicity ( IC50 = 82 µg/mL) toward the host cells.
93
 
Guttiferone E (91), xanthochymol (96), aristophenone A (94), isoxanthochymol 
(106), and cycloxanthochymol (107) showed cytotoxic activity against the SW-480 colon 
cancer cells (IC50 = 7.-33.33 µM) and antioxidant activity in the DPPH free radical assay 
(IC50 = 35-125 µM).
95
 
Guttiferone G (100) was extracted from Garcinia cochinchinensis, a tree growing 
in Vietnam, and showed inhibitory activity against the human sirtuins SIRT1 (IC50 = 9 
µM), which regulates HIV transcription, and SIRT2 (IC50 = 22 µM), which is a tubulin 
deacetylase.
120
 
Guttiferone I (95) exhibits inhibition of binding activity of the -liver X receptor 
(LXRα) (IC50 = 3.43 µM) but is less effective against the β-receptor (LXRβ) ( IC50 ≥ 15 
µM).
74
  LXR agonists are therapeutical agents for the control of plasma cholesterol 
levels, increasing reverse cholesterol transport.
74
    
         
1.7.2.4. Lalibinones A-E and their analogues 
 
Five new tricyclic phloroglucinol derivatives (lalibinones A-E 134, 137, 135, 138 
and 141) were found from the petroleum ether extract of the aerial parts of Hypericum 
papuanum.
121
 The Hypericum papuanum is a tree that grows in all mountainous regions 
of New Guinea, and its leaves are used in folk medicine for the treatment of sores and 
wound healing.
121
 Lalibinones C (135) and D (138) showed stronger antibacterial activity 
against B. cereus, S. epidermidis than lalibinones A (135) and B (138) but showed almost 
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identical activity against M. luteus.
106
 Lalibinones E (141) did not show any antibacterial 
activity in this experiment.
106
  
Also from Hypericum papuanum, scientists isolated more active compounds such 
as hyperpapuanone, 1´-hydroxyialibinones A (136), B (139), and D (140), and 
enaimeones A–C (131–133).
122
 1´-Hydroxyialibinones A (136), B (139), and D (140) 
exhibit similar or slightly lower antibacterial activity compared with lalibinones A (134), 
B (137) and D (135). Also, hyperpapuanones showed moderately potent antibacterial 
activity against all B. cereus, S. epidermidis and M. luteus. Enaimeones A–C (131–133) 
showed antibacterial activity as effective as of lalibinones A-C (134, 137, 135), but 
showed weaker cytotoxicity against the KB cells.
122
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Table 1.3: Type C PPAPs 
 
No. Structure Name Sourcea []D
b
 O
OO
O
R
HO
 
   
144 R = Ph Garcinielliptone K
25
 G. subelliptica 
+27 
(0.3) 
145 R = isopropyl Garcinielliptone M
25
 G. subelliptica 
+73 
(0.2) 
146 O
OO
O
i-Pr
HO
 
Garcinielliptone L
25
 G. subelliptica 
–41 
(0.3) 
 
aG. = Garcinia.   
bThe values in parentheses are the concentrations (solvent is CHCl3).
1.7.3. Type C PPAPs 
 
 Garcinielliptones L (146) and M (145) were isolated from the seeds of G. 
subelliptica and two have shown potent inhibitory effects on the release of β-
glucuronidase and histamine (garcinielliptones L, IC50 = 22.9 and >30 µg/mL; 
garcinielliptones M, IC50= 13.6 and 19 µg/mL). The inhibitory values explain that 146 
and 135 have potential to be an antiinflammatory agent.
25
  Garcinielliptones FB was 
isolated from the same plant and has shown moderate activity against liver (IC50= 6.8 
µg/mL), breast (IC50 = 6.3 µg/mL) and colon (IC50= 11.2 µg/mL) cancer cell lines.
123
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Chapter 2. Synthetic efforts toward PPAPs 
 
 2.1. Introduction 
 
 Because of PPAPs‘ intriguing biological activity, they are very promising targets 
for organic synthesis. Because of their challenging structure and widespread human 
consumption, only three PPAPs, (±)-garsubellin A (18), (±)-nemorosone (5), and (±)-
clusianone (112) have been made synthetically so far. Although PPAPs have been known 
for decades, it was not until 1999 that the first synthetic effort was made by Prof. 
Nicolaou.
124
 A decade after the first synthetic effort there has been only three PPAPs 
synthesized in a total of seven publications from five research groups.
63,125-130
   
So far, all the approaches towards the construction of the 
bicyclo[3.3.1]nonanetrione core structure have depended on the ´-annulation of a 
three-carbon bridge onto a cyclohexanone derivative.
24
  
 
2.2. Shibasaki’s approach to garsubellin A 
 
Shibasaki‘s first reported synthetic effort in this area was a synthesis of 8-
deprenyl-garsubellin A (18). He carried out a synthesis in which all the stereocenters 
matched their natural configurations (Scheme 2.1).
131
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.1: Shibasaki’s retrosynthesis of  8-deprenyl-garsubellin A 
 
Shibasaki‘s retrosynthetic analysis of 140 began with replacing the C(3) prenyl 
group with iodine creating the alkenyl iodide 141. The C(4)-O bond was then 
disconnected to give the enone 142, which might have cyclized via an intramolecular 
Wacker-type reaction to form the tetrahydrofuran moiety in 141. The C(1)-C(2) bond of 
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enone 142 was then disconnected, planning to introduce it via a 1,3-shift of unsaturated  
lactone 143. The C(2)-O and C(4)-C(5) bonds of 143 were then disconnected to give 
intermediates 144 and 145 (Scheme 2.1).  
 
 
Scheme 2.2: Shibasaki’s approach to 8-deprenyl-garsubellin A, part 1 
 
Shibasaki‘s synthesis started with the conjugate addition of methylmagnesium 
bromide to the -unsaturated ketone 146, which was followed by the kinetic trap of the 
magnesium enolate with isobutyraldehyde to give 147 as a single stereoisomer (Scheme 
2.2). The alcohol was then protected with a silyl group; the ketone was alkylated with 
ethyl bromoacetate to give 148. The keto ester 148 was then reduced to the keto aldehyde 
with DIBAL-H; cyanosilylation of this aldehyde produced 149 as a mixture of 
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diastereomers (1.3:1).  Addition of a higher-order cuprate reagent to the cyano group of 
149 provided the methyl ketone, which was further subjected to selective methylation and 
protection to give acetonide 150. Deprotection of the TBS group with BF3.OEt2 and 
oxidation of the secondary alcohol with Dess–Martin periodinane yielded the diketone 
151 as a diastereomeric mixture (1.3:14). After deprotonation of 151, the resulting 
enolate was treated with chloroacrylate 145. Instead of the expected bicyclo compound 
142 via addition-elimination and Dieckmann condensation, the authors isolated the 
addition-elimination product 152 together with lactone 153. The authors also found that 
152 could be converted into 153 in the presence of p-nitrophenol and base. Initially 
Shibasaki and coworkers received poor yields for the above conversion; however, 
eventually they were able to optimize the reaction conditions to allow 151 to be directly 
converted to 153 in good yields. Unfortunately, these optimized conditions gave the 
isomer 153a, which contained the unnatural relative configuration, as the major product 
in a 25:1 ratio. 
 
 
 
 
 
 
 
Scheme 2.2a: Addition-elimination reaction on the carbonate 154 
 
Shibasaki and coworkers soon discovered that the carbonate 154 gave a much less 
diastereoselective addition-elimination reaction than the acetonide compound 150 did in 
their initial attempt. From this pathway Shibaski‘s group finally acquired the major 
isomer 155b, which contained the natural relative configuration  (Scheme 2.2a).
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Scheme 2.3: Shibasaki’s approach to 8-deprenyl-garsubellin A, part 3 
 
The removal of the C(3)-C(4) unsaturated double bond of compound 155b was 
important for the formation of the C(1)-C(2) bond. The Et2NPh2Si group was introduced 
via conjugate addition of an aminosilylcuprate to form a C(4)-silyl product, which was 
immediately followed by Tamao-Fleming oxidation with m-CPBA to afford a -hydroxy 
lactone. The -hydroxy lactone was then protected with a triethylsilane group to give 156 
in 33% yield over 3 steps (Scheme 2.3). The lactone 156 was then treated with Me2AlSEt 
to give the thioester; Fukuyama reduction of the thioester gave an aldehyde, which was 
successfully converted to the bicyclo[3.3.1] core structure 157 with Al2O3 via an 
intramolecular aldol reaction. Compound 157 was then treated with Dess−Martin 
periodinane to give the ketone in 157, and -elimination by DBU gave the enone 158. 
Deprotection of the carbonate of 158 with LiOH was followed by Wacker oxidation to 
afford the -alkoxy enone 159. Finally, iodination followed by Stille coupling with 
tributylprenyltin completed the synthesis of 160. The same reaction pathway was applied 
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to the acetonide 153a with unnatural (C18 epi) configuration to afford the C(18) epimer 
of 160.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.4: 1,2-allylic strain of the reactive conformation in 151b 
 
Shibasaki was unable to induce an intramolecular aldol reaction to form the B ring in a 
different approach to garsubellin A; this failure could be due to the 1,2-allylic strain of 
the reactive conformation in 151b for the cyclization (Scheme 2.4).  
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Scheme 2.5: Shibasaki’s retrosynthesis of garsubellin A 
 
In 2005, Shibasaki and coworkers completed the racemic total synthesis of 
garsubellin A using a different approach from their early synthetic strategy (Scheme 
2.5).
126
 Shibasaki‘s retrosynthetic analysis of (±)-18 began with replacement of the C(3) 
prenyl group with iodine to give alkenyl iodide 163. The C(4)-O bond was then 
disconnected to give the enone 164, which might have cyclized via an intramolecular 
Wacker type reaction to form the tetrahydrofuran moiety in 163. The C(2)-O and C(3)-
C(4) bonds of 164 were then disconnected to give intermediate 165. The C(1)-C2)  bond 
of 165 was disconnected to give intermediate 166, which could be prepared from 167 via 
aldol condensation and O-allylation. The C(1)-C(2) and C(5)-C(6) bonds of 167 were 
then disconnected to give the known intermediate 168.    
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Scheme 2.6: Shibasaki’s forward synthesis of garsubellin A, part 1 
 
The enone 168 was prepared from the commercially available ethyl enol ether of 
1,3-cyclohexanedione 169 via prenylation followed by methylation and acidic hydrolysis 
of the vinyl ether (Scheme 2.6). Copper-catalyzed conjugate addition of MeMgBr to the 
enone 168, in situ trapping of the magnesium enolate with isobutyraldehyde and 
protection of the resulting OH group with a TIPS group gave ketone 169. The 
Mukaiyama hydration of the prenyl group followed by MOM group protection and 
prenylation on the less hindered -position gave ketone 170. Selective deprotonation of 
C(5) of ketone 170  was followed by an aldol reaction with acetaldehyde; this high-
yielding reaction took place without competing retro-aldol reaction, even in this sterically 
hindered environment. Dehydration with Martin sulfurane then gave -vinyl ketone 171. 
The prenyl group was then converted to a diol with zero diastereoselectivity using 
Sharpless dihydroxylation with AD-mix- diol protection as a carbonate and removal of 
the TIPS group followed by oxidation gave -diketone 172.  O-Allylation with allyl 
iodide followed by Claisen rearrangement on the face opposite to the C(7) prenyl group 
then gave the quaternized diketone 165 with very high diastereoselectivity. 
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Scheme 2.7: Shibasaki’s forward synthesis of garsubellin A, part 2 
 
The crucial B ring was formed using ring closing-metathesis with the Hoveyda–Grubbs 
catalyst (92% yield). The resulting diketone was oxidized in the allylic position with 
(PhSe)2 and PhIO2; removal of the MOM protection group gave triketone 166 (Scheme 
2.7). Then the carbonate protection was removed, and the alcohol and enone moieties 
were condensed oxidatively in an intramolecular Wacker oxidation. Iodination at the -
position of the enone and acid catalyzed dehydration gave the tertiary alcohol 163. 
Finally, Stille coupling of 163 with tributylprenyltin completed the total synthesis of 
garsubellin A ((±)-18) in a total of 21 steps from 168. 
The alkylation of the Li enolate of 2-cyclohexenone with prenyl bromide and a 
catalytic amount (5%) of chiral tetraamine 173 (Figure 2.1) (unpublished compound from 
Koga group) gave 6-prenyl-2-cyclohexenone with 95% enantiomeric excess in 65% 
yield; however, they did not carry this compound forward in their synthesis.  
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Figure 2.1: Chiral tetraamine 173 
 
Shibasaki’s first total synthesis of garsubellin A was an important milestone, but 
it had some drawbacks such as the dihydroxylation of 171 proceeding with no 
diastereoselectivity.  Also, the oxidation of the C(2)-C(4) enone of 166 to the -alkoxy 
enone of 163 in the intramolecular Wacker oxidation relied on an internal OH group that 
was in a position to attack the enone–Pd complex in an intramolecular fashion. Although 
Shibasaki’s method may be very useful for synthesizing PPAPs containing a 
tetrahydrofuran ring fused to the C(4)-C(5) bond, such as garsubellin A, his method is 
much less applicable when synthesizing PPAPs (such as hyperforin) that lack this feature. 
Furthermore, ring-closing metathesis cannot be used for the synthesis of hyperforin 
unless the multiple prenyl groups in the molecule are protected (Scheme 2.8).   
 
 
 
 
 
 
 
 
Scheme 2.8: Ring-closing metathesis on 174 
 
Contemplating these drawbacks and future developments towards PPAPs synthesis, 
Shibasaki and coworkers, in 2007, published another synthetic strategy for constructing 
the bicyclo[3.3.1]nonane 176 with double bridgehead quaternary centers. The authors 
hoped to extend this new synthetic route towards the synthesis of garsubellin A and 
hyperforin (Scheme 2.9). 
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Scheme 2.9: Shibasaki’s intramolecular aldol approach towards garsubellin A 
 
Shibasaki and coworkers initially constructed the bicyclic system via an 
intramolecular aldol type reaction in synthesis of 8-desprenylgarsubellin A (140). 
However, Shibaski‘s group could not use an aldol reaction to construct the bicyclic ring 
towards garsubellin A (18) due to the high congestion at the C(6) nucleophilic center 
(Scheme 2.4). The group‘s redesigned synthetic strategy began with the disconnection of 
C(4)-C(5) bond to get diketo aldehyde intermediate 177 (Scheme 2.9). They planed to 
construct the bicyclo[3.3.1]nonane ring system via intramolecular aldol reaction from 
intermediate 177. The diketo aldehyde 177 was going to be made from diketone 178. 
Disconnecting the C(5)-C(9) bond of 178 gave intermediate 179, which was going to be 
made from known cyclohexenone 168.  
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Scheme 2.10: Shibasaki’s intramolecular aldol approach towards garsubellin A, 
part 1 
 
The alcohol-protected ketone 179 was converted to its potassium enolate with 
KHMDS and prenylated from the -side (axial) at C(4); next, under basic conditions, this 
product epimerized to the -prenylated compound 180 (Scheme 2.10). Removal of the 
TIPS group followed by oxidation with PDC and O-allylation gave the allyl enol ether 
181. After Claisen rearrangement took place in an axial direction, the -allylic -diketone 
182 was formed in a good diastereomeric ratio (>33:1). Terminal olefin-selective 
hydroboration, followed by oxidative workup, and further oxidation with Dess–Martin 
periodinane gave keto aldehyde 177. The key intramolecular aldol reaction formed the 
bicyclic alcohol, with NaOEt and ethanol, and the oxidation of the resulting compound 
gave synthetic intermediate 176. With this new synthetic strategy, Shibasaki solved some 
of the problems of his previous synthesis, specifically, by using intramolecular aldol and 
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Claisen rearrangement instead of the ring-closing metathesis. However, Shibasaki did not 
carry reactions further from 176.  
 
2.3. Danishefsky’s iodocyclization approach to PPAPs 
In 2005 Danishefsky and coworkers published a total synthesis of garsubellin A 
(18), and later, in 2007, published the total syntheses of nemorosone and clusianone. His 
novel approach for these syntheses was iodolactonization to build the core structure of 
these target compounds.
129
 
2.3.1. Iodonium induced carbocyclization approach to garsubellin A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.11: Danishefsky’s retrosynthetic analysis of garsubellin A 
 
O 
O O 
H O 
H 
O 
O 
O O 
H O 
H 
I 
O 
O 
I 
O 
H O 
H 
H 
O 
O 
I 
O 
H O 
H 
H 
O 
O O 
H O 
H 
O 
H O 
H O 
H 3 C O O C H 3 
O T I P S 
H 3 C O O C H 3 
1 8 1 8 3 
1 8 4 
1 8 5 
1 8 6 1 8 7 
1 8 8 
K e c k r a d i c a l 
a l l y l a t i o n 
i o d o 
c a r b o c y c l i z a t i o n 
c o n j u g a t e 
a d d i t i o n 
e l i m i n a t i o n 
d e a r o m a t i z a t i o n 
1 
5 
1 0 
1 6 
9 
2 2 
2 3 
2 7 
2 7 
3 
6 2 1 
n u c l e o p h i l i c 
a c y l a t i o n 
 
 
 
79 
 
Danishefsky‘s retrosynthetic analysis (Scheme 2.11) began with the disconnection of the 
C(1)-C(10) bond to give 183. Intermediate 2 was going to synthesized from intermediate 
184 via Keck radical allylation followed by iodination at C(1). The C(3)-C(27) bond was 
then disconnected to give 185, and disconnection of the C(1)-C(9) bond of 185 gave 
diketone 186. Disconnecting the C(22)-O bond gave nonocyclic intermediate 187, which 
can be synthesized from protected phloroglucinol 188 via dearomatization.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.12: Danishefsky’s synthesis towards garsubellin A, part 1 
 
Danishefsky‘s synthesis started with prenylation
133
 at the ortho position of  the 
protected phloroglucinol 7. Os-catalyzed dihydroxylation on the newly installed prenyl 
group
134
 followed by acetonide formation and TBAF desilylation produce 191 in 70% 
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overall yield (Scheme 2.12). The resulting product 191 was used to make 192 with 
Pd(OAc)2, PPh3, Ti(i-PrO)4 and allyl methyl carbonate either by C-allylation or by O-
allylation followed by rapid Claisen and Cope-like rearrangement.
135-137
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.13: Danishefsky’s synthesis towards garsubellin A, part 2 
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Scheme 2.13a: TMSI assisted strained cyclopropane ring opening  
 
Treatment of acetonide 192 with perchloric acid in a water-dioxane mixture initially 
deprotected it; following a Michael-type cyclization, intermediate 193 is formed in 71% 
yield (Scheme 2.13). Conversion of intermediate 193 to 186 was carried out in 68% yield 
using Grubbs olefin cross-metathesis.
138,139
 The bicyclo[3.3.1] moiety of intermediate 185  
was constructed using an iodocarbocyclization reaction, which proceeded in 85% yield; 
under these reaction conditions, a second iodination took place at the bridgehead 
carbon.
139,140
 A third iodination at C(3) then produced 194 in 77% yield. Halogen-metal 
exchange followed by allylation gave not only allylation at C(3), but also transannular 
Wurtz cyclopropanation, giving a highly strained intermediate in 67% yield. However, 
upon addition of TMSI, the strained cyclopropane ring was opened to give tricyclic 184 
in 98% yield (Scheme 2.13a).
141,142
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Scheme 2.14: Danishefsky’s synthesis towards garsubellin A, part 3 
 
Keck radical allylation
143
 of the secondary iodide of 184 followed by Grubbs 
cross-metathesis of the resulting diallylated  intermediate gave desisobutyrylgarsubellin 
A, 195, in 73% yield (Scheme 2.14). Treatment of 195 with LDA and TMSCl followed 
by addition of iodine resulted in the iodide 183 in variable yield. Halogen–metal 
exchange of i-PrMgCl and intermediate 183 followed by addition of isobutyraldehyde 
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provided the aldol adduct 196 as a mixture of isomers. Dess–Martin oxidation followed 
by removal of TMS with Et3N(HF)3 resulted in garsubellin A in 88% yield. 
 
2.3.1 Iodonium-induced carbocyclization approach to total synthesis of nemorosone 
and clusianone 
 
 
 
Scheme 2.15:  Danishefsky’s retrosynthetic analysis of nemorosone and clusianone  
 
Nemorosone (5) and clusianone (112) are structurally similar to  garsubellin A; 
taking advantage of this, Danishefsky and coworkers
129
 were able to synthesize the 
common  intermediate 197, which leads to 5 and 112 with the help of the iodonium 
induced carbocyclization method used in their previous total synthesis of garsubellin A 
(18)  (Scheme 2.15).   
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Scheme 2.16: Danishefsky’s synthesis towards nemorosone and clusianone, part 1 
 
Danishefsky and coworkers began their synthesis of intermediate 197 with -
allylpalladium chemistry, which introduces the two allyl groups to commercial 3,5-
dimethoxyphenol 198, obtaining the diallylic intermediate 199 in 50% yield (Scheme 
2.16). The allyl groups of intermediate 199 were then converted to prenyl groups through 
a twofold using Grubbs catalyst to give 200 in 79% yield.
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  Deprotection of one of the 
methoxy groups with LiI and 2,4,6-collidine gave diketone 201 in 82% yield. Iodonium-
assisted carbocyclization gave a mixture of products containing only a 32% yield of 
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intermediate 202;
139,144
 however, the other two by-products could be converted back to 
intermediate 201 in high yields by the action of Zn in aqueous THF.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.17: Danishefsky’s synthesis towards nemorosone and clusianone, part 2 
 
As in the garsubellin synthesis, diiodide 202 was reduced to iodide 205, and Keck 
radical allylation gave the intermediate 197,
143
 which could be used for the synthesis of 
either nemorosone or clusianone. (Scheme 2.17)   
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Scheme 2.18: Danishefsky’s synthesis towards nemorosone and clusianone, part 3 
 
Intermediate 197 was treated with excess LDA in the presence of excess TMSCl, 
and quenching with iodine gave iodide 206 in 51 % yield (Scheme 2.18). Halogen–metal 
exchange of 206 followed by addition of benzaldehyde resulted in an aldol product. 
Without further purification, the intermediate was subjected to Dess–Martin oxidation 
followed by desilylation with TBAF produce 207 in 61% overall yield for the three steps. 
Addition of LDA to 207 resulted in the formation of a metal–vinyl complex; this complex 
was transformed into the corresponding higher order thienylcyanocuprate.
140
 Allylation 
occurred after addition of allyl bromide and resulted in bis-allyl intermediate 208 in 88% 
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yield. A twofold cross-metathesis 
111
 reaction converted 208 to diprenyl intermediate 209 
in 91% yield; this reaction followed by demethylation gave nemorosone (5) in 31% yield. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.19: Danishefsky’s synthesis towards nemorosone and clusianone, part 4 
  
The synthesis of clusianone was concluded from intermediate 3 (Scheme 2.19).  
Compound 197 was metallated at C(3) with LDA and treated with benzaldehyde, 
and Dess–Martin oxidation gave triketone 210 in 57% yield. Compound 210 was then 
converted into its C(1) iodo intermediate 211 via the silyl enol ether. The iodo group in 
intermediate 211 was then replaced with an allyl group by allyltributylstannane and 
triethylboron in the presence of air.
145
 Diallyl intermediate 212 was then converted to  
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diprenyl intermediate 213 in 94% yield using a double cross-metathesis reaction.
138
 The 
conversion of the methoxy group to the enol, which was accomplished using aqueous 
sodium hydroxide in 1,4-dioxane (64%  yield)  gave the target molecule clusianone. 
 
2.4. Simpkins and Marazano & Delpech Effenberger cyclization (double acylation) 
approach to total synthesis of clusianone 
 
Both Simpkins on the one hand, and Marazano & Delpech on the other, 
completed the total synthesis of clusianone by applying an Effenberger cyclization 
approach to construct the bicyclo[3.3.1]nonanetrione core structure. This approach to 
PPAPs was pioneered by Stoltz.
146
 
 
 
 
 
 
 
 
 
Scheme 2.20: Stoltz’s Effenberger cyclization approach 
 
In 1984, Effenberger and coworkers published the reaction between 
cyclohexanone methyl enol ether and malonyl dichloride to give the bicyclo[3.3.1]nonane 
trione core structure. 
147
 In 2002, Stoltz and coworkers published a modified procedure 
for the synthesis of the bicyclo[3.3.1]nonane core structure of garsubellin A  by changing 
the ratio of enol ether to malonyl dichloride and by changing methyl enol ether to a TBS 
silyl enol ether to obtain cleaner products in modest yields (Scheme 2.20).
146
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Scheme 2.21: Simpkins’ retrosynthetic analysis of clusianone 
 
In 2006 Simpkins and coworkers published a racemic total syntheis of clusianone. 
Simpkins‘ retrosynthetic analysis began with the disconnection of the C(1) prenyl 
substituent  and C(3) benzoyl substituent of 109 to give diprenyl bicyclo[3.3.1]nonane 
trione intermediate 214 (Scheme 2.21). The disconnection of the C(1)-C(2) and C(4)-
C(5) bonds gave methyl enol ether intermediate 215. Simpkins planned to install the 
C(1)-C(2) and C(4)-C(5) bonds using the Effenberger cyclization.  
 
 
 
 
Scheme 2.22: Simpkins’ synthesis towards clusianone, part 1 
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Simpkins and coworkers began their forward synthesis with prenylation of known 
vinylogous ester 217, which gave diprenylated intermediate 218;
148
 this step was 
followed by methylation with MeLi and acidic hydrolysis to give 2,3,4-substituted 
cyclohexenone 219 in 88% yield over two steps (Scheme 2.22). Copper-catalyzed 
conjugate addition of MeMgBr to enone 219 resulted in an 85:15 ratio of ketone 
diastereomers 220a and 220b in 88% yield. This mixture was then converted to 
regioisomeric mixtures of the corresponding  methyl enol ethers with the aid of tBuOK in 
DMSO, giving 221a and 221b with 75:25 ratio in 87% yield.
149
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.23: Simpkins’ synthesis towards clusianone, part 2 
 
The bicyclo[3.3.1]nonanetrione core structure 222 was achieved via Effenberger 
cyclization with malonyl dichloride and 221. The compound 222 was obtained in 30% 
yield after basic extraction, and 220a and 220b were also obtained in 55 % yield (Scheme 
2.23). The methyl enol ether was found to be more effective in this system than the silyl 
enol ether (OTBS). Diketone 222 was converted to its methyl enol ether under acidic 
conditions with trimethyl orthoformate in 24 % yield over 2 steps.  
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Scheme 2.24: Simpkins’ synthesis towards clusianone, part 3 
 
To complete the synthesis, ketone 223 was prenylated at the bridgehead carbon to 
give 224 in 91% yield (Scheme 2.24). Acylation at C(3) using LTMP and benzoyl 
chloride then gave O-methylclusianone 225 in 91% yield, 
150
 and deprotection with LiOH 
in dioxane offered the target compound in 90% yield for the last step. 
In 2007, Simpkins and coworkers expanded the Effenberger cyclization to the 
total synthesis of clusianone and a formal synthesis of garsubellin A by synthesizing a 
late intermediate in Danishefsky‘s synthesis;
63,129
 furthermore, they also advanced to a 
later intermediate in the synthesis of nemorosone from the common 
bicyclo[3.3.1]nonanetrione intermediate. 
 
2.4.1 Progress towards the synthesis of nemorosone 
 
Simpkins and coworkers followed the same strategy towards nemorosone that 
they applied for the synthesis of clusianone (Scheme 2.25). 
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Scheme 2.25: Simpkins’ synthesis towards nemorosone, part 1 
 
The synthesis of nemorosone began with known enone 168 
151
 (Scheme 2.25), which was 
converted to intermediate 226 after prenylation in 77% yield. Conjugate addition of 
MeMgBr followed by protection of the ketone with a TBS group gave silyl enol ether 
intermediate 228 in 88% and 87% yields respectively. The Effenberger cyclization was 
observed under Stoltz‘s conditions to give the bicyclo[3.3.1]nonane trione intermediate 
229, and, without purification, the enol was converted to two isomers of methyl enol 
ether (230 and 231) using Me2SO4 in the presence of a base in 29% yield.  
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Scheme 2.26: Simpkins’ synthesis towards nemorosone, part 2 
 
The next step was to install the iodine group at the bridgehead C(1) center. 
Following Danishefsky‘s strategy, 
129
 halogen–metal exchange would be used incorporate 
the acyl group (Scheme 2.26). The intermediate 232 was isolated in 74% yield after it 
was prenylated at C(3) via a higher order cyanocuprate. When attempting the iodination 
at the bridgehead carbon using LDA, TMSCl and iodine, the unexpected triene product 
233 was isolated in 60% yield.  
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Scheme 2.27: Simpkins’ synthesis towards nemorosone, part 2 
 
As a result, the alkylation and acylation steps were reversed. Compound 230 was 
protected at C(3) with LiTMP and TMSCl to give 243 in 78% yield. Then, bridgehead 
iodide 235 was obtained after using Danishefsky‘s reaction conditions in 40% yield 
(Scheme 2.27). The iodo intermediate 235 was an important intermediate towards the 
synthesis of nemorosone; however, authors did not carry out further reactions with this 
intermediate due to a lack of materials.   
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2.4.2. Formal synthesis of garsubellin A 
 
 
Scheme 2.28: Simpkins’ formal synthesis of garsubellin A, part 1 
 
Simpkins‘ formal synthesis of garsubellin A began with prenylation of the known enone 
168
151
 to given an -prenylated enone intermediate 236 in 71% yield (Scheme 2.28). The 
Cu-catalyzed conjugate addition of MeMgBr to enone 236 followed by TBS protection 
gave silyl enol ether intermediate 238 in 70% and 90% yields, respectively. The 
Effenberger cyclization was carried out with malonyl dichloride and silyl enol ether 238, 
which yielded bicyclo[3.3.1]nonanetrione 230. Next, tricyclic intermediate 239 was 
obtained via an epoxidation–cyclization sequence with mCPBA in 22% yield over two 
steps. The diastereomeric ratio for the epoxidation-cyclization was 2:1, and the major 
product was found to have the desired stereochemistry. The synthesis was continued with 
the desired isomer.   
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Scheme 2.29: Simpkins’ formal synthesis of garsubellin A, part 2 
 
The alcohol of tricyclic 239 was protected with a TMS group, and then allylation 
of C(3) with LTMP, Li(2-Th)CuCN and allyl bromide; desilylation and conversion of the 
allyl group to a prenyl group via Grubbs cross-metathesis gave Danishefsky‘s  
intermediate 241 in his garsubellin A synthesis (Scheme 2.29).
63
 The above synthetic 
strategy broadened the applicability of the Effenberger cyclization and also has a widened 
applicability to bridgehead metalation in the synthesis of PPAPs. 
In 2007, Marazano and coworkers published a similar approach towards the 
synthesis of clusianone.
125
 The key step to the bicyclo[3.31]trione core structure involved 
the Effenberger cyclization approach,
147
 the main difference between Simpkins‘ and 
Marazano‘s approach being that Simpkins used a methyl enol ether, whereas Marazano 
used a silyl enol ether (Scheme 2.30).  
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Scheme 2.30: Marazano’s retrosynthetic analysis of clusianone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.31: Marazano’s synthesis of clusianone, part 1 
 
Marazano‘s synthesis started with the protection of the known prenylated -
diketone 243 with i-PrI in the presence of a base, which gave the enol ether intermediate 
244 in 90% yield (Scheme 2.31). The second prenylated product 245 was obtained when 
treated with LDA and prenyl bromide, and, without purification, it was transformed to 
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intermediate 246 after methylation and acidification in 92% yield for the over two steps. 
The diastereomers 248 and 249 were isolated in 82% yield after conjugate addition of 
MeCu to 246 followed by a third prenylation.
125
   
 
 
Scheme 2.32. Marazano’s synthesis of clusianone, part 2 
 
The mixture of cyclohexanone intermediates 248 and 249 were converted to the silyl enol 
ether intermediate 242 in quantitative yield (Scheme 2.32).  
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.33: Marazano’s synthesis of clusianone, part 3 
 
Treatment of 242 with malonyl dichloride (1 eq) in the presence of 0.2 eq TMSOTf  at 
−10 

C gave the desired bicyclo[3.3.1]trione intermediate, in 35% yield. An unexpected 
lavandulyl-substituted phloroglucinol derivative 250 was also obtained in 38% yield 
(Scheme 2.33). However, after changing the Lewis acid TMSOTf to BF3∙Et2O, the 
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desired bicyclic product 251 was obtained in 35% yield. A by-product, cyclic ether 252 
was also isolated in 25% yield. The compound 252 is significant because it has a C(7) 
endo prenyl group (Scheme 2.34).  
 
 
Scheme 2.34: Marazano’s synthesis of clusianone, part 4 
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Scheme 2.35: Proposed mechanism for the formation of 250 
 
The proposed mechanism for the formation of 250 proceeds through the cationic 
intermediate 254, itself formed by a fragmentation process (Scheme 2.35). This cationic 
intermediate 254 can be recyclized to give the bicyclo[3.3.1]trione intermediate 255 or 
the lavandulyl derivative 256. Desilylation then gives 252 and 250, respectively.  
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Scheme 2.36: Marazano’s synthesis of clusianone, part 5 
 
Marazano and Delpech completed the total synthesis of clusianone after acylation 
with PhCOCN and Et3N in 65% yield (Scheme 2.36).
136
 
 
2.5. Porco’s total synthesis of clusianone 
 
In 2007, Porco and coworkers published a short synthesis of clusianone via a 
tandem alkylative dearomatization-annulation process to construct the 
bicyclo[3.3.1]nonanetrione core.
130
 Porco and coworkers carried out several model 
studies using different Michael donors and Michael acceptors.   
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2.5.1. Retrosynthetic analysis of clusianone  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.37: Porco’s retrosynthetic analysis of clusianone 
 
The retrosynthetic analysis of clusianone began with the disconnection of the C(9)-C(10) 
bond to give the aldehyde 257 (Scheme 2.37). Next, the C(1)-C(9) and C(5)-C(7) bonds 
of 257 were going to be installed via Michael addition–elimination reactions of 
clusiaphenone B 258 with -acetoxy enal 259. The clusiaphenone B 258 intermediate 
would be synthesized from commercially available acylphloroglucinol 260.   
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Scheme 2.38: Porco’s synthesis of clusianone, part 1 
 
The polyisoprenylated benzophenone clusiaphenone B 258 was synthesized in 
40% yield by C-prenylation of acylphloroglucinol 260 (Scheme 2.38).
137
 The reaction of 
clusiaphenone B intermediate 260 with -acetoxymethyl acrylate 261 in the presence of 
LiHMDS at 0 

C allowed for a diastereoselective dearomatization–annulation process in 
which an additional Michael–elimination reaction occurred to afford the 
bicyclo[3.3.1]nonanetrione intermediate 263 in 70% yield. NMR data and X-ray crystal 
structure of the p-bromobenzoate of the enol ether derivative confirmed the backbone 
structure of the bicyclo intermediate 263. The second acrylate molecule approached the 
262 from the convex face; this resulted in an addition–elimination process, yielding a 
single diastereomeric bicyclo intermediate 262. After screening several analogs of 
clusiaphenone derivatives and acrylate derivatives, the authors discovered the sterically 
hindered -acetoxymethyl acrylate derivatives do not undergo the second addition–
elimination process, and the reaction stopped after the reaction of the first acrylate 
derivative with the clusiaphenone derivative.  
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Scheme 2.39: Porco’s synthesis of clusianone, part 2 
 
Treatment of clusiaphenone B 258 with KHMDS and -acetoxy enal 259 in THF 
afforded the desired annulated product (Scheme 2.39). Without purification, the crude 
compound was transformed to its methyl enol ether 264 in 54% yield.
137
  The addition of 
vinylmagnesium bromide to the aldehyde 264 followed by acetylation of the resultant 
alcohol yielded the allylic ester 265 in 74% yield. The Pd-catalyzed formate reduction
142
 
of 265 afforded the C-7 allyl intermediate in 90% yield. Next, the C-7 allyl group was 
converted to a prenyl group with the Grubbs cross-metathesis
138
 reaction to give O-
methylclusianone 266 in 89% yield. The total synthesis of clusianone was completed 
after demethylation of 266 with the help of LiOH in dioxane or LiCl in DMSO (77% and 
89% yield, respectively).  
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2.6. Other approaches towards PPAPs 
 
In addition to the above synthetic routes towards PPAPs, several groups have 
contributed and are still contributing to the goal of finding more paths towards the 
synthesis of not only garsubellin A, clusianone, or nemorosone but also more complex 
PPAPs such as hyperforin and xanthochymol.  
 
2.6.1. Nicolaou’s Se-mediated electrophilic cyclization approach 
 
In 1999, Nicolaou and coworkers published the first synthetic effort toward 
PPAPs in which they prepared a model compound of garsubellin A.
124,139
  The group 
initially developed the selenium-mediated cyclization to build the bicyclo[3.3.1]nonane 
core structure and applied this method towards their synthesis of the model compound 
267 (Scheme 2.40).  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.40: Nicolaou’s model compound of garsubellin A 
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Scheme 2.41: Nicolaou’s Se-mediated electrophilic cyclization approach, part 1 
 
In the synthesis, allylic enol acetate intermediate 268 was treated with 
N-(phenylseleno)phthalimide (N-PSP) and SnCl4 at –78 

C;  this enol intermediate 
underwent selenium-induced cyclization via the proposed intermediate 269 to grant the 
desired bicyclo product 270 (Scheme 2.41).  
 
Scheme 2.42: Nicolaou’s Se-mediated electrophilic cyclization approach, part 2 
 
Later, Nicolaou‘s group successfully applied Se-mediated electrocyclization to achieve 
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addition of nBu3SnH and AIBN gave  intermediate 271 (Scheme 2.42). After a few 
reactions from 271, Nicolaou‘s group was able to complete the model synthesis of 267.  
 
2.6.2. Nicolaou’s Michael addition–aldol reaction approach  
 
In 2005, Nicolaou and coworkers tried an alternative approach to construct the 
bicyclo[3.3.1]nonane core of the model systems hyperforin and perforatumone (Scheme 
2.43).
152
 They used acrolein derivatives and cyclic -keto ester derivatives (272) in a 
Michael addition–aldol reaction pathway to form the desired bicyclic core structure of 
PPAPs (Scheme 2.44). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.43:  Hyperforin and perforatumone 
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Scheme 2.44: Nicolaou’s Michael addition-aldol reaction approach 
 
The bicyclic enone intermediate 274 was observed after the Michael addition–
aldol reaction of methacrolein and -keto ester 272 followed by oxidation. This reaction 
strategy could be an effective and short method to synthesize the bicyclic core of 
hyperforin and other PPAPs. Next, dihydroxylation and fragmentation of intermediate 
274 afforded intermediate 276 and, after this, transformation took place via intermediate 
275.    
 
2.6.3. Kraus’s Mn-mediated oxidative free radical cyclication approach 
 
Kraus and coworkers utilized a Mn(III) acetate and Cu(II) acetate-based, 
oxidative free-radical Snider protocol
153
 to construct the bicyclic ring core 279 of PPAPs 
(Scheme 2.45).
154,155
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Scheme 2.45: Kraus’s Mn-mediated oxidative free radical cyclication approach 
 
 
The reaction of keto ester 277 with Mn(OAc)3 (2 eq) and Cu(OAc)3 (1 eq)  
predominantly  gave bicyclo intermediate 280. Then, bromination of 280 with 3.5 
equivalents of NBS resulted 278 in 55% yield. Substitution of the bromide 278 with O-
allyl followed by Claisen rearrangement gave expected 279. The yields for the last two 
steps were not reported. 
  
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.46: Proposed mechanism for the Mn mediated cyclization  
 
A possible mechanism for the Mn mediated cyclization of 279 can be proposed as 
follows (Scheme 2.46). The Mn(III) reacts with the carbonyl oxygen to form Mn(III)-
based enol ether intermediate 281, which undergoes an electron transfer with loss of 
O 
C O 2 M e 
1 . M n ( O A c ) 3 
C u ( O A c ) 3 
O 
C O 2 M e H 
O B r 
O 
C O 2 M e H 
H O O 
2 . 3 . 5 e q N B S 
1 . N a 
O H 
2 . 1 4 0 o C 
( 5 5 % 2 s t e p s ) 
2 7 7 2 7 8 2 7 9 
O 
C O 2 M e 
2 8 0 2 7 9 
M n ( O A c ) 3 
C u ( O A c ) 3 
O 
C O 2 M e 
( 3 ) M n - ( M n ( I I ) O 
C O 2 M e 
2 8 1 2 8 2 
O 
C O 2 M e H 
 
 
 
110 
 
Mn(II) to afford a stable keto radical. Then, the radical reacts with the  electrons of the 
double bond to give a 6-endo cyclic radical product; Cu(III) is then added to oxidize this 
resultant radical product. 
153
   
 
2.6.3. Kraus’s addition elimination-addition approach 
 
Kraus and coworkers have come up with an alternative pathway to create the 
bicyclic core structure of PPAPs via a Michael addition–elimination reactions of cyclic -
ketoester 283 and -sulfonate acrolein (284) derivative 285 (Scheme 2.47). 156  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.47: Kraus’s addition elimination-addition approach, part 1 
 
Michael addition-elimination of cyclic -keto ester 283 and  gave 285 in 71% 
yield and then, acetate 285 was converted to pivalate 286 in 80% yield. Reaction of 286 
with 
t
BuOK afforded 287 in 56% yield. 
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 Scheme 2.48: Kraus’s addition elimination-addition approach, part 2 
 
Recently, Kraus and coworkers applied Michael addition–elimination to construct 
a bicyclic intermediate 290 (Scheme 2.48).
157
 Reaction of keto ester 288 and methyl 
acrylate followed by Birch reduction and cyclization gave diol 289 in 85% yield. Then, 
the compound 289 was oxidized with PCC and the resulting diketone was silylated to 
give 290.  
 
 
2.6.4. Mehta’s Pd-mediated oxidative cyclization 
 
In 2004, Mehta and coworkers published the first enantiospecific approach 
towards PPAPs; they performed this feat by synthesizing the bicyclic framework 31 using 
Kende cyclization.
158,159
  The stereochemistry at C(7) was established by starting the 
synthesis with -pinene. 
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Scheme 2.49: Mehta’s Pd-mediated oxidative cyclization 
  
(−)--Pinene was converted to ketone 291 after several steps. Then the compound 291 
was transformed to the TMS enol ether 292.  Pd(OAc)2-mediated Kende cyclization gave 
bicyclic intermediate 293 in 30% yield over 2 steps (Scheme 2.49).
158
   
 
2.6.5. Mehta’s intramolecular enol lactonization, retro-aldol and re-aldol cyclization 
 
In recent years, Mehta and coworkers published another pathway to construct the 
bicyclic 36 by using intramolecular enol-lactonization followed by a retro-aldol–aldol 
strategy (Scheme 2.50).
160
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Scheme 2.50: Mehta’s intramolecular enol lactonization 
 
LDA mediated regioselective prenylation of 294 gave prenylated ketone in 69% 
yield and the reaction of the resulting ketone with methyl acrylate gave keto ester 295 in 
74% yield. Hydrolysis of ester 295 under basic conditions followed by lactonization gave 
296 in 83% yield. Then, DIBAL-H assisted retro-aldol and aldol reactions of 296 gave 
expected bicyclo alcohol 35 in 62% yield. Oxidation of 297 with PCC and LDA-
promoted prenylation gave 298 (Scheme 2.50).  
 
2.6.6. Young’s intramolecular allene-nitrile oxide [3 + 2] cycloaddtion 
 
Young and coworkers published a unique synthetic route to construct the bicyclic 
core structure of 303 using intramolecular allene-nitrile oxide [3 + 2] cycloaddition 
(Scheme 2.51).
161
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Scheme 2.51: Young’s intramolecular allene-nitrile oxide [3 + 2] cycloaddtion 
 
Lewis acid-catalyzed Mukaiyama aldol condensation of silyl enol ether 299 and 
300 gave methoxy diastereomers 301 in 44% yield. Then, 301 was allowed to react with 
phenyl isocyanate in refluxing benzene to give 302. Finally, reductive cleavage of 302 
gave 303 in quantitative yield.   
 
2.6.7. Grossman’s alkynylation–aldol approach 
 
Grossman and Ciochina, in 2003, published another approach towards the 
construction of the bicyclo[3.3.1]nonane ring core of PPAPs.
162
 The main idea was to 
prepare the bicyclo ring by an intramolecular aldol reaction of a cis enal. Grossman 
explained that the cis enal creates better reaction moiety with an enol or enolate and 
better undergoes intramolecular aldol reactions than a regular aldehyde. Grossman and 
Ciochina attempted this new idea towards a synthesis of compound 39 (Scheme 2.52).
162
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Scheme 2.52: Grossman’s alkynylation–aldol approach 
 
Reaction of the diketone 304 with Pb(OAc)4 followed by addition of alkynyltributyltin 
gave -alkynylated product in 48% yield. Then, acid-mediated deprotection of resulting 
product gave alynal 305 in 71% yield. The alynal 305 was then reacted with Co2(CO)8 to 
give the Co2(CO)6 complex in 87% yield, and syn hydrosilylation of the resulting 
complex gave (E)--silyl eneal 306 in 94% yield with complete regio- and 
stereoselectivity. Acid catalyzed cyclization of 306 gave two diastereomeric alcohols (1:1 
dr) in 72% yield, and oxidation of these alcohols with NMO and TPAP gave -silyl 
enone 307 in 87% yield. 
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2.6.8. Nakada’s Lewis acid promoted regioselective ring-opening reaction of the   
cyclopropane approach 
 
In 2006, Nadaka and coworkers published another approach towards the 
construction of the bicyclic core structure of PPAPs.
163
 The key reaction in this approach 
was the Lewis acid mediated, region selective ring-opening of tricyclic[4.4.0.0]dec-2-ene 
derivative 311 to grant the bicyclo[3.3.1]nonane core structure 312 (Scheme 2.53).
163,164
 
 
 
 
Scheme 2.53: Nakada’s Lewis acid promoted regioselective ring-opening 
 
The aldehyde 308 was successfully synthesized from a commercially available 
source. Then, aldehyde 308 was oxidized to its carboxylic acid, which was converted to a 
-keto ester and thence to -diazo -keto ester 309 in 64% yield over three steps. 
Compound 309 was allowed to react with CuOTf (5 mol%) and ligand 310 to give the 
tricyclo[4.4.0.0]dec-2-ene 311. Without isolating the resulted tricyclic compound, a 
Lewis acid-promoted ring-opening reaction was carried out to give bicyclic intermediate 
312.    
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2.6.9. Takagi’s acid catalyzed cyclization approach towards adamantane core of 
plukenetione type PPAPs 
 
For the first time, Takagi and coworkers published an acid-catalyzed cyclization 
approach towards the synthesis of the adamantane core  319 of the plukenetione type 
PPAPs (Scheme 2.54).
165
 
 
 
 
Scheme 2.54: Takagi’s acid catalyzed cyclization approach towards adamantane 
core 
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allylic oxidation gave keto enol intermediate 316. The secondary alcohol group was 
oxidized, and the tertiary alcohol then protected with TMS group to prevent a hetero-
Michael reaction. A benzoyl group was attached to the -position of the enone using 
LTMP and benzoyl chloride. Finally, acid-catalyzed cyclization gave 319 in 59% yield. 
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Chapter 3.   Our synthesis towards 7-epi-clusianone 
 
Many of the PPAPs have shown potentially useful bioactivity, such as anticancer, 
antibiotic and anti-HIV activity. For example hyperforin, a type A PPAP widely known 
for its anti-depression activity, is considered to be the main bioactive agent in Hypericum 
perforatum L (St. John‘s wort).
16,61,72
 The type B PPAPs xanthochymol
17
 and garcinol
14
 
have shown antibiotic activity against methicillin-resistant S. aureus.
43
 PPAPs are often 
found in bitter-tasting fruits that have been popular in folk medicine, and most PPAPs 
that have been tested for toxicity have shown low toxicity.
166
 Apart from PPAPs‘ 
interesting bioactivities, their structures are enriched with acyl group, prenyl groups, 
geranyl groups and many adjacent quaternary centers, and a bicyclo[3.3.1] chemical 
moiety with specific stereochemistry, making them challenging to synthesis.
24
  
Though PPAPs are very promising targets for organic synthesis considering their 
intriguing biological activity, challenging structure and wide spread human consumption, 
only three PPAPs — (±)-garsubellin A, (±)-nemorosone and (±)-clusianone — have so 
far been made synthetically.
63,125-130  
PPAPs have been known for decades, but the first 
synthetic effort was reported only in 1999 by Prof. Nicolaou. After a decade from the 
first synthetic effort, only three PPAPs have been synthesized by a total of seven 
publications from five research groups. All synthetic strategies have been focused on 
PPAPs that have a prenyl group at C(7) with exo stereochemistry.  However, a large 
majority of type B and large minority of type A PPAPs have the C(7) prenyl group in the 
more sterically congested endo orientation. Our goal is to develop a stereocontrolled 
synthesis towards the C(7) endo type B PPAP, 7-epi-clusianone. To date, there are no 
synthetic efforts found in the literature towards 7-epi-clusianone. Like many PPAPs, 7-
epi-clusianone has shown very interesting bioactivities such as anticancer and antibiotic 
properties. 
73,91,113-115
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3.1. Initial retrosynthetic analysis 
 
 
 
Scheme 3.1: Our initial retrosynthetic analysis 
 
Our initial retrosynthetic analysis of 7-epi-clusianone (101) (Scheme 3.1) began with the 
disconnection of the benzoyl group and replacement of the sensitive prenyl groups with 
more robust allyl group to give bicyclo[3.3.1]nonanetrione intermediate 320. The C(2)-O 
bond and C(4)-C(5) bonds were disconnected  to give the cis enal intermediate 321. This 
compound might cyclize by an intramolecular aldol reaction (IA) from 321a, but would 
be expected to assume its thermodynamically more favorable conformer and 
diastereomer 321b. We believed that the 321a-321b equilibrium could be shifted towards 
321a during the IA reaction. We thought the cis enal of 321 could be made from the -
allyl--ketoester intermediate 322. The -ketoester intermediate 323 could be obtained 
after disconnection of axial allylic group of intermediate 322. From a stereochemical 
point of view, it would be crucial to establish the cis relationship between the C(1) ester 
and C(7) allyl group of 322 to install the C(7) endo stereochemistry of our target. 
Intermediate 323 could be synthesized from tetrasubstituted cyclohexanone 324, which 
could be synthesized easily from commercially available 1,3-cyclohexanedione (325). 
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3.2 Forward synthesis  
 
Our forward synthesis began from the commercially available, cheap 1,3-
cyclohexanedione.    
 
3.2.1 Synthesis of 2,4-diallyl-3-methyl-2-cyclohexenone  
 
 
 
 
 
 
 
 
Scheme 3.2: Synthesis of 2,4-diallyl-3-methyl-2-cyclohexenone   
 
Allylation of 1,3-cyclohexanedione with KOH and allyl bromide gave -allyl--
diketone 326 in 47% yield.
167
 The original paper claimed 79% yield for this reaction after 
crystallization. The role of Cu in the reaction is unclear, but yields are better in its 
presence. Diketone 326 was converted to its vinylogous ester 327 with isobutyl alcohol, 
and a catalytic amount of p-TsOH∙2H2O in benzene in 75% yield (Scheme 3.2). 
151,168
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3.2.2 Allylation, methylation and acidification 
 
 
 
Scheme 3.3: Allylation, methylation and acidification 
 
The allylation at the -position of intermediate 327 gave ´-diallylic 
vinylogous ester 328.
169
 Without purification, the crude oily compound was subjected to 
methylation followed by acidification to give intermediate 2,4-diallyl-3-methyl-2-
cyclohexenone 329 in 89% yield (Scheme 3.3). 
151
  
 
3.2.3 Alternate pathway towards 2,4-diallyl-3-methyl-2-cyclohexeone.  
 
We also devised another route to 11 that began with methyl acetoacetate.  
 
3.2.3.1 Allylation  
 
 
 
 
 
 
Scheme 3.4: Alternate pathway towards 2,4-diallyl-3-methyl-2-cyclohexeone 
 
Methyl -allylacetoacetate 331 was obtained from commercially available 
methylacetoacetate, NaH and allyl bromide in 73–81% yield. 
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was transformed to -allylic intermediate 332 with the agency of NaH, BuLi and allyl 
bromide in 67% yield (Scheme 3.4).
171
 
 
3.2.3.2 Michael addition, cyclization and decarboxylation 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.5: Michael addition, cyclization and decarboxylation 
 
The Michael addition of diallylic β-ketoester intermediate 332 to acrolein catalyzed 
by triphenylphosphine in acetonitrile gave β-ketoester aldehyde intermediate 333 in 74% 
yield. To close the ring, an aldol reaction was performed on intermediate 333 with 
sodium methoxide in methanol to give the β-ketoester 334 and carboxylic acid 335 
intermediates. The mixture of 334 and 335 was decarboxylated under Krapcho conditions 
to afford α,β-unsaturated ketone 336 in 87% yield over 2 steps (Scheme 3.5).
172
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Scheme 3.6: Methylation of cyclohexenone intermediate 336 using MeLi/CeCl3   
 
 
Methylation of cyclohexenone intermediate 336 using MeLi/CeCl3  afforded  
alcohol 337 in 85% yield, and  PCC oxidation
173
 gave cyclohexenone 329 in 68% yield 
(Scheme 3.6).
174
  
 
3.2.4 Conjugate addition, trapping enolate with TMS group followed by desilylation 
 
 
 
 
 
       
 
 
 
Scheme 3.7:  Conjugate addition, trapping enole with TMS group followed by 
desilylation 
 
Conjugate addition of Me2CuLi to 2,4-diallyl-3-methyl-2-cyclohexenone 329 
followed by simultaneous trapping of the resulting enolate with TMSCl gave TMS enol 
ether 338 in 84% yield.
175
  Direct conjugate addition without trapping the enolate resulted 
in low yields. The TMS group was then removed to get 2,4-diallyl-3,3-
dimethylcyclohexanone 324 in 3:1 diastereomeric ratio in 80%  yield (Scheme 3.7).
68
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3.2.5. Carbonylation and allylation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.8: Carbonylation and allylation 
 
The 2,4-diallyl-3,3-dimethylcyclohexanone 324 was converted to -keto ester 323 with 
dimethyl carbonate, cat. KH and NaH in benzene.
176
 Mander‘s carboxylation with LDA 
and MeO2CCN failed in this system. The catalytic amount of KH was not necessary for 
the reaction to proceed, but it gave cleaner crude product. Without further purification, 
Pd-catalyzed allylation of 323 with allyl acetate and triethylamine in methanol gave 
diastereomeric allylic products 322a and 322b. The major diastereomer was 322a, an 
axial allylic product, as confirmed using NMR studies (Scheme 3.8). 
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3.2.5.1. Structure and stereochemistry determination of 322a 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Structure and stereochemistry determination of 322a using NOE 
 
The 
1
H NMR chemical shifts of 322a and 322b were assigned by COSY 
experiments, and the stereochemistry of 322a was unambiguously determined by a 
NOESY experiment. In particular, the C(6) and C(4) H atoms and the H atoms of the 
C(2) allyl group all had strong NOE interactions, confirming that they were all axial.  
  
3.2.6. Reduction and oxidation 
 
 
Scheme 3.9: Reduction and oxidation of 322a  
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Keto ester 322a was reduced to its diol 339 with LAlH4 in Et2O. 
177
 The crude product of 
339 was oxidized to keto aldehyde 340 with Dess–Martin periodinane in CH2Cl2 in 50% 
yield (Scheme 3.9).
178
  
 
3.2.7 Still–Gennari reaction, reduction and oxidation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.10: Still–Gennari reaction, reduction and oxidation 
 
The keto aldehyde 340 was converted to Z unsaturated ester 342 using highly 
stereoselective modified Horner–Emmons olefination with  bis(trifluoroethyl)phosphono-
acetate 341 and NaHMDS in THF in 82% yield and 15.1 dr.
179
 Without separation, 
LiAlH4 reduction followed by Dess–Martin periodinane oxidation gave the key 
intermediate Z aldehyde 321 in 45% yield along with a small amount of 343 (Scheme 
3.10).
177,178
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3.2.8 Aldol reaction 
 
 
 
 
 
 
 
 
Scheme 3.11: Aldol reaction 
 
We were anticipating the intramolecular aldol reaction of 321 to result in the 
bicyclo[3.3.1]nonane core structure 344 (Scheme 3.11). 
 
3.2.8.1 Aldol reaction under acidic conditions  
 
 
 
 
 
 
 
 
Scheme 3.12: Aldol reaction under acidic conditions 
 
Unfortunately, all our attempts to carry out the aldol reaction in acidic medium 
resulted in the isomerization of 321 to the E aldehyde 345 (Scheme 3.12) (Table 1). 
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Table 3.1: Acid and solvent used for aldol reaction 
 
 
 
 
 
 
 
 
 
We initially used HCl, TFA and conc. H2SO4 for the reaction (Table 1). We 
hypothesized that, the acids‘ conjugate bases were capable of assisting the conversion of 
321 to 345 (Scheme 3.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.13: Proposed mechanism for cis-trans isomerization   
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Therefore, we exposed 321 to triflic acid, whose conjugate base (CF3SO3
-
) was 
nonnucloephilic, but the result was the same. 
 
3.2.8.2 Aldol reaction under basic conditions 
 
 
 
 
 
 
 
 
Scheme 3.14: Aldol reaction under basic conditions 
 
 
Table 3.2: Bases and solvent used for aldol reaction 
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Unfortunately, even in the various basic conditions (Table 2), we did not observe 
any signs of an aldol reaction. The main isolated product was the bicyclic unsaturated 
lactone 346 (Scheme 3.14), the product of a Tishchenko reaction. 
After analyzing the above data, it became very clear that the Z aldehyde 321 was 
strongly inhibited from enolizing under acidic or basic conditions, which was necessary 
for a successful aldol product.  
 
3.3 The role of 1,2-allylic strain 
 
 
 
 
 
 
Scheme 3.15: The role of 1,2-allylic strain 
 
The 1,2-allylic strain (1,2-A strain) is defined as the steric interaction between the alkene 
moiety and the methyl group in compound 347. This interaction plays an important role 
in influencing the conformational equilibria of the alkenes.
180,181
 For example, steric 
interactions between the geminal dimethyl groups and the C(sp
2
) methyl group 
destabilize 347b compared to 347a and 347c (Scheme 3.15).
181
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Scheme 3.16: 1,2-allylic strain of 321 
 
We hypothesized that 1,2-A strain inhibited the enol and enolate formation in 321, 
as necessary for the aldol reaction (Scheme 3.16). The conformation 321d, the most 
important intermediate for intramolecular aldol product and the enolate form of 321a, 
experiences severe 1,2-A strain. This factor may raise the energy of the 321d sufficiently 
high that the aldol reaction cannot proceed at a reasonable rate
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3.4 Redesigning the synthesis  
 
The outcome of our initial route encouraged us to redesign the synthesis in a way to 
minimize the 1,2-A strain of the enolate intermediate for the aldol reaction. Considering 
these factors, we thought to disconnect the C(1)-C(2) bond of 2 instead of C(4)-C(5) 
(Scheme 18) to get the intermediate (Z)-keto aldehyde 27 (27a and 27b) for the 
intramolecular aldol reaction.  
 
Scheme 3.17: Second retrosynthetic analysis 
 
3.4.1 New retrosynthetic analysis 
 
 The C(4)-O bond and C(1)-C(2) (instead of C(4)-C(5)) bonds of 320 were 
disconnected to give cis enal intermediate 348. We thought that this compound might 
cyclize by an intramolecular aldol reaction (IA) from 348a, but we expected it to assume 
its thermodynamically more favorable conformer 348b. We believed that the 348a–348b 
equilibrium could be shifted towards 348a during the IA reaction. The enolate of 348 
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would not be expected to have significant 1,2-allylic strain. We thought the cis enal of 
348 could be made from -allyl -ketoester intermediate 349. The -ketoester 
intermediate 350 could be obtained after disconnection of the axial allylic group of 
intermediate 349. From a stereochemical point of view, it would be crucial to allylate 350 
trans to the C(7) allyl group in order to install the C(7) endo stereochemistry of our 
target. Intermediate 350 could be synthesized from disubstituted cyclohexenone 351, 
which could be synthesized easily from commercially available 1,3-cyclohexanedione 
(Scheme 3.17).   
 
3.4.2 Forward synthesis 
 
Our forward synthesis began with the synthesis of 4-allyl-3-methylcyclohexenone 
from the commercially available, inexpensive starting material 1,3-cyclohexanedione. 
 
3.4.2.1 Isobutyl protection, allylation, methylation and acidification  
 
  
 
 
 
 
 
 
Scheme 3.18: Isobutyl protection, allylation, methylation and acidification 
 
The 1,3-cyclohexanedione was converted to its vinylogous ester 352 in 95% 
yield.  Ketone 352 was allylated with LDA and allyl bromide.
146
 Without purification, the 
crude oily material was subjected to methylation
151
 followed by acidification to give 4-
allyl-3-methyl-2-cyclohexenone 351 in 90% yield over 3 steps (Scheme 3.18). 
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3.4.2.2 Conjugate addition and carbonylation 
 
 
        
   
 
 
 
Scheme 3.19: Conjugate addition and carbonylation 
 
To the resulted enone 351, dimethylcuprate, HMPA, and methyl cyanoformate 
were added, and -keto ester intermediate 350 was obtained in 71% yield (Scheme 
3.19).
182
 The reaction produced approximately equal amounts of O-acylation and C-
acylation without the co-solvent HMPA. A common replacement for HMPA is DMPU, 
but the reaction gave lower yields with DMPU, and in higher scale we obtained 
substantial amounts of recovered by-products.  
 
3.4.2.3 Allylation and Claisen rearrangement 
 
 
 
 
 
 
 
 
Scheme 3.20: Failed Pd-catalyzed allylation reaction  
 
 
The introduction of an axial allyl group to the -position of 350 was important to 
establish the C(7) endo stereochemistry of the target molecule. Unfortunately, the Pd-
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catalyzed allylation reaction failed, possibly due to steric hindrance around the reaction 
moiety (Scheme 3.20). 
 
 
 
 
 
 
 
 
Scheme 3.21: O-allylation   
 
However, NaH and allyl bromide gave the O-allylated product 353 in 75% yield 
(Scheme 21),
183
 and heating the allyl enol ether intermediate 353 at 150 

C in toluene in a 
sealed tube  gave two diastereomeric Claisen rearrangement products, 354a and 354b, in 
3:1 d.r (Scheme 3.22).
126
  
 
 
 
 
  
 
 
 
Scheme 3.22: Claisen rearrangement 
 
 
After carefully analyzing COSY and NOESY spectra of the two isomers, we found that 
the major product, 354a, had the desired trans relationship between the two allylic 
groups.  In particular, one of the C(2) allylic H atoms had strong NOE interactions with 
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the C(4) H and the C(3) methyl H atoms, which confirmed that C(2) allylic group was 
axial.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Steriochemistry determination of 354a using NOE 
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3.4.2.3.1 Structure and stereochemistry determination of 354a 
 
3.4.2.3.2 Proposed model for the stereochemical products for the Claisen 
rearrangement  
 
 
 
 
Scheme 3.23: Proposed model for the stereochemical products for the Claisen 
rearrangement 
 
The stereoselectivity can be explained as above (Scheme 3.23). The most stable 
conformation of 353 is half-chair with the C(7) allyl group in the equatorial position. For 
the Claisen rearrangement, 353 can go though the TS1, TS2, TS3 and TS4 transition 
states to afford 354a or 354b (Scheme 24). In TS1, the Claisen rearrangement proceeds 
on the top face to avoid the steric repulsion from C(6) axial methyl group, where TS2 
experiences steric interactions between the C(6) methyl group and the incoming allyl 
group. As a result, TS1 has lower energy, resulting in the diastereomer 354a 
predominantly. TS3 and TS4 have higher energy transitions due to steric repulsion from 
the C(4) allyl group.  
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3.4.2.4 Methyl enol ether protection, reduction and oxidation 
 
 
 
 
Scheme 3.24: Methyl enol ether protection, reduction and oxidation 
 
The ketone of -keto ester intermediate 354a was protected with trimethyl 
orthoformate and a catalytic amount of concentrated sulfuric acid in methanol to give the 
enol ether intermediate 355 in 95%  yield.
184
 The aldehyde 356 was obtained in 91% 
yield after LiAlH4 reduction followed by Dess–Martin periodinane oxidation (Scheme 
3.24).
177,178
  
Our original plan was to convert the aldehyde 346 to its cis enal with the Still–
Gennari reagent, which we used in the previous synthesis.
179
 Unfortunately, the expected 
reaction failed, possibly due to the steric crowdedness of the reaction center. As a result, 
we decided to proceed with two sequential one-carbon homologations of the aldehyde.    
 
3.4.2.5 Alkynylation 
 
 
 
 
 
 
 
Scheme 3.25: Alkynylation 
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The aldehyde 356 was then converted to keto-protected terminal alkyne 357 with 
lithiated TMSCHN2 in 66% yield. Methyl enol ether protection was crucial for this 
reaction. Other protecting groups such as a triethylsilyl group caused many equivalents 
(10 eq) of the reagents to be required, and the yields were variable (Scheme 3.25).
184,185
  
 
3.4.2.6 O-Allylation and carbonylation  
 
 
 
Scheme 3.26: O-Allylation and carbonylation 
 
The methyl enol ether 357 was transformed into its allyl enol ether 358 in 96% 
yield by refluxing in allyl alcohol and a catalytic pTsOH∙2H2O in benzene.
186
  One-
carbon homologation of alkyne 358 was carried out using palladium-catalyzed 
carbonylation in methanol to afford alkynoate 359 in 72% yield (Scheme 3.26).
187
  
 
3.4.2.7 Reduction, Claisen rearrangement and oxidation 
 
 
 
 
Scheme 3.27: Reduction, Claisen rearrangement and oxidation 
 
O 
H O H 2 C 
1 . L i A l H 4 , E t 2 O 
- 7 8 o C t o - 3 0 o C 
( 9 4 % ) 
3 6 0 
O 
M e O 2 C 3 5 9 
2 . P y r i d i n e ,  
( 7 5 % ) 
O 
O H C 
D M P / C H 2 C l 2 
( 7 8 % ) 
3 6 1 
M e O 
C O , P d C l 2 
C u C l 2 , N a O A c 
M e O H , 
a l l y l O H , T s O H 
B e n z e n e 
( 9 6 % ) 
( 7 2 % ) 3 5 7 
O 
3 5 8 
O 
M e O 2 C 3 5 9 
 
 
 
141 
 
After LiAlH4 reduction of 359, Claisen rearrangement in pyridine heated in a 
sealed tube gave the C-allylic ketone intermediate 360 in 75% yield.
186
 Dess–Martin 
oxidation then gave alkynal 361 in 78% yield (Scheme 3.27). 
 
3.4.2.8 Syn reduction of alkynal and intramolecular aldol reaction 
 
The syn reduction of the alkynal moiety of intermediate 39 was very crucial for 
the intramolecular aldol reaction. The reduction had to be carried out in the presence of 
several allyl groups in a sterically crowded environment. Palladium-catalyzed 
hydrogenation reactions are very commonly used for syn reduction of alkynes, but they 
gave multiple products in the present system, 
188-190
 including reduction of double 
bonds.
190
  
 
3.4.2.8.1 Complex with Co2(CO)8 and hydrosilylation 
 
One method for syn reduction of complex systems like this was to heat the Co2(CO)6 
complex of the sterically hindered alkyne with Et3SiH.
162
  
 
 
 
 
 
 
 
 
 
 
 
   Scheme 3.28: Complex with Co2(CO)8 and hydrosilylation 
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In the present case, alkynal 361 reacted with Co2(CO)8  to give the Co2(CO)6 
complex in 60% yield. The Co2(CO)6 complex was treated with Et3SiH and 
Me3SiC≡CSiMe3 in (CH2Cl)2 to give  (E)-α-silyl enal 362 in 58% yield with complete 
regio- and stereoselectivity (Scheme 3.28).  However, the
 1
H NMR spectrum of Co2(CO)6 
complex appeared very broad, the yields were not consistent, and the reaction was very 
slow.  
 
 
 
 
 
Scheme 3.29: Intramolecular aldol product 
 
 
Nevertheless, sufficient amounts of enal 362 were obtained to subject it to acidic 
conditions to promote an intramolecular aldol (IA) reaction. The IA product, 
bicyclo[3.3.1]-nonane intermediate 363, was obtained as two diastereomers (1:1). 
Without purification, 363 was oxidized with Dess–Martin‘s periodinane,
178
 and 
desilylation with TBAF gave the bicyclo[3.3.1]nonane target 364 in 25% yield over 3 
steps (Scheme 3.29).
191,192
 An X-ray crystallographic study of 364 established its 
structure unambiguously.  
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Figure 3.3:  X-ray data structure of 364 
 
 
The successful preparation of the 7-endo-allylbicyclo[3.3.1]nonane skeleton 
shows the validity of our approach to synthesis 7-endo PPAPs and supports our 
hypothesis on the failure of our initial route.  
 
3.4.2.8.2 Hydrostannylation  
 
Even though this is a viable route to 364, the observed poor yields for the last few 
steps restricted the amount of material for further reactions towards the target molecule. 
Examples of hydrogenation of alkynals, apart from the H2 and transition metal catalyst 
reactions, are very limited in the literature. But the Pd-catalyzed syn hydrostannylation of 
alkynoates is a well known reaction.
193,194
 Even though there was no precedent for the 
hydrostannylation of alkynals, we decided to try to hydrostannylate our alkynal 
intermediate 361.  
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Scheme 3.30: Hydrogenation  
 
The result was very surprising. Instead of hydrostannylation, we observed a 
highly stereoselective syn hydrogenation to give product 348 in 84% yield (dr = 90:10). 
If we increased the reaction temperature, larger amounts of the other isomer (trans/anti) 
were obtained. The mechanism of the above reaction is unclear at the moment (Scheme 
3.30). 
 
3.4.2.8.3 Addition of thiophenol to keto alkynal 39 
 
 
 
 
 
 
Scheme 3.31: Addition of thiophenol to keto alkynal 39 
 
In another potential approach to a cis-enal, addition of thiophenol to ynal 361 
gave enal 365 as a single diastereomer.  Unfortunately, NOESY experiments showed that 
the isomer that we obtained was the (Z)-enal, 365, which was not a suitable substrate for 
the intramolecular aldol reaction (Scheme 3.31).  In particular, the C(2) H atom of enal 
had strong NOE interaction with H atoms of C(4) allylic, C(5) methyl and aromatic ring, 
which confirmed that C(2) H atom and  aldehyde H atom were trans to each other. We 
further confirmed the stereochemistry by the chemical shift of C(2) H atom (6.61 
ppm).
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3.4.2.8.4 Structure and stereochemistry determination of 365 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Structure and stereochemistry determination of 365 
 
 
3.4.2.8.5 Intramolecular aldol and oxidation reactions 
 
 
   
 
 
 
 
 
Scheme 3.32: Intramolecular aldol and oxidation reactions 
 
The intramolecular aldol reaction of hydrostannylation product 348 under acidic 
conditions
162
 yielded both the desired aldol product and the trans isomer of the 
intermediate 348. However, under basic conditions, the intramolecular aldol product was 
observed as a clean mixture of two diastereomeric products.
197
 Without purification, the 
alcohol was oxidized with Dess–Martin periodinane to grant the bicyclo[3.3.1]nonane 
intermediate 364 in 78%  yield for the last 2 steps (Scheme 3.32).
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the alkyne alkynal 361 with Bu3SnH, intramolecular aldol reaction, and oxidation gave 
higher yields than the previous pathway towards 364. 
 
3.4.3 Attempts to form the 2,4,9-triketone system 
 
 
 
 
 
 
 
Scheme 3.33: Attempts to form the 2,4,9-triketone system 
 
Our next goal was to install the hydroxyl group on the -position of the 
intermediate 364 to afford the intermediate 320. Previous model studies of our group
190
 
and recently published results by Marazano and Delpech
198
 had shown that many 
common tools such as epoxidation across the -unsaturated double bond followed by 
ring opening and oxidation failed to give the target product.  In the dissertation of Dr. 
Ciochina, apart from the epoxidation, she attempted several pathways towards the 
formation of a 2,4,9-triketone intermediate, such as silylation, borylation, and other paths, 
but none of these routes were successful (Scheme 3.33).
190
 Therefore it was urgent and 
necessary to develop new pathways towards the 2,4,9-triketone intermediate 320.  
 
3.4.3.1. Curtius rearrangement approach  
3.4.3.1.1. Synthetic plan 1 
 
Our plan to prepare the 2,4,9-triketone intermediate is shown in Scheme 3.34. We 
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undergo  Curtius rearrangement to give the -amino enone. Acidic workup would then 
give the target intermediate. 
  
 
 
 
 
 
 
 
 
Scheme 3.34: Curtius rearrangement approach, plan 1 
 
3.4.3.1.2. 1,2-addition of Bu3SnCH2OMOM  and allylic oxidation 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.35: 1,2-addition of Bu3SnCH2OMOM  and allylic oxidation 
 
The 1,2-addition product intermediate 367 was obtained in 62% yield after the 
reaction of intermediate 364 with 366 and BuLi. 
199
 However, allylic oxidation of 367 
with PCC gave only starting material, whereas Jones oxidation
200
 and CrO3 oxidation in 
the presence of 3,5-dimethylpyrazole gave back diketone 364 (Scheme 3.35).  
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Scheme 3.36: Proposed mechanism of oxidative cleavage 
 
We hypothesized that CrO3 was capable of assisting the conversion of 367 to 
diketone 364 via the mechanism shown (Scheme 3.36). 
 
3.4.3.1.3. 1,2-addition of MeLi and allylic oxidation 
 
 
Scheme 3.37: 1,2 addition of MeLi and allylic oxidation 
 
 
The diketone 364 was transformed to alcohol 368 via 1,2-addition of MeLi in 
THF in  75% yield.
201
 Unfortunately, allylic oxidation of 368 failed with PCC. We 
observed only the 1,2-eliminated product 369 and starting diketone 364 (Scheme 3.37).  
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3.4.3.1.4. Synthetic plan 2 
 
 
 
 
Scheme 3.38: Curtius rearrangement approach, plan 2 
 
Since our previous reaction plan was unsuccessful, we devised another synthetic 
plan to prepare the 2,4,9-triketone. We thought to introduce a methyl group by 1,4-
addition to the  enone  and reinstall the double bond to give -methylated enone. Then, 
oxidation of the -methyl group to give a carboxylic acid might be followed by Curtius 
rearrangement and acidic workup to achieve the target intermediate (Scheme 3.38) 
3.4.3.1.5. Me2CuLi addition to bicyclo enone 364 
 
 
 
 
 
 
 
 
Scheme 3.39: Me2CuLi addition to bicyclo enone 364 
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Table 3.3: Reagents and conditions of Me2CuLi addition 
 
Reagent/Solvent Temperature Product 
Me2CuLi/Et2O 
(CuI/MeLi) 
   0 
o
C 368 
    −15 
o
C 368 
    −40 
o
C 368 
    −78 
o
C 368 
Me2CuLi/ TMSCl/ Et2O 
(CuI/MeLi) 
  −78 
o
C 370 
Me2CuLi/ TMSCl/Et2O 
(CuCN/MeLi) 
  −78 
o
C- −40 
o
C 370 
Me2CuLi/ Et2O 
(CuBr.Me2S/MeLi) 
  −78 
o
C- −40 
o
C 368 
 
Unfortunately, all attempts at 1,4-addition to 364 gave the unexpected 1,2-adduct 
370. We hypothesized that C(4) was too hindered, and the boat conformation of 364 
made C(4) even more hindered to methylate (Scheme 3.39) (Table 3).   
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Figure 3.2: X-ray structure of 1,2-adduct 368 
 
3.6. Experimental Section 
 
For all the compounds reported, the melting points were taken on an Electrothermal 910 
and the IR data were collected on a Nicolet Magna-IR 560 spectrometer. The 400 MHz 
1
H NMR and 100 MHz 
13
C NMR data were collected on a Varian VXR-400S. The 50 
MHz 
13
C NMR data were collected on a Varian Gemini 200. 
 
 
 
323 
 
 
 
 
 
O O 
O 
 
 
 
152 
 
 Methyl 3,5-diallyl-4,4-dimethyl-2-oxocyclohexanecarboxylate (323): 
 
A mixture of NaH (0.50 g, 12.5 mmol), dimethyl carbonate (4.24 mL, 50.0 mmol) and 
2,4-diallyl-3,3-dimethyl-cyclohexanone (1.03 g, 5.00 mmol) in dry benzene (24.0 mL) 
was refluxed for 1 hour under N2. Then, a catalytic amount of KH (10.0 mg) was added. 
The resulting mixture was further refluxed overnight at 80-83 

C. The cooled reaction 
mixture was acidified with acetic acid (2.10 mL) and partitioned with a mixture of ether 
and water. The organic layer was washed with water and brine and dried over MgSO4. 
Evaporation of the solvent left a colorless oil which was used for the next reaction step 
without further purification.  1H NMR (400 MHz, CDCl3): 12.2 (s, 1H), 5.54 (m, 2H), 
5.10 (m, 4H), 3.3 (s, 3H), 2.79 (dd, Jd = 14.10 Hz, Jd = 6.53 Hz, 1H), 2.52 (m, 1H), 2.41 
(dd, Jd = 14.79 Hz Jd = 10.32 Hz, 1H), 2.26 (m, 1H), 2.0-1.7 (m, 3H), 1.1 (m, 1H), 1.00 
(s, 3H), 0.8 (s, 3H). 
13
C NMR (400 MHz, CDCl3):  195.1, 158.6, 124.1, 123.7, 120.1, 
105.8, 103.5, 102.2, 42.7, 39.2, 29.6, 28.3, 24.4, 24.2, 20.4, 18.0, 14.6, 10.0, 9.5.  Calcd 
for  C16H24O3.  
 
 
 
322a 
 
 
 
 
Methyl (1R
*
,3S) 1,3,5-triallyl-4,4-dimethyl-2-oxocyclohexanecarboxylate (322a): 
 
A solution of crude keto ester (1.52 g, 5.00 mmol), allyl acetate (0.60 mL, 5.50 mmol), 
triethyl amine (0.50 mL, 5.50 mmol) and Pd(PPh3)4 (5 mol%, 0.28 g, 0.25 mmol) in 10 
mL of methanol was refluxed under nitrogen atmosphere overnight. The solution was 
evaporated to dryness under a vacuum, the residue was dissolved in ether and the solution 
was filtered through a short silica column. Solvents were evaporated, and the resulting 
O 
O 
O 
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yellow colored crude product was then chromatographed with 10% EtOAc and petroleum 
ether. The major diastereomer 322a (0.69 g, 2.30 mmol, 46%) was isolated. 1H NMR 
(400 MHz, C6D6): 5.83 (m, 2H), 5.48(m, 1H), 5.01 (m, 6H), 3.42 (s, 3H), 2.7 (dd, Jd = 
14.0 Hz Jd = 7 Hz, 2H), 2.48 (dd, dd, Jd = 7.3 Hz Jd = 3.5 Hz, 1H), 2.29 (dd,  dd, Jd = 2.4 
Hz Jd = 9.7 Hz, 1H), 2.20 (t, J = 13.5 Hz, 1H), 2.16 (dddd, Jd = 10.5 Hz Jd = 4.1 Hz Jd = 
1.5 Hz Jd = 1.8 Hz, 1H), 2.05 (dd, Jd = 14.3 Hz Jd = 3.3 Hz, 1H), 1.9 (dddd, Jd = 14.0 Hz 
Jd = 7.7 Hz Jd = 1.1 Hz Jd = 1.1 Hz, 1H), 1.52 (m, 2H), 0.8 (s, 3H), 0.3 (s, 3H).  Calcd for 
C19H28O3. 
 
 
 
2D NMR data for compound 322a 
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340 
 
 
 
(1R
*
,3R)-1,3,5-triallyl-4,4-dimethyl-2-oxocyclohexanecarboxaldehyde (340): 
 
The keto ester 322a (0.14 g, 0.46 mmol) was dissolved in 10 mL of dry ether and cooled 
to 0 

C. Then lithium aluminum hydride (0.05 g, 1.40 mmol) was added and slowly 
warmed to room temperature. The reaction mixture was stirred for 2.5 hours and again 
cooled to 0 

C, and then the reaction mixture was quenched with 0.05 mL of water, 0.05 
mL of 15% NaOH and 0.15 mL of water. White precipitate was filtered and the filtrate 
was collected in a round-bottom flask. The ether was evaporated and the crude product 
used to carry out the next reaction.  
The crude alcohol was dissolved in 3.8 mL of CH2Cl2 at room temperature. In a 
separate round-bottom flask, Dess–Martin periodinane (0.54 g, 1.3 mmol) was dissolved 
O 
H 
O 
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in 1.5 mL of CH2Cl2 and added slowly to the reaction mixture. This was then stirred 4 h 
at room temperature and after the reaction was complete, 1.3 mL of 1M NaOH was added 
and the organic component was extracted with ether. The ether layer was then washed 
with water and brine and dried with anhydrous Na2SO4. The organic solvents were 
evaporated and the remaining crude oil was chromatographed with 5% ethyl acetate and 
petroleum ether to give 0.064 g (50%, 0.232 mmol) of 340. 1H NMR (400 MHz, CDCl3): 
 9.48 (s, 1H), 5.57 (m, 1H), 5.52 (m, 2H), 5.05 (m, 6H), 2.74 (m, 1H), 2.44 (m, 2H), 
2.23 (m, 2H), 1.75 (m, 1H), 1.60 (m, 3H), 1.42 (m, 1H), 0.85 (s, 3H), 0.38 (s, 3H). Calcd 
for  C18H26O2.  
 
 
 
 
 342 
 
 
 
Methyl (Z)-3- ((1R
*
,3R)-1,3,5-triallyl-4,4-dimethyl-2-oxocyclohexyl)acrylate  (342): 
A solution of  bis(2,2,2-trifluoroethyl) (methoxycarbonylmethyl)phosphonate (0.3 g, 1.0 
mmol) in 20 mL of dry THF was cooled to –78 

C under nitrogen and treated with 
NaHMDS (0.5 mL, 2.0 M in THF, 1.0 mmol). The keto aldehyde 340 (0.27 g, 1.0 mmol) 
was then added and the resulting mixture was stirred for 1 h at –78 

C. TLC was taken 
and the reaction was quenched with saturated NH4Cl.  The products were extracted into 
ether ( 3 mL). The ether layer was then washed with water and brine and dried with 
anhydrous Na2SO4. The organic solvents were evaporated and the remaining crude oil 
was chromatographed with 5% ethyl acetate and petroleum ether to give 0.27 g (0.82 
mmol, 82%) of 342. 1H NMR (400 MHz, CDCl3): 6.60 (d, 13.07 Hz, 1H), 5.91 (d, 
13.07 Hz, 1H), 5.70 (m, 2H), 5.41 (m, 1H), 4.02 (m, 6H), 3.68 (s, 3H), 2.95 (m, 2H), 2.61 
(m, 1H), 2.58 (m, 2H), 2.41 (m, 2H), 2.10 (m, 1H), 1.95 (m, 1H), 2.64 (m, 1H), 1.14 (s, 
3H), 0,63 (s, 3H). 
13
C NMR (400 MHz, CDCl3): 210.0, 166.7¸147.4, 138.6, 137.8, 
O 
O 
O 
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133.1, 121.1, 118.4, 116.4, 115.3, 56.8, 54.2, 51.2, 43.8, 42.4, 40.7, 38.0, 34.7, 28.2, 27.2, 
15.2. Calcd for  C21H30O3. 
 
 321 
 
 
(Z)-3-((1R
*
,3R)-1,3,5-triallyl-4,4-dimethyl-2-oxocyclohexyl)acrylaldehyde (321): 
The enester 342 (0.14 g, 1.00 mmol) was dissolved in 20 mL of dry ether and cooled to 0 

C. Lithium aluminum hydride (0.11 g, 2.80 mmol) was added and slowly warmed to 
room temperature. The reaction mixture was stirred for 4 hours and again cooled to 0 

C, 
and then the reaction mixture was quenched with 0.1 mL of water, 0.1 mL of 15% NaOH 
and 0.3 mL of water. White precipitate was filtered and the filtrate was collected into a 
round-bottom flask. The ether was evaporated and the crude products used to carry out 
the next reaction.  
The crude alcohol was dissolved in 8 mL of CH2Cl2 at room temperature. In a 
separate round-bottom flask, Dess–Martin periodinane (1.08 g, 2.60 mmol) was dissolved 
in 3 mL of CH2Cl2 and added slowly to the reaction mixture. This was then stirred 4h at 
room temperature and after the reaction was completed, 2.6 mL of 1 M NaOH was added 
and the organic component was extracted with ether. The ether layer was then washed 
with water and brine and dried with anhydrous Na2SO4. The organic solvents were 
evaporated and the remaining crude oil was chromatographed with 5% ethyl acetate and 
petroleum ether to give 0.15 g (0.50 mmol, 50%) of 2. 1H NMR (400 MHz, CDCl3): 
9.53 (d, 7.91 Hz, 1H), 6.52 (d, 12.73 Hz, 1H), 5.99 (dd, Jd = 12.73 Hz, Jd = 8.26 Hz, 
1H), 5.71 (m, 2H), 5.43 (m, 1H), 5.0 ( m, 6H), 2.86 (dd, Jd = 14.1, Jd = 6.88 Hz, 1H), 2.58 
(m, 3H), 2.41 (ddd, Jd = 16.51 Hz, Jd = 5.16 Hz, Jd = 2.4 Hz, 1H), 2.31 (dd, Jd = 14.1 Hz, 
O 
O 
H 
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Jd = 3.78 Hz, 1H), 2.23 (ddd, Jd = 13.07 Hz, Jd = 7.23 Hz, Jd = 1.38 Hz, 1H), 1,94 (m, 
1H), 1.58 (m, 2H), 1.1 (s, 3H). 
13
C NMR (400 MHz, CDCl3):  209.9, 192.0, 150.1, 
138.0, 137.3, 131.64, 131.1, 120.0, 117.0, 115.9, 57.3, 55.3, 43.8, 43.6, 42.7, 41.8, 34.6, 
28.0, 27.0, 15.4. Calcd for  C20H28O2.                        
 
 
 
346 
 
 
 
(2Z,4aR
*
,6R,9S)-4a,6,8-Triallyl-7,7-dimethyl-4a,5,6,7,8,8a-hexahydro-2H-chromen-
2-one (346): 
The enal 342 (0.03 g, 0.10 mmol) was dissolved in THF (0.50 mL) and 
t
BuOK was added 
slowly at the room temperature. Then the mixture was stirred for 3 h and TLC was taken. 
The reaction was quenched with water and extracted with ether (5 mL). The ether layer 
was then washed with water and brine and dried with anhydrous Na2SO4. The organic 
solvents were evaporated and the remaining crude oil was chromatographed with 5% 
ethyl acetate and petroleum ether. 1H NMR (400 MHz, CDCl3):  6.63 (d, 9.63 Hz, 1H), 
6.0 (m, 1H), 5.9 (d, 9.28 Hz, 1H), 5.56 (m, 2H), 5.0 (m, 6H), 4.0 (d, 12.04 Hz, 1H), 2.44 
(dd, 8.26 Hz, 1H), 2.30 (m, 1H), 2.20 (m, 4H), 1.65 ((ddd, Jd = 10.04 Hz, Jd = 5.16 Hz, Jd 
= 4.470Hz, 1H), 1.55 (m, 1H), 1.42 (m, 1H), 1.25 (s,3H), 0.66 (s, 3H).
13
C NMR (400 
MHz,CDCl3):  

Calcd for  C20H28O2. 
 
 
O 
O 
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350 
 
 
Methyl 5-allyl-6,6-dimethyl-2-oxocyclohexanecarboxylate (350): 
 
To a stirred suspension of copper(I) iodide (1.90 g, 10.0 mmol ) in dry diethyl ether (41.5 
mL) at –5 

C, MeLi (1.6 M in diethyl ether, 12.5 mL, 20.0 mmol) was added under 
nitrogen atmosphere. The mixture was stirred at the same temperature (–5 

C) for 1 h, 
and  4-allyl-3-methylcyclohexenone (0.75 g, 5.0 mmol) in 3.6 mL of dry diethyl ether 
was added very slowly. The reaction mixture was stirred for 1 h further at 0 

C. HMPA ( 
6 mL, 36 mmol) was then added dropwise under vigorous stirring.  The mixture was 
cooled to –78  

C, and methyl cyanoformate (2.4 mL, 24 mmol) and diethyl ether (6 mL) 
were added slowly. The dry ice bath was removed, and the mixture was allowed to warm 
to room temperature. After stirring 1 h at room temperature saturated aqueous NH4Cl/ 
NH4OH solution was added and the organic phase was extracted multiple times with 
ether. The organic layers were combined, washed with brine and dried with anhydrous 
NaSO4, and the solvent was evaporated. The resulting yellow crude product was then 
chromatographed with 10% EtOAc and petroleum ether and 1.59 g (71%, 7.1 mmol) of a 
mixture of diastereomers (350) was isolated. 1H NMR (400 MHz, CDCl3):  11.92 (s, 
1H), 5.79 (m, 1H), 5.0 (m, 2H), 3.7 (s+m, 3H), 3.1 (s, 1H), 2.82 (m, 1H), 2.38 (m, 2H), 
2.2 (m, 1H), 2.05 (m, 1H), 1.70 (m, 1H), 1.4 (m, 1H), 1.05 (s+s, 3H), 0.83 (s+s, 3H). 
Calcd for  C13H20O3.   
 
 
 
 
O 
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353 
 
 
Methyl 5-allyl-2-allyloxy-6,6-dimethyl-1-cyclohexenecarboxylate (353): 
 
NaH (60% in oil, 0.53 g, 13.1 mmol) was washed with petroleum ether (10.0 mL, 3 
times) in a 100 mL round-bottom flask and THF (26 mL) was added. The suspension was 
cooled to 0 

C, and methyl 3-allyl-2,2-dimethyl-6-oxocyclohexanecarboxylate (350) 
(2.54 g, 11.4 mmol) in THF (26 mmol) was added dropwise over 5 min. The ice bath was 
removed and the reaction mixture was allowed to warm to room temperature. The 
reaction was stirred at room temperature for 1 h and allyl bromide (1.15 mL, 13.1 mmol) 
dissolved in THF (1.40 mL) was added dropwise. After the addition, the reaction mixture 
was stirred at 60 

C for 36 h. TLC was taken, and the reaction mixture was then cooled in 
an ice bath with water (10 mL) added dropwise. The organic components were extracted 
with ether (20 mL, 3 times) and the organic layers were combined, washed with water 
and brine, dried with anhydrous NaSO4 and filtered. The filtrate was evaporated under 
reduced pressure. The crude oil was chromatographed with 10% ethyl acetate and 
petroleum ether to give 2.25 g (75%, 8.55 mmol) of 353. 1H NMR (400 MHz, CDCl3): 
5.85 (m, 1H), 5.73 (m, 1H), 5.26 ( d, 17.12 Hz, 1H), 5.13 ( d, 10.79 Hz, 1H), 5.0 (m, 
2H), 4.23 (s, 2H), 3.71 (s, 3H), 2.3 ( d, 13 Hz, 1H), 2.14 (m, 1H), 1.8 (m, 1H), 1.68 (dd, 
Jd = 23.08 Hz Jd = 10.05 Hz, 1H), 1.4 (m, 1H), 1.28 (m,1H), 1.07 (s, 3H), 0.8 (s, 3H). 13C 
NMR (400 MHz, CDCl3):  170.2, 152.2, 138.3, 121.6, 116.7, 116.2, 68.6, 51.5, 43.4, 
36.1, 34.0, 27.3, 24.1, 22.6, 22.5.  Calcd for  C16H24O3. 
 
O 
O 
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354a 
Methyl (4R*,6S)-1,3-diallyl-2,2-dimethyl-6-oxocyclohexanecarboxylate: (354a) 
 
Methyl 5-allyl-2-(allyloxy)-6,6-dimethyl-1-cyclohexenecarboxylate (353) (2.18 g, 8.27 
mmol)  and dry toluene (26 mL) were heated at 150 

C for 8 h in a sealed (pressure) tube. 
TLC was taken, toluene was removed and crude oil was chromatographed with 10% ethyl 
acetate and petroleum ether to give 2.18 g (100%, 8.27 mmol) of  354a in 3:1 
diastereomeric ratio. 1H NMR (400 MHz, CDCl3): 5.70 (m, 1H), 5.60 (m, 1H), 5.01 
(m, 4H), 3.70 (s, 3H), 2.72 (m, 1H), 2.55 (m, 2H), 2.37 (ddd, Jd = 12.86 Hz, Jd = 5.55 Hz, 
Jd = 1.76 Hz, 1H), 2.22 (m, 1H), 1.94 (m, 1H), 1.81 (m, 2H), 1.58 (m, 1H),  1.05 (s, 3H), 
0.9 (s, 3H). 13C NMR (400 MHz, CDCl3):  207.6, 171.1, 137.6, 134.0, 117.5, 116.5, 
68.7, 51.5, 42.6, 42.5, 38.0, 35.3, 33.8, 25.2, 24.6, 21.5 IR (neat): 3076, 2976, 2948, 
1745, 1713, 1639, 1434, 1225 cm-1. Calcd for  C16H24O3.   
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2D NMR data for 354a 
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355 
 
 
Methyl(4R*,6R)-1,5-diallyl-2-methoxy-6,6-dimethyl-2-cyclohexenecarboxylate (355): 
 
Methyl 1,3-diallyl-2,2-dimethyl-6-oxocyclohexanecarboxylate (354a) (0.52 g, 2.00 
mmol) and dry trimethyl orthoformate (10 mL) in methanol (2 mL) were added to a 100 
mL round-bottom flask at room temperature. Then, a few drops of conc. H2SO4 were 
added and stirred at room temperature for 48 h. After completion of the reaction, the 
solvents were completely removed. Saturated NaHCO3 was added, and the organic 
components were extracted with ether. The organic phase was washed with water and 
brine and dried using anhydrous Na2SO4. The organic solvents were evaporated, and the 
remaining crude oil was chromatographed with 5% ethyl acetate and petroleum ether to 
give 0.52 g (1.90 mmol, 95%,) of 355. 1H NMR (400 MHz, CDCl3): 5.73 (m, 2H), 4.89 
(m, 2H), 4.86 (d, 10.5 Hz, 1H), 4.47 (d, 4.84 Hz, 1H), 3.62 (s, 3H), 3.41 (s, 3H), 2.78 (m, 
1H), 2.51 (dd, Jd = 9.3 Hz, Jd = 14.52, 1H), 2.26 (m, 1H), 2.12 (dt, Jd = 16.9, Jt = 5.58, 
1H), 1.8-1.6 (m, 3H), 1.00 (s, 3H), 0.69 (s, 3H). 
13
C NMR (400 MHz, CDCl3): 174.0, 
154.4, 138.3, 137.1, 115.8, 115.0, 96.1, 59.6, 54.3, 51.4, 39.2, 38.8, 38.3, 34.3, 26.8, 22.5, 
20.1. Calcd for  C17H26O3. 
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371 
 
(4R*,6S)-1-Methoxy- 6-hydroxymethyl-4,4-diallyl-5,5-dimethylcyclohexene (371): 
 
The ester (355) (3.50 g, 12.6 mmol) was dissolved in 126 mL of dry ether and the 
mixture was cooled in an ice bath. Then LiAlH4 (0.76 g, 20.1 mmol) was added very 
slowly. After addition was completed, the ice bath was removed and the mixture was 
stirred 4 h at room temperature. TLC was taken and the reaction mixture was again 
cooled to 0 

C. Then 0.75 mL of water and 0.75 mL of 10% NaOH were added. A few 
minutes later another 2 mL of water was added. The reaction mixture was diluted with 
ether and the solution was filtered. The filtrate was concentrated and the resulting 
colorless oil was oxidized.  1H NMR (400 MHz, CDCl3): 5.83 (m, 1H), 5.77 (m, 1H), 
4.95 (m, 4H), 4.72 (d, 3.35 Hz, 1H), 3.75 (dd, Jd = 11.92, Hz, Jd = 5.96 Hz, 1H), 3.64 (dd, 
Jd = 11.16, Hz, Jd = 8.19 Hz, 1H), 3.42 (s, 3H), 2.50 (m, 1H), 2.24 (m, 3H), 2.11 (dt, Jd = 
16.74, Hz, Jt = 5.22 Hz, 1H), 1.80 (m, 1H), 1,64 (m, 2H), 0.90 (s, 3H), 0.82 (s, 3H). 13C 
NMR (400 MHz, CDCl3):  157.3, 138.6, 138.1, 115.5, 114.9, 95.7, 65.4, 54.0, 49.8, 
39.1, 38.3, 38.2, 34.4, 27.1, 22.0, 17.9. Calcd for  C16H26O2. 
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356 
 
(1R
*
,5R)-1,5-diallyl-2-methoxy-6,6-dimethyl-2-cyclohexenecarboxaldehyde (356): 
The crude alcohol (371) was dissolved in 100 mL of CH2Cl2 at room temperature. In a 
separate round-bottom flask, Dess–Martin periodinane (7.50 g, 17.6 mmol) was dissolved 
in 40 mL of CH2Cl2 and added slowly to the reaction mixture. This was then stirred 4h at 
room temperature. After the reaction was complete, 75 mL of 1M NaOH was added and 
the organic components were extracted with ether. The ether layer was then washed with 
water and brine and dried with anhydrous Na2SO4. The organic solvents were evaporated 
and the remaining crude oil was chromatographed with 5% ethyl acetate and petroleum 
ether to give 3.34 g (11.2 mmol, 89%) of 356.  1H NMR (400 MHz, CDCl3): 9.61 (s, 
1H), 5.70 (m, 2H), 4.95 (m, 5H), 3.41 (s, 3H), 2.70 (dd, Jd = 8.57 Hz, Jd = 5.24 Hz, 1H), 
2.21 (m, 3H), 1.7 (m, 3H), 0.93 (s, 3H), 0.87 (s, 3H). 13C NMR (400 MHz, CDCl3):  
205.1, 154.1, 137.9, 136.6, 116.0, 114.8, 96.0, 60.6, 54.2, 40.0, 38.2, 35.4, 33.6, 27.3, 
22.2, 18.3. IR (neat): 3074, 2974, 2925, 2834, 1724, 1672, 1639, 1212 cm-1. Calcd for  
C16H24O2.   
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(4R,6R
*
)-4,6-diallyl-6-ethynyl-5,5-dimethylcyclohex-1-en-1-yl methyl ether (357): 
 
THF (27 mL) and hexane (3.5 mL) were added to a round-bottom flask and cooled to –78 

C under nitrogen. Then trimethylsilyldiazomethane (2 M in ether, 3.60 mL, 7.20 mmol) 
was added  to the above mixture at –78 

C, and after a few minutes BuLi (2.4 M in 
hexane, 3.00 mL, 7.20 mmol) was added. The reaction mixture was stirred 10 to 15 
minutes at the same temperature, and aldehyde 356 (5.96 mmol, 1.47 g) in 24 mL of THF 
was added slowly. The reaction mixture was stirred for another 10 to 15 minutes at –78 

C and warmed to 0 

C. After warming to 0 

C, the reaction mixture was stirred 1 h 
before completely warming to room temperature. After completely warming to room 
temperature the reaction was quenched with water and the organic components were 
extracted with ether. The ether layer was then washed with brine and dried with 
anhydrous Na2SO4. The organic solvents were evaporated and the remaining crude oil 
was chromatographed with 5% ethyl acetate and petroleum ether to give 0.96 g (3.96 
mmol, 67%) of 357. 1H NMR (400 MHz, CDCl3): 5.98 (m, 1H), 5.72 (m, 1H), 5.04-
4.90 (m, 4H), 4.55 (m, 1H), 3.4 (s, 3H), 2.56 (dd, Jd = 13.4, Hz, Jd = 5.95 Hz, 1H), 2.40 
(dd, Jd = 13.4, Hz, Jd = 8.19 Hz, 1H), 2.31 (dd, Jd = 6.33 Hz, Jd = 2.31 Hz, 1H), 2.23 (s, 
1H), 2.16 (dt, Jd = 17.12 Hz, Jt = 4.47 Hz, 1H), 1.78 (m, 2H), 1.63 (m, 1H), 1.08 (s, 3H), 
1.00 (s, 3H). 13C NMR (400 MHz, CDCl3):  154.7, 138.1, 136.5, 115.8, 115.1, 93.3, 
85.7, 71.9, 54.4, 43.0, 39.6, 37.1, 35.4, 27.3, 23.3, 23.2, 19.3. IR (neat): 3304, 3075, 
2975, 2941, 2833, 2109, 1669, 1639, 1216 cm-1.  Calcd for  C17H24O. 
O 
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358 
 
(4R
*
,6R)-1-Allyloxy-4,6-diallyl-6-ethynyl-5,5-dimethylcyclohexene (358): 
 
To a 25 mL round-bottom flask benzene (3.75 mL), allyl alcohol (0.70 mL) and p-
TsOH∙H2O (0.001 g, 0.005 mmol) were added and then refluxed for 1 h with a Dean-
Stark apparatus. The reaction mixture was then cooled to room temperature and methyl 
enol ether 357 (0.06 g, 0.25 mmol) in 1.25 mL of benzene was added. The reaction 
mixture was allowed to reflux for 2 h, and after the reaction was complete, the mixture 
was cooled to room temperature. The solvent was removed completely, and saturated 
NaHCO3 was added. The organic layer was extracted with ether (25 mL) and washed 
with water (10 mL) and brine (10 mL). The separated organic layer was dried with 
anhydrous NaSO4 and the solvent was removed to get the crude product. The crude oil 
was chromatographed with 5% ethyl acetate and petroleum ether to give 0.065 g (96%, 
0.24 mmol) of 358.  1H NMR (400 MHz, CDCl3): 6.03 (m, 1H), 5.9 (m, 1H), 5.72 (m, 
1H), 5.33 (d, 17.49 Hz, 1H), 5.14 (d, 10.79 Hz, 1H), 4.95 (m, 4H), 4.54 (s, 1H), 4.22 (dd, 
Jd = 13.03 Hz, Jd = 3.72 Hz, 1H), 4.04 (dd, Jd = 13.03 Hz, Jd = 3.35 Hz, 1H), 2.56 (dd, Jd = 
13.4, Hz, Jd = 5.95 Hz, 1H), 2.40 (dd, Jd = 13.4, Hz, Jd = 8.19 Hz, 1H), 2.30 (m, 1H), 2.20 
(s, 1H), 2,15 ((dt, Jd = 17.5 Hz, Jt = 3.72 Hz, 1H), 1.74 (m, 2H), 1.62 (dd, Jd = 8.55 Hz, Jd 
= 16.75 Hz, 1H), 1.08 (s, 3H), 1.00 (s, 3H).  
13
C NMR (400 MHz, CDCl3) : 153.5, 
138.2, 136.8, 133.8, 116.3, 115.8, 114.9, 94.5, 85.6, 72.0, 67.7, 50.0, 43.0, 39.6, 37.1, 
35.4, 27.3, 23.3, 19.3. IR (neat): 3306, 3076, 2975, 2922, 2359, 1669, 1639, 1205 cm
-1
. 
Calcd for  C19H26O. 
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Methyl3-[(1S
*
,5R)-1,5-diallyl-2-allyloxy-6,6-dimethyl-2-cyclohexen-1-yl]-2-
propynoate (359): 
 
PdCl2 (3.54 mg, 0.02 mmol), CuCl2 (144 mg, 0.85 mmol), and NaOAc (69.9 mg, 0.85 
mmol) were placed in a 25 mL round-bottom flask and alkyne 358 (108 mg, 0.40 mmol) 
in methanol (4.24 mL) were added. A rubber balloon filled with carbon monoxide was 
attached to the flask, and mixture was allowed to stir at room temperature. The green 
solution turned black after 2 h, and the reaction was stopped by adding 2 mL of water. 
The organic layer was extracted with ether (10 mL) and then EtOAc (5 mL). The organic 
fractions were combined and washed with brine and dried over anhydrous NaSO4. The 
crude oil was chromatographed with 5% ethyl acetate and petroleum ether to give (0.28 
mmol, 0.09 g, 72% yield) of 359. 1H NMR (400 MHz, CDCl3):  6.02-5.84 (m, 2H), 5.7 
(m, 1H), 5.34 (dd, Jd = 17.43 Hz, Jd = 1.47 Hz, 1H), 5.53 (dd, Jd = 10.58 Hz, Jd = 1.47 
Hz,1H), 5.02-5.46 (m, 4H), 4.54 (m, 1H), 4.20 (dd, Jd = 13.22 Hz, Jd = 4.47 Hz, 1H), 4.00 
(dd, Jd = 13.23 Hz, Jd = 2.94 Hz, 1H), 3.70 (s, 3H), 2.58 (dd, Jd= 13.81 Hz, Jd = 6.17 Hz, 
1H), 2.43 (dd, Jd = 13.52 Hz, Jd = 8.23 Hz, 1H), 2.29 (dd, Jd = 9.70 Hz, Jd = 5.88 Hz, 1H), 
2.15 (dt, Jd = 17.34 Hz, Jt = 4.41 Hz, 1H), 1.74 (m, 2H), 1,62 (dd, Jd = 8.23 Hz, Jd = 17.34 
Hz, 1H), 1.06 (s, 3H), 0.90 (s, H). 13C NMR (400 MHz, CDCl3):  152.3, 137.8, 135.8, 
133.5, 116.2, 116.0, 115.6, 94.8, 91.2, 76.5, 67.5, 52.6, 42.4, 40.0, 37.1, 35.1, 27.2, 23.6, 
19.5. IR (neat):  3409, 3076, 2975, 2949, 2840, 2231, 1715, 1672, 1640, 1434, 1244 cm
-1
. 
Calcd for  C21H28O3. 
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3-[(1S
*
,5R)-1,5-diallyl-2-allyloxy-6,6-dimethylcyclohex-2-en-1-yl]-2-propyn-1-ol: 
 
The alkyne ester (359) (1.30 g, 3.99 mmol) was dissolved in 40 mL of dry ether and the 
mixture was cooled to –78 

C in a dry ice/acetone bath. Then LiAlH4 (0.242 g, 6.38 
mmol) was added very slowly. After addition was completed, reaction mixture was 
warmed to 30 

C and stirred for 6 h. TLC was taken and 0.24 mL of water and 0.24 mL 
of 10% NaOH were added. A few minutes later another 0.7 mL of water was added. The 
reaction mixture was diluted with ether and the solution was filtered. Then the crude 
eluted with 15% EtOAc in petroleum ether. Solvent was evaporated and pure alcohol was 
obtained 1.12 g (94%, 3.73 mmol). 1H NMR (400 MHz, CDCl3): 5.99 (m, 1H), 5.9 (m, 
1H), 5.7 (m, 1H), 5.32 (d, 17.2 Hz, 1H), 5.13 (d, 10.8 Hz, 1H), 5.52 (m, 4H), 4.52 (s, 
1H), 4.28 (d, 5.20 Hz, 2H), 4.2 (d, 13.2 1H), 4.02 (d, 12.4 Hz, 1H), 2.5 (dd, Jd = 14.00 
Hz, Jd = 6.00 Hz, 1H), 2.37 (dd, Jd = 12.8 Hz, Jd = 8.4 Hz, 1H), 2.3 (m, 1H), 2,14 (d, 17.2 
Hz, 1H), 1.86 (m, 1H), 1.73 (m, 2H), 1.62 (dd, Jd = 7.6 Hz, Jd = 17.2 Hz, 1H), 1.01 (s, 
3H), 0.99 (s, 3H). 
13
C NMR ( 400 MHz, CDCl3):  153.7, 138.2, 136.9, 133.9, 116.2, 
115.8, 114.8, 94.6, 87.1, 82.3, 77.4, 67.6, 51.7, 43.0, 39.8, 37.1, 35.4, 27.4, 23.5, 19.5. IR 
(neat): 3395, 3074, 2973, 2919, 1669, 1639, 1204 cm
-1
. Calcd for  C20H28O2. 
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2,4,6-triallyl-2-(3-hydroxy-1-propyn-1-yl)-3,3-dimethylcyclohexanone (360): 
 
O-allyl enol ether (1.12 g, 3.73 mmol) and dry pyridine (33 mL) were heated at 150 

C 
for 1.5 h in a sealed (pressure) tube. TLC was taken, pyridine was removed and crude 
was isolated as a brown/red colored oil. The crude was purified using column 
chromatography and the pure compound 360 (0.83 g, 2.79 mmol, 75%) was isolated. 1H 
NMR (400 MHz, CDCl3):  5.70 (m, 3H), 5.05 (m, 6H), 4.33 (d, 5.55 Hz, 2H), 2.75 (m, 
1H), 2.45 (m, 3H), 2.31 ( m, 1H), 2.04 (m, 1H), 1.92 (m, 2H), 1.75 (m, 1H), 1.66 (m, 
2H), 1.18 (s, 3H), 0.80 (s, 3H). 
13
C NMR (400  
MHz, CDCl3):  208.3, 137.6, 136.4, 133.1, 118.3, 116.7, 116.6, 85.7, 84.9, 62.0, 51.6, 
45.9, 44.5, 40.4, 39.0, 35.3, 34.5, 34.1, 24.0, 19.1. IR (neat): 3434, 3075, 2973, 2937, 
2834, 1715, 1640, 912 cm
-1
.  Calcd for  C20H26O2. 
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3-((1S
*
, 3R)-1,3,5-triallyl-2,2-dimethyl-6-oxocyclohexyl)-2-propynal (361): 
 
The alcohol 360 (825 mg, 2.77 mmol) was dissolved in 20 mL of CH2Cl2 at room 
temperature. In a separate round-bottom flask, Dess–Martin periodinane (1.53 g, 3.60 
mmol) was dissolved in 7.7 mL of CH2Cl2 and added slowly to the reaction mixture. 
Then the mixture was stirred for 3 h at room temperature and after the reaction was 
complete, 15 mL of 1M NaOH was added and the organic components were extracted 
with ether. The ether layer was then washed with water and brine and dried with 
anhydrous Na2SO4. The organic solvents were evaporated and the remaining crude oil 
was chromatographed with 5% ethyl acetate and petroleum ether to give 0.68 g of 361 
(2.29 mmol, 83%). 1H NMR (400 MHz, CDCl3): 9.21 (s, 1H), 5.63 (m, 3H), 5.0 (m, 
6H), 2.80 (dd, Jd = 12.81 Hz, Jd = 8.24 Hz, 1H), 2.54-2.34 (m, 3H), 2.65 (d, 12.11 Hz, 
1H), 2.4 (dd, Jd = 16.30 Hz, Jd= 4.35 Hz, 1H), 1.9 (m, 2H), 1.65 (m, 2H), 1,10 (s, 3H), 
0,84 (s, 3H). 
13
C (400 MHz, CDCl3):  207.1, 177.0, 137.1, 121.8, 119.3, 117.0, 116.9, 
96.9, 87.5, 62.8, 44.9, 44.7, 40.3, 38.2, 34.9, 34.3, 33.9, 24.0, 19.2. IR (neat): 3077, 2975, 
2940, 2212, 1716, 1667, 1640 cm
-1
. Calcd for  C20H26O2. 
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2-Triethylsilyl-3-(1,3,5-triallyl-2,2-dimethyl-6-oxocyclohexyl)acrylaldehyde (362): 
 
Co2(CO)8 (0.31 g, 0.91 mmol) was added to a solution of eynal 361 (0.24 g, 0.81 mmol) 
in CH2Cl2 (6.5 mL) at 0 °C. After about 7 h at room temperature, TLC was taken and  the 
solvent was evaporated.  The residue was filtered through a short column of silica gel, 
eluting with hexane (the brown eluant was discarded) and then with 30% EtOAc in 
petroleum ether.  The solvent was evaporated and resulted in the Co2(CO)6 complex of 
enal (0.28 g, 0.48 mmol, 87% yield) as a dark red oil.   
 The complex (0.28 g, 0.48 mmol,) was redissolved in dry (CHCl)2 (3.25 mL), and 
bis(trimethylsilyl)acetylene (0.22 g, 0.98 mmol) and triethylsilane ( 0.40 mL, 2.80 mmol) 
were added. The mixture was stirred at 65 °C for 2 h (monitored by TLC).  The solvent 
was evaporated, and the residue was filtered through a short column of silica gel, eluting 
with hexane (the brown eluant was discarded) and then with 10% EtOAc in petroleum 
ether.  The solvent was evaporated to provide enal 362 (0.11 g, 0.28 mmol, 58% yield) as 
a colorless liquid.   
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Four drops of 6 M HCl were added to a solution of enal (0.20 g, 0.48 mmol) in THF (5 
mL). After 4.5 h (monitored by TLC), water was added.  The aqueous layer was extracted 
with ether (2  30 mL), and the combined organic layers were washed with brine, dried 
over MgSO4, and then evaporated. The remaining crude oil was chromatographed with 
10% ethyl acetate and petroleum ether to give two diastereomers.  
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, CDCl3): 5.85 (s+m, 2H), 5.55 (m,1H), 5.47 (m, 1H), 5.13-4.88 
(m, 6H), 4.17 (d, 7.91 Hz, 1H), 2.74 (dd, Jd =13.2 Hz, Jd = 5.20 Hz, 1H), 2.38 (dd, Jd = 
8.0 Hz, Jd = 7.20 Hz, 2H), 2.14 (d, 10.4 Hz, 1H), 1.88 (dd, Jd = 13.2 Hz, Jd = 8.80 Hz, 
1H),  1.75 (dd, Jd = 14.00 Hz, Jd = 3.60 Hz, 1H), 1.6 ( t, 13.2 Hz, 1H), 1.1 (m, 1H), 0.92 
(t, 8 Hz, 9H), 0.88 (s, 3H), 0.87 (s, 3H), 0.63 (m, 6H).   
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1H NMR (400 MHz, CDCl3): 6.0 (m, 1H), 5.66 (s, 1H), 5.58 (m, 1H), 5.38 (m, 1H), 
5.15 (d, 16.99 Hz, 1H), 5.04 (d, 9.96 Hz, 1H), 4.98 (m, 4H), 4.15 (d, 5.57 Hz, 1H), 2.72 
(dd, Jd = 13.6 Hz, Jd = 5.20 Hz, 1H), 2.44 (d, 8.4 Hz, 2H), 2,20 (d, 14.8, 1H), 2.13 (dd, Jd 
= 14.0 Hz, Jd = 13.60 Hz, 1H), 1.92 (dd, Jd = 13.2 Hz, Jd = 8.80 Hz, 1H), 1.85 (d, 6.8 Hz, 
1H), 1.68 (m, 1H), 1.31( m, 1H), 1.06 (m, 1H), 0.94(t, 7.6 Hz, 9H), 0,93 (s, 3H), 0,91 (s, 
3H), 0.65 (m, 6H). 
 
 
 
372 
 
 
 
3-triethylsilyl-1,5,7-triallyl-6,6-dimethylbicyclo[3.3.1]non-3-ene-2,9-dione (372) 
 
The crude alcohol (without separating the diastereomers) (0.05 g, 0.13 mmol) was 
dissolved in 2.00 mL of CH2Cl2 in 25 mL round-bottom flask under nitrogen. The Dess–
Martin periodinane (0.08 g, 0.18 mmol) was dissolved in 0.5 mL of CH2Cl2 and added to 
the reaction mixture and stirred for 2 h at room temperature. The reaction was quenched 
by adding 0.25 mL of 1 M NaOH and the product was extracted with ether. The organic 
layer was washed with brine, dried with anhydrous NaSO4, and evaporated in the solvent. 
The remaining crude oil was used to do the next reaction. 1H NMR (400 MHz, CDCl3):  
6.85 (s, 1H), 5.8 (m, 1H), 5.48 (m, 1H), 5.36 (m, 1H), 5.10-4.84 (m, 6H), 2.88 (dd, Jd = 
O 
H O 
S i E t 3 
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13.39 Hz, Jd = 4.10 Hz, 1H), 2.46 (dd, Jd = 13.77 Hz, Jd = 6.7 Hz, 1H), 2.39 (dd, Jd = 
13.77 Hz, Jd = 7.82 Hz, 1H), 2.2 (d, 3.77 Hz, 1H), 2.0 (m, 3 H), 1.72 (m, 2H), 1.32 (m, 
1H), 1.05 (s, 3H), 0.80 (s, 3H), 0.85 (t, 7.83 Hz, 9H), 0.64 (m, 6H). 
13
C NMR (400 MHz, 
CDCl3):  209.7, 202.4, 162.9, 138.6, 137.2, 134.5, 134.3, 118.6, 118.4, 177.6, 65.3, 
58.3, 45.4, 37.3, 35.3, 34.7, 37.7, 26.0, 20.47, 7.5, 2.9. IR (neat): 3435, 3056, 2956, 2876, 
1724, 1664, 1639, 1585, 1418 cm
-1
.  
 
 
 
348 
 
 
 
 
3-((1R
*
, 3R)-1,3,5-triallyl-2,2-dimethyl-6-oxocyclohexyl)acrylaldehyde (348): 
Ynal 361 (90.0 mg, 0.30 mmol) and Pd(PPh3)4 (17.3 mg, 0.01 mmol, 5 mol%) were 
dissolved in 0.3 mL of dry THF under nitrogen and cooled to 0 

C. Bu3SnH (0.08 mL, 
0.31 mmol) in 0.3 mL of THF was added dropwise via syringe and stirred at 0 

C for 1 h. 
After completion, the reaction THF was removed by a rotary evaporator and cold pentane 
(10 mL) was added. The precipitated Pd was removed by filtering the solution through a 
cilite column. Then, pentane was removed and the collected yellow colored crude oil 
crude was chromatographed with 5% ethyl acetate and petroleum ether to give 0.07 g 
(0.25 mmol, 84%) of 348. 1H NMR (400 MHz, CDCl3): 9.7 (d, 7.94 Hz, 1H), 6.49 (d, 
13.51 Hz, 1H), 6.10 (dd, Jd = 13.23, Hz, Jd = 7.93 Hz, 1H), 3.03 (dd, Jd = 15.28, Hz, Jd = 
7.5 Hz, 1H), 2.68 (m, 2H), 2.45 (m, 1H), 2.31 (dd, Jd = 13.52, Hz, Jd = 3.82 Hz, 1H), 2.11 
(m, 2H), 1.95 (ddd, Jd = 14.11, Hz, Jd = 7.35 Hz, Jd = 6.76 Hz, 1H), 1.68 (ddd, Jd = 13.52, 
Hz, J d= 9.40 Hz, Jd = 4.12 Hz, 1H), 1.08 (s, 3H), 0.70 (s, 3H). 
13
C NMR (400 MHz, 
CDCl3):  211.6, 193.2, 145.1, 137.4, 136.2, 132.4, 132.1, 119.7, 117.0, 116.9, 64.4, 
45.6, 45.5, 40.8, 38.2, 35.2, 34.8, 34.3, 22.9, 18.9. IR (neat): 3076, 2975, 2938, 1705, 
1673, 1640, 1440, 1370, 914 cm
-1
. Calcd for  C20H28O2. 
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 373 
 
1,5,7-Triallyl-4-hydroxy-8,8-dimethylbicyclo[3.3.1]non-2-en-9-one (373): 
 
Cis-enal (348) (0.96 g, 0.32 mmol) was dissolved in 3.2 mL of ethanol under nitrogen 
atmosphere. Then, NaOEt (0.04 g, 0.64 mmol) was added slowly to the above reaction 
mixture and stirred at room temperature for 2 h. The reaction mixture was quenched by 
adding water, (1 mL) and the organic compounds were extracted in ether (10 mL) in 
multiple extractions. Collected organic layers were pooled and solvent was removed.  
Without purification the crude alcoholic compound was subjected to the next step.  
 
 
 
364 
 
 
 
 
(1R
*
,5R,7R)-1,5,7-Triallyl-6,6-dimethylbicyclo[3.3.1]non-3-ene-2,9-dione (364): 
The crude alcoholic compound was dissolved in 3.23 mL of CH2Cl2 in 25 mL round-
bottom flask under nitrogen. The Dess–Martin periodinane (0.20 g, 0.48 mmol) was 
dissolved in 1 mL of CH2Cl2, added to the reaction mixture, and stirred for 2 h at room 
temperature.  The reaction was quenched by adding 2 mL of 1 M NaOH and extracted in 
ether. The organic layer was washed with brine, dried with anhydrous NaSO4, and 
evaporated in the solvent, and the remaining crude oil was chromatographed with 5% 
ethyl acetate and petroleum ether to give 0.08 g (0.28 mmol, 88% for 2 steps) of yellow 
solid 364. 1H NMR (400 MHz, CDCl3): 6.8 (d, 10.25 Hz, 1H), 6.13 (d, 10.2 Hz, 1H), 
O 
H O 
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5.82 (m, 1H), 5.44 (m, 2H), 5.0 (m, 6H), 2.91 (dd, Jd = 14.0, Hz, Jd = 5.2 Hz, 1H), 2.56 
(m, 2H), 2.45 (m, 2H), 2.27 (m, H), 2.05 (m, 3H), 1.84 (ddd, Jd = 16.0 Hz, Jd = 10.4 Hz, 
Jd = 4.0 Hz, 1H), 1.4 (m, 1H), 1.01 (s, 3H), 0.99 (s, 3H). 13C NMR (400 MHz, CDCl3):  
209.1, 199.5, 153.4, 137.4, 134.1, 134.1, 129.4, 118.8, 118.8, 117.1, 64.5, 57.2, 45.2, 
38.0, 35.7, 34.7, 34.6, 29.9, 26.3, 21.1. IR (neat): 3076, 2976, 1727, 1678, 1639, 1614 
cm
1
. Calcd for  C20H26O2. 
 
  
368                                    
 
 
 
(1R
*
,5R
*
,7R,4R)-1,5,7-Triallyl-4-hydroxy-4,8,8-trimethylbicyclo[3.3.1]non-2-en-9-
one (368): 
 
The bicyclic enone 364 (0.03 g, 0.10 mmol) was dissolved in 1.5 mL of THF under 
nitrogen. Then, the reaction mixture was cooled to 0 

C and MeLi (0.11 mmol, 1.6 M in 
Et2O, 0,06 mL) was added. TLC was taken after 3 h at 0 

C, and the reaction was 
quenched with water. The organic layer was extracted with ether, and the ether layer was 
then washed with water, brine, and dried with anhydrous Na2SO4. The organic solvents 
were evaporated, and the remaining crude oil was chromatographed with 5% ethyl 
acetate and petroleum ether to give 0.023 g (0.07 mmol, 75%) of 368.  1H NMR (400 
MHz, CDCl3): 5.92 (m, 1H), 5.6 (d, 9.99 Hz, 1H), 5.56 (m, 1H), 5.42 (d, 10.28 Hz, 
1H), 5.35 (m, 1H), 5.12 (d, 17.05 Hz, 1H), 5.03 (d, 9.99 Hz, 1H), 4.93 (m, 4H), 2.69 (dd, 
Jd = 13.51, Hz, Jd = 5.87 Hz, 1H), 2.50 (dd, Jd = 13.51, Hz, Jd = 5.58 Hz, 1H), 2.32 (dd, Jd 
= 13.52, Hz, Jd = 9.4 Hz, 1H), 2.16 (m, 2H), 1.8 (m, 3H), 1.58 (m, 1H), 1.05 (s, 3H), 0.87 
(s, 3H), 0.85 (s, 3H). 
13
C NMR (400 MHz, CDCl3):  214.5, 137.6, 135.2, 135.0, 134.9, 
131.7, 118.7, 117.5, 116.7, 80.2, 58.2, 54.6, 44.7, 43.2, 35.1, 34.6, 34.0, 33.9, 25.2, 24.4, 
18.3. Calcd for  C21H30O2 
O H O 
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367 
 
 
 
 
4-[(Methoxymethoxy)methyl]-(1R
*
,5R
*
,7R,4R)-1,5,7-triallyl-4-hydroxy-8,8-
dimethylbicyclo[3.3.1]non-2-en-9-one (367): 
 
(Methoxymethoxy)methyltributyltin (0.07 g, 0.20 mmol) was dissolved in 0.5 mL of 
THF under nitrogen. Then, the reaction mixture was cooled to  

C and MeLi (0.20 
mmol, 1.6 M in Et2O, 0.12 mL) was added and stirred for 20 minutes. Then, enone 364 
(0.02 g, 0.10 mmol) was added and stirred for 4 h at the same temperature. TLC was 
taken and the reaction was quenched with water. The organic layer was extracted with 
ether, and the ether layer was then washed with water, brine, and dried with anhydrous 
Na2SO4. The organic solvents were evaporated and the remaining crude oil was 
chromatographed with 5% ethyl acetate and petroleum ether to give 0.02 g (0.06 mmol, 
62%) of 2. 1H NMR (400 MHz, CDCl3): 5.88 (m, 1H), 5.67 (d, 10 Hz, 1H), 5.58 (m, 
1H), 5.54 (d, 10 Hz, 1H), 5.40 (m, 1H), 5.10 (d, 16.8 Hz, 4.95 (m, 5H), 4.58 (d, 6.4 Hz, 
1H), 4.53 (d, 6.4 Hz, 1H), 3.40 (d, 10.4 Hz, 1H), 3,31 (s, 3H), 3.24 (d, 10 Hz, 1H), 2.83 
(s, 1H), 2.70 (dd, Jd = 13.6 Hz, Jd = 6 Hz, 1H), 2.53 (dd, Jd = 13.2, Hz, Jd = 6 Hz, 1H), 
2.26 (m, 2H), 2.13 (dd, Jd = 13.6, Hz, Jd = 2.8 Hz, 1H), 1.83 (m, 2H), 1.6 (m, 1H), 1.05 
(m, 1H), 0.88 (s, 3H), 0.87 (s, 3H). 13C NMR (400 MHz, CDCl3):  214.1, 137.5, 135.0, 
134.8, 133.8, 132.3, 97.2, 80.6, 72.4, 56.8, 55.7, 54.7, 44.1, 35.2, 34.5, 34.2.  Calcd for  
C23H34O4. 
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Chapter 4. Conclusion 
 
Plant Rheedia gardneriana produces an interesting type B PPAP, 7-epi-
clusianone, and it has shown in vitro anti-HIV, anticancer and antibiotic activities. . 7-
epi-Clusianone, like a large majority of type B PPAPs and a large minority of type A 
PPAPs, is a 7-endo PPAP. To this date, there are no synthetic efforts found in the 
literature towards 7-endo PPAPs. 
The goal of my research project was to develop a stereocontrolled synthesis of 7-
epi-clusianone. A successful synthesis of this molecule will give a synthetic route to 7-
endo-PPAPs and will enable to contribute to the current synthetic tools by developing 
new methodologies and procedures. 
During our first approach, we hypothesized that the 1,2-allylic strain inhibits the 
enolization of the keto aldehyde to undergo intramolecular aldol reaction. After 
redesigning the synthesis, we were able to construct the bicyclo[3.3.1]nonane core with 
correct C(7) endo stereochemistry. Successful preparation of the 7-endo-
allylbicyclo[3.3.1]nonane skeleton shows the validity of our approach in synthesising of 
7-endo PPAPs and supports our hypothesis on the failure of our initial route. This 
synthetic pathway also led us to find other unusual reaction patterns such as the 
hydrogenation of an alkynal with Pd(PPh3)4 and Bu3SnH. This reaction has not been 
reported in the literature, and further investigation of it is being carried out in our 
laboratory.  
Finally, in our lab, we were able to develop a catalytic classical resolution method to 
synthesize enantiomerically pure 3,4-substituted 2-cyclohexenones. If a racemic synthesis 
of 7-epi-clusianone can be completed, then with the help of enantiopure starting 
meterials, we may be able to complete the first enantioselective total synthesis of 7-epi-
clusianone as well.  
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Appendix 
 
 
      Table A.1: Crystal data and structure refinement for 364 
  
  
      Identification code               364 
  
      Empirical formula                 C20H26O2 
  
      Formula weight                    298.41 
  
      Temperature                       90.0(2) K 
  
      Wavelength (Å)                    1.54178  
  
      Crystal system, space group       Monoclinic, P 21/c 
  
      Unit cell dimensions  
             
  a (Å)         9.1543(2)   
   
α (°)           90 
                                         
b (Å)                            25.4610(7)    
   
β (°)                         109.647(1) 
                                         
c (Å)                             7.7090(2)     
 
      γ (°)                             90 
  
      Volume (Å
3
)                       1692.19(7) 
  
      Z, Calculated density (Mg/m3)     4, 1.171  
  
      Absorption coefficient (mm-1)      0.573  
 
      F(000)                            648 
  
      Crystal size (nm)                 0.35 x 0.15 x 0.06 
  
      Θ range for data collection (°)   3.47 to 69.44 
  
      Limiting indices                  -10≤h≤10  
                                          
                                        -30≤k≤30 
 
                                        -9≤l≤7 
  
      Reflections collected / unique    22129 / 3088  
 
 
 
 
181 
 
                                        [R(int) = 0.0405] 
  
      Completeness to θ = 69.44         97.2 % 
  
      Absorption correction             Semi-empirical from equivalents 
  
      Max. and min. transmission        0.966 and 0.793 
  
      Refinement method                 Full-matrix least-squares on F2 
  
      Data / restraints / parameters    3088 / 0 / 202 
  
      Goodness-of-fit on F2             1.161 
  
      Final R indices [I>2σ(I)]         R1 = 0.0400, wR2 = 0.1048 
  
      R indices (all data)              R1 = 0.0420, wR2 = 0.1065 
  
      Extinction coefficient            0.0037(6) 
  
     Largest diff. peak and hole       0.314 and -0.224 (e·Å
–3
)  
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         Table A.2: Atomic coordinates ( x 104) and equivalent isotropic 
         displacement parameters (A2 x 103) for 364 
         U(eq) is defined as one third of the trace of the 
orthogonalized 
         Uij tensor. 
  
         
________________________________________________________________ 
  
                         x             y             z           U(eq) 
         
________________________________________________________________ 
  
          C(1)         6896(2)       3519(1)       5929(2)       18(1) 
          C(2)         6900(2)       2958(1)       6596(2)       19(1) 
          C(3)         5764(2)       2608(1)       5932(2)       20(1) 
          C(4)         4307(2)       2747(1)       4482(2)       18(1) 
          C(5)         4061(2)       3337(1)       4093(2)       18(1) 
          C(6)         3733(2)       3573(1)       5808(2)       19(1) 
          C(7)         4736(2)       4053(1)       6605(2)       20(1) 
          C(8)         6517(2)       3933(1)       7299(2)       20(1) 
          C(9)         5600(2)       3564(1)       4082(2)       17(1) 
          O(10)        5765(1)       3762(1)       2734(1)       21(1) 
          C(11)        8501(2)       3615(1)       5723(2)       21(1) 
          C(12)        8947(2)       3209(1)       4574(2)       23(1) 
          C(13)       10141(2)       2887(1)       5193(2)       29(1) 
          C(14)        4194(2)       4309(1)       8106(2)       25(1) 
          C(15)        2571(2)       4523(1)       7371(2)       29(1) 
          C(16)        2217(2)       5024(1)       7220(2)       35(1) 
          C(17)        2727(2)       3433(1)       2276(2)       21(1) 
          C(18)        2304(2)       4002(1)       1880(2)       22(1) 
          C(19)        1006(2)       4213(1)       1935(2)       27(1) 
          O(20)        3340(1)       2421(1)       3696(2)       24(1) 
          C(21)        7364(2)       4455(1)       7315(2)       26(1) 
          C(22)        7079(2)       3705(1)       9252(2)       24(1) 
         
________________________________________________________________ 
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           Table A.3: Bond lengths [Å] and angles [°] for 364 
           
_____________________________________________________________ 
  
            C(1)-C(2)                     1.519(2) 
            C(1)-C(9)                     1.5201(19) 
            C(1)-C(11)                    1.5494(19) 
            C(1)-C(8)                     1.6101(19) 
            C(2)-C(3)                     1.333(2) 
            C(2)-H(2)                     0.9500 
            C(3)-C(4)                     1.467(2) 
            C(3)-H(3)                     0.9500 
            C(4)-O(20)                    1.2176(18) 
            C(4)-C(5)                     1.534(2) 
            C(5)-C(9)                     1.5250(19) 
            C(5)-C(17)                    1.537(2) 
            C(5)-C(6)                     1.5694(19) 
            C(6)-C(7)                     1.529(2) 
            C(6)-H(6A)                    0.9900 
            C(6)-H(6B)                    0.9900 
            C(7)-C(14)                    1.5474(19) 
            C(7)-C(8)                     1.566(2) 
            C(7)-H(7)                     1.0000 
            C(8)-C(22)                    1.532(2) 
            C(8)-C(21)                    1.537(2) 
            C(9)-O(10)                    1.2099(17) 
            C(11)-C(12)                   1.504(2) 
            C(11)-H(11A)                  0.9900 
            C(11)-H(11B)                  0.9900 
            C(12)-C(13)                   1.322(2) 
            C(12)-H(12)                   0.9500 
            C(13)-H(13A)                  0.9500 
            C(13)-H(13B)                  0.9500 
            C(14)-C(15)                   1.504(2) 
            C(14)-H(14A)                  0.9900 
            C(14)-H(14B)                  0.9900 
            C(15)-C(16)                   1.312(2) 
            C(15)-H(15)                   0.9500 
            C(16)-H(16A)                  0.9500 
            C(16)-H(16B)                  0.9500 
            C(17)-C(18)                   1.503(2) 
            C(17)-H(17A)                  0.9900 
            C(17)-H(17B)                  0.9900 
            C(18)-C(19)                   1.318(2) 
            C(18)-H(18)                   0.9500 
            C(19)-H(19A)                  0.9500 
            C(19)-H(19B)                  0.9500 
            C(21)-H(21A)                  0.9800 
            C(21)-H(21B)                  0.9800 
            C(21)-H(21C)                  0.9800 
            C(22)-H(22A)                  0.9800 
            C(22)-H(22B)                  0.9800 
            C(22)-H(22C)                  0.9800 
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            C(2)-C(1)-C(9)              107.45(11) 
            C(2)-C(1)-C(11)             106.80(12) 
            C(9)-C(1)-C(11)             111.15(11) 
            C(2)-C(1)-C(8)              111.72(11) 
            C(9)-C(1)-C(8)              107.02(11) 
            C(11)-C(1)-C(8)             112.62(11) 
            C(3)-C(2)-C(1)              125.87(13) 
            C(3)-C(2)-H(2)              117.1 
            C(1)-C(2)-H(2)              117.1 
            C(2)-C(3)-C(4)              121.52(13) 
            C(2)-C(3)-H(3)              119.2 
            C(4)-C(3)-H(3)              119.2 
            O(20)-C(4)-C(3)             122.50(13) 
            O(20)-C(4)-C(5)             122.47(13) 
            C(3)-C(4)-C(5)              114.97(12) 
            C(9)-C(5)-C(4)              107.23(11) 
            C(9)-C(5)-C(17)             112.81(12) 
            C(4)-C(5)-C(17)             110.68(12) 
            C(9)-C(5)-C(6)              107.40(11) 
            C(4)-C(5)-C(6)              105.43(11) 
            C(17)-C(5)-C(6)             112.87(11) 
            C(7)-C(6)-C(5)              112.64(11) 
            C(7)-C(6)-H(6A)             109.1 
            C(5)-C(6)-H(6A)             109.1 
            C(7)-C(6)-H(6B)             109.1 
            C(5)-C(6)-H(6B)             109.1 
            H(6A)-C(6)-H(6B)            107.8 
            C(6)-C(7)-C(14)             109.75(12) 
            C(6)-C(7)-C(8)              113.40(12) 
            C(14)-C(7)-C(8)             112.67(12) 
            C(6)-C(7)-H(7)              106.9 
            C(14)-C(7)-H(7)             106.9 
            C(8)-C(7)-H(7)              106.9 
            C(22)-C(8)-C(21)            108.52(12) 
            C(22)-C(8)-C(7)             112.12(12) 
            C(21)-C(8)-C(7)             107.41(12) 
            C(22)-C(8)-C(1)             108.75(12) 
            C(21)-C(8)-C(1)             110.60(11) 
            C(7)-C(8)-C(1)              109.44(11) 
            O(10)-C(9)-C(1)             123.50(13) 
            O(10)-C(9)-C(5)             123.03(13) 
            C(1)-C(9)-C(5)              113.47(11) 
            C(12)-C(11)-C(1)            113.97(12) 
            C(12)-C(11)-H(11A)          108.8 
            C(1)-C(11)-H(11A)           108.8 
            C(12)-C(11)-H(11B)          108.8 
            C(1)-C(11)-H(11B)           108.8 
            H(11A)-C(11)-H(11B)         107.7 
            C(13)-C(12)-C(11)           124.72(15) 
            C(13)-C(12)-H(12)           117.6 
            C(11)-C(12)-H(12)           117.6 
            C(12)-C(13)-H(13A)          120.0 
            C(12)-C(13)-H(13B)          120.0 
            H(13A)-C(13)-H(13B)         120.0 
            C(15)-C(14)-C(7)            113.29(13) 
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            C(15)-C(14)-H(14A)          108.9 
            C(7)-C(14)-H(14A)           108.9 
            C(15)-C(14)-H(14B)          108.9 
            C(7)-C(14)-H(14B)           108.9 
            H(14A)-C(14)-H(14B)         107.7 
            C(16)-C(15)-C(14)           124.71(17) 
            C(16)-C(15)-H(15)           117.6 
            C(14)-C(15)-H(15)           117.6 
            C(15)-C(16)-H(16A)          120.0 
            C(15)-C(16)-H(16B)          120.0 
            H(16A)-C(16)-H(16B)         120.0 
            C(18)-C(17)-C(5)            114.15(12) 
            C(18)-C(17)-H(17A)          108.7 
            C(5)-C(17)-H(17A)           108.7 
            C(18)-C(17)-H(17B)          108.7 
            C(5)-C(17)-H(17B)           108.7 
            H(17A)-C(17)-H(17B)         107.6 
            C(19)-C(18)-C(17)           124.14(14) 
            C(19)-C(18)-H(18)           117.9 
            C(17)-C(18)-H(18)           117.9 
            C(18)-C(19)-H(19A)          120.0 
            C(18)-C(19)-H(19B)          120.0 
            H(19A)-C(19)-H(19B)         120.0 
            C(8)-C(21)-H(21A)           109.5 
            C(8)-C(21)-H(21B)           109.5 
            H(21A)-C(21)-H(21B)         109.5 
            C(8)-C(21)-H(21C)           109.5 
            H(21A)-C(21)-H(21C)         109.5 
            H(21B)-C(21)-H(21C)         109.5 
            C(8)-C(22)-H(22A)           109.5 
            C(8)-C(22)-H(22B)           109.5 
            H(22A)-C(22)-H(22B)         109.5 
            C(8)-C(22)-H(22C)           109.5 
            H(22A)-C(22)-H(22C)         109.5 
            H(22B)-C(22)-H(22C)         109.5 
           
_____________________________________________________________ 
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Table A.4: Anisotropic displacement parameters (A2 x 103) for 364. The 
anisotropic displacement factor exponent takes the form: 
    -2 Π2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ] 
  
    
_______________________________________________________________________ 
  
              U11        U22        U33        U23        U13        
U12 
    
_______________________________________________________________________ 
  
    C(1)     18(1)      22(1)      16(1)      -1(1)       7(1)      -
2(1) 
    C(2)     20(1)      24(1)      15(1)       2(1)       8(1)       
3(1) 
    C(3)     22(1)      20(1)      19(1)       2(1)      10(1)       
2(1) 
    C(4)     19(1)      22(1)      18(1)      -2(1)      11(1)      -
1(1) 
    C(5)     18(1)      21(1)      16(1)      -1(1)       7(1)      -
1(1) 
    C(6)     19(1)      22(1)      18(1)       1(1)      10(1)       
1(1) 
    C(7)     25(1)      21(1)      16(1)       0(1)       9(1)       
0(1) 
    C(8)     24(1)      22(1)      16(1)      -2(1)       9(1)      -
3(1) 
    C(9)     19(1)      17(1)      16(1)      -2(1)       8(1)       
1(1) 
    O(10)    22(1)      27(1)      17(1)       2(1)      10(1)       
0(1) 
    C(11)    17(1)      28(1)      19(1)       0(1)       6(1)      -
4(1) 
    C(12)    17(1)      32(1)      21(1)      -1(1)       8(1)      -
4(1) 
    C(13)    22(1)      36(1)      32(1)       1(1)      12(1)      -
1(1) 
    C(14)    32(1)      25(1)      20(1)      -2(1)      13(1)       
1(1) 
    C(15)    35(1)      32(1)      25(1)      -4(1)      17(1)       
2(1) 
    C(16)    44(1)      36(1)      29(1)      -1(1)      18(1)       
7(1) 
    C(17)    18(1)      26(1)      18(1)      -2(1)       6(1)       
0(1) 
    C(18)    22(1)      27(1)      18(1)       1(1)       6(1)      -
1(1) 
    C(19)    23(1)      26(1)      30(1)      -1(1)       7(1)       
1(1) 
    O(20)    23(1)      24(1)      26(1)      -4(1)       9(1)      -
4(1) 
    C(21)    31(1)      26(1)      25(1)      -6(1)      13(1)      -
7(1) 
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    C(22)    26(1)      30(1)      16(1)      -1(1)       6(1)      -
1(1) 
    
_______________________________________________________________________ 
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         Table A.5:  Hydrogen coordinates ( x 104) and isotropic 
         displacement parameters (Å
2
 x 103) for 364. 
  
         
_______________________________________________________________________ 
  
                         x             y             z           U(eq) 
         
_______________________________________________________________________ 
  
          H(2)         7791          2846          7575          23 
          H(3)         5902          2261          6410          24 
          H(6A)        2625          3673          5442          22 
          H(6B)        3930          3299          6773          22 
          H(7)         4538          4314          5583          24 
          H(11A)       8495          3965          5160          26 
          H(11B)       9300          3621          6965          26 
          H(12)        8325          3183          3312          27 
          H(13A)      10788          2902          6448          35 
          H(13B)      10351          2640          4384          35 
          H(14A)       4250          4044          9067          30 
          H(14B)       4914          4598          8693          30 
          H(15)        1742          4278          6988          35 
          H(16A)       3015          5281          7589          42 
          H(16B)       1162          5131          6741          42 
          H(17A)       3023          3287          1251          25 
          H(17B)       1800          3239          2312          25 
          H(18)        3016          4222          1571          27 
          H(19A)        270          4003          2240          33 
          H(19B)        808          4576          1671          33 
          H(21A)       8487          4399          7844          40 
          H(21B)       7042          4713          8059          40 
          H(21C)       7104          4586          6052          40 
          H(22A)       7002          3974         10126          37 
          H(22B)       8161          3593          9569          37 
          H(22C)       6434          3403          9309          37 
         
_______________________________________________________________________ 
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         Table A.6: Torsion angles [°] for 364. 
         
________________________________________________________________ 
  
C(9)-C(1)-C(2)-C(3)                                 -14.83(19) 
C(11)-C(1)-C(2)-C(3)                               -134.17(15) 
C(8)-C(1)-C(2)-C(3)                                 102.27(16) 
C(1)-C(2)-C(3)-C(4)                                  -3.0(2) 
C(2)-C(3)-C(4)-O(20)                                170.50(14) 
C(2)-C(3)-C(4)-C(5)                                 -12.15(19) 
O(20)-C(4)-C(5)-C(9)                               -139.78(13) 
C(3)-C(4)-C(5)-C(9)                                  42.87(15) 
O(20)-C(4)-C(5)-C(17)                               -16.35(18) 
C(3)-C(4)-C(5)-C(17)                                166.29(12) 
O(20)-C(4)-C(5)-C(6)                                106.00(15) 
C(3)-C(4)-C(5)-C(6)                                 -71.36(14) 
C(9)-C(5)-C(6)-C(7)                                  16.03(16) 
C(4)-C(5)-C(6)-C(7)                                 130.13(12) 
C(17)-C(5)-C(6)-C(7)                               -108.93(14) 
C(5)-C(6)-C(7)-C(14)                                172.13(12) 
C(5)-C(6)-C(7)-C(8)                                 -60.89(15) 
C(6)-C(7)-C(8)-C(22)                                -83.30(15) 
C(14)-C(7)-C(8)-C(22)                                42.14(16) 
C(6)-C(7)-C(8)-C(21)                                157.58(12) 
C(14)-C(7)-C(8)-C(21)                               -76.99(14) 
C(6)-C(7)-C(8)-C(1)                                  37.46(15) 
C(14)-C(7)-C(8)-C(1)                                162.90(11) 
C(2)-C(1)-C(8)-C(22)                                 28.91(16) 
C(9)-C(1)-C(8)-C(22)                                146.27(12) 
C(11)-C(1)-C(8)-C(22)                               -91.29(14) 
C(2)-C(1)-C(8)-C(21)                                147.98(13) 
C(9)-C(1)-C(8)-C(21)                                -94.67(14) 
C(11)-C(1)-C(8)-C(21)                                27.78(17) 
C(2)-C(1)-C(8)-C(7)                                 -93.88(14) 
C(9)-C(1)-C(8)-C(7)                                  23.48(14) 
C(11)-C(1)-C(8)-C(7)                                145.92(12) 
C(2)-C(1)-C(9)-O(10)                               -131.95(14) 
C(11)-C(1)-C(9)-O(10)                               -15.43(19) 
C(8)-C(1)-C(9)-O(10)                                107.93(15) 
C(2)-C(1)-C(9)-C(5)                                  48.46(15) 
C(11)-C(1)-C(9)-C(5)                                164.97(11) 
C(8)-C(1)-C(9)-C(5)                                 -71.67(14) 
C(4)-C(5)-C(9)-O(10)                                116.96(14) 
C(17)-C(5)-C(9)-O(10)                                -5.15(19) 
C(6)-C(5)-C(9)-O(10)                               -130.15(14) 
C(4)-C(5)-C(9)-C(1)                                 -63.45(14) 
C(17)-C(5)-C(9)-C(1)                                174.45(11) 
C(6)-C(5)-C(9)-C(1)                                  49.45(15) 
C(2)-C(1)-C(11)-C(12)                                52.34(16) 
C(9)-C(1)-C(11)-C(12)                               -64.57(16) 
C(8)-C(1)-C(11)-C(12)                               175.34(12) 
C(1)-C(11)-C(12)-C(13)                             -116.16(17) 
C(6)-C(7)-C(14)-C(15)                               -63.99(16) 
C(8)-C(7)-C(14)-C(15)                               168.62(13) 
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C(7)-C(14)-C(15)-C(16)                             -109.33(18) 
C(9)-C(5)-C(17)-C(18)                               -65.55(16) 
C(4)-C(5)-C(17)-C(18)                               174.31(12) 
C(6)-C(5)-C(17)-C(18)                                56.42(16) 
C(5)-C(17)-C(18)-C(19)                             -109.68(17) 
________________________________________________________________
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 Table A.8: Crystal data and structure refinement for 368. 
  
  
      Identification code               368 
  
      Empirical formula                 C21H30O2 
  
      Formula weight                    314.45 
  
      Temperature                       90.0(2) K 
  
      Wavelength (Å)                 1.54178 
  
      Crystal system, space group       Triclinic, P -1 
  
      Unit cell dimensions              
  
 a (Å)                             6.3410(1)    
 
 α (°)                             82.198(1) 
                                        
 b (Å)                             8.9482(2)    
 
 β (°)                         84.205(1) 
                                         
 c (Å)                             17.1320(3)     
 
 γ (°)                             70.411(1) 
  
      Volume                            905.74(3) A3 
  
      Z, Calculated density (Mg/m3)      2, 1.153 
  
      Absorption coefficient (mm-1)      0.555 
   
      F(000)                            344 
  
      Crystal size (nm)                 0.22 x 0.05 x 0.04 mm 
  
      θ range for data collection (°)   2.61 to 67.97 
  
      Limiting indices                  -6≤h≤7  
 
          -10≤k≤10 
 
    -20≤l≤20 
  
      Reflections collected / unique    12602 / 3239  
 
                                        [R(int) = 0.0378] 
  
      Completeness to θ = 67.97         97.9 % 
  
      Absorption correction             Semi-empirical from equivalents 
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      Max. and min. transmission        0.9781 and 0.8876 
  
      Refinement method                 Full-matrix least-squares on F2 
  
      Data / restraints / parameters    3239 / 0 / 213 
  
      Goodness-of-fit on F2             1.090 
  
      Final R indices [I>2σ(I)]         R1 = 0.0398, wR2 = 0.1002 
  
      R indices (all data)              R1 = 0.0412, wR2 = 0.1014 
  
      Extinction coefficient            0.0042(12) 
  
      Largest diff. peak and hole       0.300 and -0.186 (e·Å
–3
)  
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         Table A.9:  Atomic coordinates ( x 104) and equivalent 
isotropic 
         displacement parameters (A2 x 103) for 368. 
         U(eq) is defined as one third of the trace of the 
orthogonalized 
         Uij tensor. 
  
         
_______________________________________________________________________ 
  
                         x             y             z           U(eq) 
         
_______________________________________________________________________ 
  
          C(1)          950(2)       2860(1)       3184(1)       18(1) 
          C(2)         -833(2)       2360(2)       3718(1)       19(1) 
          C(3)        -1091(2)        938(2)       3782(1)       20(1) 
          C(4)          284(2)       -395(2)       3305(1)       19(1) 
          C(5)         1403(2)        346(1)       2560(1)       18(1) 
          C(6)         -463(2)       1489(1)       2032(1)       18(1) 
          C(7)           -7(2)       3051(2)       1739(1)       20(1) 
          C(8)          -48(2)       4047(1)       2426(1)       20(1) 
          C(9)         2558(2)       1352(1)       2880(1)       18(1) 
          O(10)        4579(1)        984(1)       2901(1)       23(1) 
          C(11)        2159(2)       3583(2)       3691(1)       22(1) 
          C(12)        2776(2)       2637(2)       4476(1)       25(1) 
          C(13)        2647(2)       3268(2)       5138(1)       33(1) 
          C(14)       -1585(2)       3999(2)       1086(1)       25(1) 
          C(15)       -1038(3)       3224(2)        337(1)       34(1) 
          C(16)       -2447(4)       2821(2)        -37(1)       53(1) 
          C(17)        3084(2)       -972(2)       2108(1)       22(1) 
          C(18)        4045(2)       -417(2)       1330(1)       25(1) 
          C(19)        6199(2)       -672(2)       1148(1)       30(1) 
          C(20)        1986(2)      -1653(2)       3823(1)       26(1) 
          O(21)       -1082(1)      -1213(1)       3057(1)       21(1) 
          C(22)        1418(2)       5096(2)       2133(1)       26(1) 
          C(23)       -2411(2)       5128(2)       2640(1)       25(1) 
         
_______________________________________________________________________ 
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           Table A.10:  Bond lengths [Å] and angles [°] for 368 
           
_____________________________________________________________ 
  
            C(1)-C(9)                     1.5148(17) 
            C(1)-C(2)                     1.5273(16) 
            C(1)-C(11)                    1.5422(17) 
            C(1)-C(8)                     1.5991(17) 
            C(2)-C(3)                     1.3258(18) 
            C(2)-H(2)                     0.9500 
            C(3)-C(4)                     1.5075(17) 
            C(3)-H(3)                     0.9500 
            C(4)-O(21)                    1.4317(15) 
            C(4)-C(20)                    1.5252(18) 
            C(4)-C(5)                     1.5736(16) 
            C(5)-C(9)                     1.5179(17) 
            C(5)-C(17)                    1.5380(17) 
            C(5)-C(6)                     1.5553(16) 
            C(6)-C(7)                     1.5299(16) 
            C(6)-H(6A)                    0.9900 
            C(6)-H(6B)                    0.9900 
            C(7)-C(14)                    1.5398(17) 
            C(7)-C(8)                     1.5626(17) 
            C(7)-H(7)                     1.0000 
            C(8)-C(23)                    1.5262(17) 
            C(8)-C(22)                    1.5360(17) 
            C(9)-O(10)                    1.2152(15) 
            C(11)-C(12)                   1.5015(19) 
            C(11)-H(11A)                  0.9900 
            C(11)-H(11B)                  0.9900 
            C(12)-C(13)                   1.318(2) 
            C(12)-H(12)                   0.9500 
            C(13)-H(13A)                  0.9500 
            C(13)-H(13B)                  0.9500 
            C(14)-C(15)                   1.496(2) 
            C(14)-H(14A)                  0.9900 
            C(14)-H(14B)                  0.9900 
            C(15)-C(16)                   1.316(2) 
            C(15)-H(15)                   0.9500 
            C(16)-H(16A)                  0.9500 
            C(16)-H(16B)                  0.9500 
            C(17)-C(18)                   1.5011(18) 
            C(17)-H(17A)                  0.9900 
            C(17)-H(17B)                  0.9900 
            C(18)-C(19)                   1.319(2) 
            C(18)-H(18)                   0.9500 
            C(19)-H(19A)                  0.9500 
            C(19)-H(19B)                  0.9500 
            C(20)-H(20A)                  0.9800 
            C(20)-H(20B)                  0.9800 
            C(20)-H(20C)                  0.9800 
            O(21)-H(21)                   0.8400 
            C(22)-H(22A)                  0.9800 
            C(22)-H(22B)                  0.9800 
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            C(22)-H(22C)                  0.9800 
            C(23)-H(23A)                  0.9800 
            C(23)-H(23B)                  0.9800 
            C(23)-H(23C)                  0.9800 
  
            C(9)-C(1)-C(2)              106.28(10) 
            C(9)-C(1)-C(11)             110.71(10) 
            C(2)-C(1)-C(11)             107.86(10) 
            C(9)-C(1)-C(8)              106.53(9) 
            C(2)-C(1)-C(8)              112.99(10) 
            C(11)-C(1)-C(8)             112.31(10) 
            C(3)-C(2)-C(1)              125.28(11) 
            C(3)-C(2)-H(2)              117.4 
            C(1)-C(2)-H(2)              117.4 
            C(2)-C(3)-C(4)              124.29(11) 
            C(2)-C(3)-H(3)              117.9 
            C(4)-C(3)-H(3)              117.9 
            O(21)-C(4)-C(3)             111.24(9) 
            O(21)-C(4)-C(20)            105.19(10) 
            C(3)-C(4)-C(20)             109.54(10) 
            O(21)-C(4)-C(5)             109.54(10) 
            C(3)-C(4)-C(5)              108.26(10) 
            C(20)-C(4)-C(5)             113.08(10) 
            C(9)-C(5)-C(17)             111.45(10) 
            C(9)-C(5)-C(6)              107.60(10) 
            C(17)-C(5)-C(6)             112.14(10) 
            C(9)-C(5)-C(4)              105.33(9) 
            C(17)-C(5)-C(4)             110.88(10) 
            C(6)-C(5)-C(4)              109.16(9) 
            C(7)-C(6)-C(5)              111.68(10) 
            C(7)-C(6)-H(6A)             109.3 
            C(5)-C(6)-H(6A)             109.3 
            C(7)-C(6)-H(6B)             109.3 
            C(5)-C(6)-H(6B)             109.3 
            H(6A)-C(6)-H(6B)            107.9 
            C(6)-C(7)-C(14)             110.32(10) 
            C(6)-C(7)-C(8)              112.63(10) 
            C(14)-C(7)-C(8)             113.44(10) 
            C(6)-C(7)-H(7)              106.7 
            C(14)-C(7)-H(7)             106.7 
            C(8)-C(7)-H(7)              106.7 
            C(23)-C(8)-C(22)            108.58(10) 
            C(23)-C(8)-C(7)             112.13(10) 
            C(22)-C(8)-C(7)             106.78(10) 
            C(23)-C(8)-C(1)             109.51(10) 
            C(22)-C(8)-C(1)             110.55(10) 
            C(7)-C(8)-C(1)              109.26(9) 
            O(10)-C(9)-C(1)             122.59(11) 
            O(10)-C(9)-C(5)             123.69(11) 
            C(1)-C(9)-C(5)              113.72(10) 
            C(12)-C(11)-C(1)            114.07(11) 
            C(12)-C(11)-H(11A)          108.7 
            C(1)-C(11)-H(11A)           108.7 
            C(12)-C(11)-H(11B)          108.7 
            C(1)-C(11)-H(11B)           108.7 
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            H(11A)-C(11)-H(11B)         107.6 
            C(13)-C(12)-C(11)           124.47(14) 
            C(13)-C(12)-H(12)           117.8 
            C(11)-C(12)-H(12)           117.8 
            C(12)-C(13)-H(13A)          120.0 
            C(12)-C(13)-H(13B)          120.0 
            H(13A)-C(13)-H(13B)         120.0 
            C(15)-C(14)-C(7)            112.47(12) 
            C(15)-C(14)-H(14A)          109.1 
            C(7)-C(14)-H(14A)           109.1 
            C(15)-C(14)-H(14B)          109.1 
            C(7)-C(14)-H(14B)           109.1 
            H(14A)-C(14)-H(14B)         107.8 
            C(16)-C(15)-C(14)           125.55(17) 
            C(16)-C(15)-H(15)           117.2 
            C(14)-C(15)-H(15)           117.2 
            C(15)-C(16)-H(16A)          120.0 
            C(15)-C(16)-H(16B)          120.0 
            H(16A)-C(16)-H(16B)         120.0 
            C(18)-C(17)-C(5)            115.76(10) 
            C(18)-C(17)-H(17A)          108.3 
            C(5)-C(17)-H(17A)           108.3 
            C(18)-C(17)-H(17B)          108.3 
            C(5)-C(17)-H(17B)           108.3 
            H(17A)-C(17)-H(17B)         107.4 
            C(19)-C(18)-C(17)           124.83(13) 
            C(19)-C(18)-H(18)           117.6 
            C(17)-C(18)-H(18)           117.6 
            C(18)-C(19)-H(19A)          120.0 
            C(18)-C(19)-H(19B)          120.0 
            H(19A)-C(19)-H(19B)         120.0 
            C(4)-C(20)-H(20A)           109.5 
            C(4)-C(20)-H(20B)           109.5 
            H(20A)-C(20)-H(20B)         109.5 
            C(4)-C(20)-H(20C)           109.5 
            H(20A)-C(20)-H(20C)         109.5 
            H(20B)-C(20)-H(20C)         109.5 
            C(4)-O(21)-H(21)            109.5 
            C(8)-C(22)-H(22A)           109.5 
            C(8)-C(22)-H(22B)           109.5 
            H(22A)-C(22)-H(22B)         109.5 
            C(8)-C(22)-H(22C)           109.5 
            H(22A)-C(22)-H(22C)         109.5 
            H(22B)-C(22)-H(22C)         109.5 
            C(8)-C(23)-H(23A)           109.5 
            C(8)-C(23)-H(23B)           109.5 
            H(23A)-C(23)-H(23B)         109.5 
            C(8)-C(23)-H(23C)           109.5 
            H(23A)-C(23)-H(23C)         109.5 
            H(23B)-C(23)-H(23C)         109.5 
           
_____________________________________________________________ 
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    Table A.11: Anisotropic displacement parameters (A2 x 103) for 368. 
    The anisotropic displacement factor exponent takes the form: 
    -2 pi2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ] 
  
    
_______________________________________________________________________ 
  
              U11        U22        U33        U23        U13        
U12 
    
_______________________________________________________________________ 
  
C(1)     14(1)      19(1)      24(1)      -4(1)       2(1)      -8(1) 
C(2)     13(1)      23(1)      22(1)      -5(1)       1(1)      -7(1) 
C(3)     13(1)      25(1)      22(1)      -1(1)       1(1)      -8(1) 
C(4)     14(1)      19(1)      26(1)      -1(1)       1(1)      -8(1) 
C(5)     14(1)      18(1)      24(1)      -2(1)       1(1)      -7(1) 
C(6)     16(1)      19(1)      22(1)      -4(1)       1(1)      -8(1) 
C(7)     17(1)      20(1)      23(1)      -2(1)       1(1)      -9(1) 
C(8)     18(1)      17(1)      25(1)      -3(1)       1(1)      -7(1) 
C(9)     15(1)      20(1)      20(1)      -1(1)       2(1)      -8(1) 
O(10)    13(1)      28(1)      30(1)      -6(1)       1(1)      -8(1) 
C(11)    18(1)      26(1)      26(1)      -8(1)       3(1)     -12(1) 
C(12)    17(1)      32(1)      30(1)      -6(1)       0(1)     -11(1) 
C(13)    26(1)      44(1)      31(1)      -8(1)      -3(1)     -10(1) 
C(14)    28(1)      23(1)      27(1)       3(1)      -4(1)     -12(1) 
C(15)    52(1)      32(1)      24(1)       5(1)      -4(1)     -23(1) 
C(16)    90(2)      55(1)      32(1)       5(1)     -15(1)     -49(1) 
C(17)    18(1)      19(1)      29(1)      -6(1)       3(1)      -7(1) 
C(18)    28(1)      21(1)      27(1)      -9(1)       4(1)      -9(1) 
C(19)    31(1)      31(1)      31(1)      -8(1)       8(1)     -15(1) 
C(20)    20(1)      26(1)      31(1)       1(1)      -1(1)      -9(1) 
O(21)    15(1)      19(1)      32(1)      -2(1)      -1(1)      -9(1) 
C(22)    29(1)      24(1)      29(1)      -3(1)       2(1)     -16(1) 
C(23)    21(1)      21(1)      31(1)      -4(1)       2(1)      -5(1) 
    
_______________________________________________________________________ 
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         Table A.12: Hydrogen coordinates ( x 104) and isotropic 
         displacement parameters (Å2 x 103) for 368. 
  
         
________________________________________________________________ 
  
                         x             y             z           U(eq) 
         
________________________________________________________________ 
  
          H(2)        -1838          3131          4029          23 
          H(3)        -2215           746          4153          24 
          H(6A)        -553           955          1572          22 
          H(6B)       -1927          1727          2337          22 
          H(7)         1551          2753          1488          23 
          H(11A)       3541          3671          3393          27 
          H(11B)       1177          4675          3780          27 
          H(12)        3294          1506          4497          31 
          H(13A)       2135          4394          5139          40 
          H(13B)       3066          2596          5615          40 
          H(14A)      -3150          4099          1274          31 
          H(14B)      -1478          5087           978          31 
          H(15)         452          3003           112          41 
          H(16A)      -3954          3020           167          63 
          H(16B)      -1957          2332          -512          63 
          H(17A)       4338         -1563          2448          26 
          H(17B)       2330         -1732          2014          26 
          H(18)        3025           159           939          30 
          H(19A)       7269         -1244          1524          36 
          H(19B)       6681          -283           642          36 
          H(20A)       1218         -1961          4312          39 
          H(20B)       3119         -1215          3949          39 
          H(20C)       2715         -2593          3539          39 
          H(21)       -2345          -555          2950          32 
          H(22A)        927          5691          1624          38 
          H(22B)       2987          4419          2072          38 
          H(22C)       1275          5846          2518          38 
          H(23A)      -2383          5654          3103          38 
          H(23B)      -3413          4488          2760          38 
          H(23C)      -2953          5938          2195          38 
         
________________________________________________________________ 
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         Table A.13: Torsion angles [°]for 368. 
         
________________________________________________________________ 
  
C(9)-C(1)-C(2)-C(3)                                 -10.23(17) 
C(11)-C(1)-C(2)-C(3)                               -128.99(13) 
C(8)-C(1)-C(2)-C(3)                                 106.25(14) 
C(1)-C(2)-C(3)-C(4)                                  -3.0(2) 
C(2)-C(3)-C(4)-O(21)                               -139.34(12) 
C(2)-C(3)-C(4)-C(20)                                104.78(14) 
C(2)-C(3)-C(4)-C(5)                                 -18.94(16) 
O(21)-C(4)-C(5)-C(9)                                173.01(9) 
C(3)-C(4)-C(5)-C(9)                                  51.55(12) 
C(20)-C(4)-C(5)-C(9)                                -70.02(13) 
O(21)-C(4)-C(5)-C(17)                               -66.31(12) 
C(3)-C(4)-C(5)-C(17)                                172.23(10) 
C(20)-C(4)-C(5)-C(17)                                50.66(14) 
O(21)-C(4)-C(5)-C(6)                                 57.72(12) 
C(3)-C(4)-C(5)-C(6)                                 -63.74(12) 
C(20)-C(4)-C(5)-C(6)                                174.69(10) 
C(9)-C(5)-C(6)-C(7)                                  22.04(13) 
C(17)-C(5)-C(6)-C(7)                               -100.86(12) 
C(4)-C(5)-C(6)-C(7)                                 135.86(10) 
C(5)-C(6)-C(7)-C(14)                                168.13(10) 
C(5)-C(6)-C(7)-C(8)                                 -63.99(13) 
C(6)-C(7)-C(8)-C(23)                                -86.53(12) 
C(14)-C(7)-C(8)-C(23)                                39.69(14) 
C(6)-C(7)-C(8)-C(22)                                154.66(10) 
C(14)-C(7)-C(8)-C(22)                               -79.12(13) 
C(6)-C(7)-C(8)-C(1)                                  35.06(13) 
C(14)-C(7)-C(8)-C(1)                                161.29(10) 
C(9)-C(1)-C(8)-C(23)                                150.38(10) 
C(2)-C(1)-C(8)-C(23)                                 34.05(14) 
C(11)-C(1)-C(8)-C(23)                               -88.25(12) 
C(9)-C(1)-C(8)-C(22)                                -90.03(11) 
C(2)-C(1)-C(8)-C(22)                                153.64(10) 
C(11)-C(1)-C(8)-C(22)                                31.35(13) 
C(9)-C(1)-C(8)-C(7)                                  27.21(12) 
C(2)-C(1)-C(8)-C(7)                                 -89.11(12) 
C(11)-C(1)-C(8)-C(7)                                148.59(10) 
C(2)-C(1)-C(9)-O(10)                               -130.99(12) 
C(11)-C(1)-C(9)-O(10)                               -14.12(16) 
C(8)-C(1)-C(9)-O(10)                                108.27(13) 
C(2)-C(1)-C(9)-C(5)                                  48.20(13) 
C(11)-C(1)-C(9)-C(5)                                165.07(10) 
C(8)-C(1)-C(9)-C(5)                                 -72.54(12) 
C(17)-C(5)-C(9)-O(10)                               -12.53(16) 
C(6)-C(5)-C(9)-O(10)                               -135.85(12) 
C(4)-C(5)-C(9)-O(10)                                107.79(13) 
C(17)-C(5)-C(9)-C(1)                                168.29(10) 
C(6)-C(5)-C(9)-C(1)                                  44.96(13) 
C(4)-C(5)-C(9)-C(1)                                 -71.39(12) 
C(9)-C(1)-C(11)-C(12)                               -70.97(13) 
C(2)-C(1)-C(11)-C(12)                                44.92(14) 
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C(8)-C(1)-C(11)-C(12)                               170.08(10) 
C(1)-C(11)-C(12)-C(13)                             -141.21(13) 
C(6)-C(7)-C(14)-C(15)                               -69.78(14) 
C(8)-C(7)-C(14)-C(15)                               162.78(11) 
C(7)-C(14)-C(15)-C(16)                              124.75(16) 
C(9)-C(5)-C(17)-C(18)                               -70.46(14) 
C(6)-C(5)-C(17)-C(18)                                50.25(14) 
C(4)-C(5)-C(17)-C(18)                               172.55(10) 
C(5)-C(17)-C(18)-C(19)                              121.07(14) 
         
________________________________________________________________ 
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Table A.14. Hydrogen bonds for 368 [[Å] and [°]]. 
 
_______________________________________________________________________ 
  
 D-H...A                      d(D-H)      d(H...A)    d(D...A)    
<(DHA) 
  
 O(21)-H(21)...O(10)#1        0.84        1.98        2.8080(12)  169.9 
 
_______________________________________________________________________ 
  
 Symmetry transformations used to generate equivalent atoms: #1 x-1,y,z     
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